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SUMMARY 
Cyclic dipeptides have limited conformational freedom due to their diketopiperazine 
backbone and their small size. They are relatively simple to synthesise, making them 
ideal subjects for investigation into their biological effects. Cyclic dipeptides have also 
been known for their multitude of biological activities, including antimicrobial, anticancer 
and haematological properties. 
In this study the cyclic dipeptides, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro), were 
synthesised from their corresponding linear precursors using a modified phenol-induced 
cyclisation procedure. The phenol induced cyclisation procedure resulted in good yields 
and purity of the cyclic dipeptides. Quantitative analysis and evaluation of the 
physiochemical properties of the cyclic dipeptides was achieved using high-
performance liquid chromatography, scanning electron microscopy, thermal analysis 
and X-ray powder diffraction. Structural elucidation of the cyclic dipeptides was done by 
means of infrared spectroscopy, mass spectroscopy, nuclear magnetic resonance 
spectroscopy and molecular modelling. 
The study‟s aim was to determine the biological activity of cyclo(Phe-4Cl-Pro) and 
cyclo(D-Phe-4Cl-Pro) with respect to their anticancer, antimicrobial, haematological and 
ant-diabetic studies. Anticancer studies revealed that cyclo(Phe-4Cl-Pro) and cyclo(D-
Phe-4Cl-Pro) inhibited the growth of HeLa (cervical cancer), HT-29 (colon cancer) and 
MCF-7 (breast cancer) cancer cell lines. Both cyclic dipeptides also inhibited the growth 
of certain selected Gram-positive, Gram-negative and fungal microorganisms in the 
antimicrobial study. Although the inhibition of growth in the anticancer and antimicrobial 
studies was statistically significant, the clinical relevance is questionable, since the 
inhibition produced by both cyclic dipeptides was very limited compared to other pre-
existing anticancer and antimicrobial agents. Both cyclic dipeptides caused a significant 
shortening of the APTT and PT clotting times and an increase in the fibrin and D-Dimer 
formation. Cyclo(D-Phe-4Cl-Pro) at a screening concentration of 12.5 mM and 3.125 
mM, showed significant anti-platelet activity. Both cyclic dipeptides failed to produce any 
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inhibition of the α-Glucosidase enzyme and very limited inhibition of the α-Amylase 
enzyme. 
Key words: Cyclic dipeptides, cyclo(Phe-4Cl-Pro), cyclo(D-Phe-4Cl-Pro), anticancer, 
antimicrobial, antifungal, anti-diabetic, haemostasis      
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CHAPTER 1 
INTRODUCTION 
1.1 Background and problem definition 
All living tissues consist of proteins. Proteins play a major role in regulating most signal 
transductions in eukaryotic cells and as hormones, neurotransmitters and 
neuromodulaters (Nelson and Cox, 2005). Even though the use of peptides as novel 
drug compounds has been limited by their poor chemical and physical properties, 
structural similarities of cyclic dipeptides, also known as diketopiperazines (DKPs), cyclo 
dipeptides, 2,5-diketopiperazines (DKPs), 2,5-dioxopiperazines (DOPs), or dipeptide 
anhydrides to peptides, the abundance of their ring structure in several natural products 
coupled with the simplicity of their chemical structure has inspired new research (Witak 
and Wei, 1990).  
2,5-Diketopiperazines (DKPs) are cyclic dipeptide derivatives, which show a multitude 
of interesting biological activities including efficient interactions with opioid receptors, 
potent cytotoxic effects and neuroprotective effects. Recently, they have also been 
associated with blockade of L-type calcium channels, tryptase inhibition, oxytocin 
receptor antagonism and plasminogen activator inhibition (Wyatt et al., 2005). 
No extensive research has yet been undertaken to determine the biological activity of 
cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro). Chlorine was introduced on the side 
chain to increase the lipid solubility, optimise cell penetrability and the physiological 
response.  In a study (Brauns et al., 2004), selected cyclic dipeptides were evaluated for 
anti-cancer activity against a number of cell lines, namely MCF-7 (breast carcinoma), 
HeLa (cervical carcinoma) and HT-29 (colon carcinoma), indicating that one of the 
compounds tested, cyclo(phe-pro), showed inhibition of proliferation of some cell lines, 
2 
 
and in addition induced apoptosis in the HT-29 cell line. It thus indicates the potential for 
proline- and phenylalanine-containing cyclic dipeptides to inhibit the growth of tumours 
in vivo. Studies of cyclic dipeptides are therefore warranted.   
1.2 Aim 
The primary aim of this study is to synthesise, elucidate and determine the biological 
activity of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro), utilising qualitative and 
quantitative experimental approaches. 
1.3 Objectives 
Based on the aim, the objectives of the study can be outlined as follows: 
 To successfully synthesise and purify cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-
Pro) from their respective amino acid precursors. 
 To elucidate the structures by means of fast atom bombardment mass 
spectrometry, nuclear magnetic resonance spectroscopy, and infrared 
spectroscopy.  
 To determine the physicochemical characteristics of cyclo(Phe-4Cl-Pro) and 
cyclo(D-Phe-4Cl-Pro) using the following: Scanning electron microscopy, 
differential scanning calorimetry, thermogravimetric analysis and X -Ray powder 
diffraction. 
 To determine the biological effects of the synthesised compounds with respect to 
their antimicrobial, anticancer, haematological and anti-diabetic activities.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Background 
The fundamental objectives of organic and medicinal chemistry involve the discovery, 
development, identification and interpretation of the mode of action of biologically active 
compounds at the molecular level. Even though the emphasis is put on drugs, medicinal 
chemistry also involves the study, identification and the synthesis of the metabolic by-
products of drugs and related compounds (Wermuth, 2003). 
The battle between scientific research and disease has been constant throughout 
human history and for all the success we have witnessed in the 20th century, only about 
one third of the 30,000 known diseases can be treated effectively (Rozek and Tully, 
1999). Several diseases remain difficult to treat successfully such as cancer, auto-
immune disorders, viral diseases (e.g., influenza), and central nervous system disorders 
(e.g., Alzheimers disease) (Kourounakis and Rekka, 1994). The emergence of multi-
drug resistant microorganisms have added to the urgency in discovering new novel 
drugs or agents, a process that can take many years before a product is regarded as 
safe and efficient and reaches the market place (Shlaes et al., 2004). 
The costs associated with the development of new drugs (especially clinical evaluation) 
have increased dramatically in recent years, and therefore fewer ground-breaking drugs 
have made their way onto the market. There is a great need for the development of 
more active and selective drugs with minimal side effects, agents useful in prophylaxis 
and drugs that will cause less harmful contamination in an already polluted environment 
(Kourounakis and Rekka, 1994). 
The demand for peptides and proteins as therapeutic agents is increasing rapidly with 
time. During the past 35 years the discovery of a vast range of naturally occurring 
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peptides with potent and specific biological activities has further increased their 
importance (Suresh Babu, 2001). 
Peptide ligands can act as either agonists or antagonists at cell-surface receptors or 
acceptors that modulate cell function and animal behavior. This area encompasses 
approximately 50% of current drugs and will become even more important in the future. 
The biological and behavioral activities that are controlled or modulated by these 
interactions include response to stress, pain, inflammation, addiction, learning, memory, 
feeding behavior, sexual behavior, reproduction, the immune response, thermal control, 
cardiovascular function/regulation and kidney function. The development of peptide or 
peptidomimetic ligands that can target receptors or acceptors that modulate or control 
these biological activities thus remains a top priority of every pharmaceutical scientist 
(Hruby, 2002). 
Biologically active peptides range in size from small molecules, containing only two or 
three amino acids, to large molecules containing many amino acids. Neuropeptides, 
hypothalamic hormones (releasing and releasing inhibiting hormones), proteohormones 
of the pituitary, thyroid hormones, gastrointestinal peptides, muramyl peptides, peptides 
of immunological significance, peptide vaccines, plasma kinins, atrial nutriuretic 
peptides, peptide antibiotics, peptide toxins, peptide insecticides and herbicides are 
some of the important classes (Suresh Babu, 2001). 
Cyclic dipeptides also known as 2,5-dioxopiperazines, 2,5-diketopiperazines, cyclo 
dipeptides or dipeptide anhydrides, are relatively simple dipeptides and are therefore 
commonly found in nature. Since their discovery at the start of the 20th century, a vast 
amount of peptides have been identified from natural origins (Anteunis,1978) and are 
currently attracting considerable attention due to certain biological activities 
(Prasad,1995). Some peptides are well known for their biological importance as 
antibiotics, hormones toxins and ion transport regulators (Ovchinnikov and Ivanov, 
1975). The therapeutic potential of these compounds ranges from antibiotic, antiviral, 
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anti-tumour, tenso-active to muscle relaxant activity, to only name a few (Milne et al., 
1998).  
2.2 Amino acids, peptides and proteins 
Amino acids are classified as non-essential, essential and conditionally essential amino 
acids (Meier, 2005). Food and tissue proteins consist of twenty amino acids of 
nutritional importance. Nine of these amino acids (histidine, isoleucine, leucine, lysine, 
methionine, phenylalanine, threonine, tryptophan and valine) are known as essential or 
indispensible nutrients since they cannot be synthesized by the body and must 
therefore be obtained from the diet. The remaining eleven amino acids (alanine, 
arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine, glycine, proline, 
serine and tyrosine) are known as nutritionally dispensable or non-essential nutrients 
since they can be synthesized by the body, but are also ordinarily obtained from the 
diet. They are equally as important as the indispensible amino acids for both nutrition 
and normal functioning of cells and organs (Campbell and Farrell, 2003). There are only 
a few diseases that may result in isolated amino acid deficiencies. In catabolic diseases, 
some of the amino acids (arginine, cysteine, glutamine, histidine, serine and tyrosine) 
become conditionally essential. The supplementation of these amino acids has been 
shown to have a positive effect on clinical outcome under specific conditions (Meier, 
2005).The general structure of an amino acid (Figure 2.1) contains an amino group and 
a carboxyl group, both of which are bonded to the α-carbon (Campbell and Farrell, 
2003). 
 
Figure 2.1    General structure of an amino acid (Campbell and Farrell, 2003). 
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Amino acids are a special kind of carboxylic acid consisting of a basic amine (NH2) 
group and an acidic carbonyl (COOH) group. This dipolar ion can undergo 
intermolecular acid-base reactions and exist primarily in the form of zwitterions. 
Zwitterions show physical properties associated with salts, having large dipole 
moments, are soluble in water, insoluble in hydrocarbons and have very high melting 
points (McMurry, 2008). Amino acids can be distinguished on the basis that the amino 
and carboxylic functions are both linked to the same carbon. For example α-amino acids 
(shorter distance between functional groups) can be distinguished from β; γ; δ and ε-
amino acids (greater distance between functional groups) as is illustrated in Figure 2.2 
(Jakubke and Jeschkeit, 1977). 
---CH2CH2(NH2)COOH               α-Amino acid 
---CH2CH2(NH2)CH2COOH         β-Amino acid 
---CH2 (NH2)(CH2 )4COOH          ε- Amino acid 
Figure 2.2    Illustrating the difference between α; β and ε- amino acids.  (Jakubke and Jeschkeit, 1977). 
Amino acids also form left (levo or L) and right (dextro or D) handed isomers. Only L-
isomers of amino acids are found naturally in proteins (Campbell and Farrell, 2003). 
The cellular tissue and fluid of living organisms contains a permanent reservoir of free 
amino acids. These free amino acids take part in numerous metabolic reactions 
illustrated in Figure 2.3 (Jakubke and Jeschkeit, 1977). 
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Figure 2.3    Schematic representation of the amino acid reservoir (Jakubke and Jeschkeit, 1977). 
Apart from the metabolic roles they play, amino acids are also key precursors that can 
be converted to both hormones and neurotransmitters (Campbell and Farrell, 2003). 
Tryptophan is a key amino acid precursor that can be converted to both hormones and 
neurotransmitters. 
Figure 2.4 Illustrates the conversion of tryptophan to serotonin (5-HT), melatonin and 
niacin, which is known to play a key role in several disease states, one being serotonin 
syndrome that is evoked by an interaction between serotonergic agents (5-HT re-uptake 
blockers and MAO (mono-amine oxidase)) inhibitors (Katzung, 2009). 
Proteins 
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Α-Keto acids 
Amino acids 
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free amino 
acids 
Porphyrins 
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Figure 2.4    Conversion of tryptophan to serotonin, melatonin and niacin (Campbell and Farrell, 2003) 
The compounds under investigation in this study are the phenylalanine-containing and 
proline-containing cyclic dipeptides, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro), as 
illustrated in Figures 2.5 and 2.6, respectively.  
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Figure 2.5    Structure of Cyclo(Phe-4Cl-Pro) 
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Figure 2.6    Structure of Cyclo(D-Phe-4Cl-Pro) 
Phenylalanine (Phe or F); (2-amino-3-phenyl-propanoic acid); is a neutral, aromatic 
amino acid with the formula HOOCCH(NH2)CH2C6H5. It is classified as nonpolar 
because of the hydrophobic nature of the benzyl side chain (Katzung, 2009). Tyrosine 
and phenylalanine play a significant role not only in protein structure, but also as 
important precursors for thyroid and adrenocortical hormones as well as in the synthesis 
of neurotransmitters such as dopamine and noradrenaline (Katzung, 2009). The genetic 
disorder phenylketonuria (PKU) is the inability to metabolize phenylalanine. This is 
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caused by a deficiency of the enzyme, phenylalanine hydroxylase with the result that 
there is an accumulation of phenylalanine in body fluids. Individuals with this disorder 
are known as "phenylketonurics" and must abstain from consumption of phenylalanine. 
A non food source of phenylalanine is the artificial sweetener aspartame (L-aspartyl-L-
phenylalanine methyl ester) which is metabolized by the body into several by-products 
including phenylalanine. The side chain of phenylalanine does not undergo side 
reactions, but during catalytic hydrogenations the aromatic ring can be saturated and 
converted to a hexahydrophenylalanine residue (Campbell and Farrell, 2003). 
Proline (Pro or P); ((S)-Pyrrolidine-2- carboxylic acid); is a nonpolar, neutral amino acid 
and is regarded as a helix breaker. The aliphatic side chain of proline differs from other 
amino acids in that its side chain is bonded to both to the α-carbon and nitrogen. Proline 
contains a secondary rather than a primary amino group, which makes it an imino acid 
(Campbell and Farrell, 2003). Proline can only act as a hydrogen bond acceptor, and 
not as a hydrogen bond donor, since it lacks hydrogen on the amide group. Proline is 
the only residue which leads to an N-Alkyl amide bond when incorporated into a 
peptide. Proline is therefore unique in having no amide proton to participate in hydrogen 
bonding and in having a cyclic side chain which establishes conformational restrictions 
(the pyrrolidine ring decreases the conformational mobility of the DKP moeity, so that 
the side-chain rotamers for the non-prolyl residue is well defined (Campbell and Farrell, 
2003). Proline can cause reversal of direction of peptide chains in globular proteins 
(Campbell and Farrell, 2003) and acts as a conformational determinant in structural 
proteins e.g., collagen. Inclusion of proline in DKPs increases the solubility of the 
compounds in chloroform. Furthermore, studies have shown that proline has the ability 
to izomerise and undergoes a transition from the all-cis form (polyproline I) to the all-
trans form (polyproline II) (Campbell and Farrell, 2003). 
Proline is found in naturally occurring biologically active peptides, including peptide 
hormones e.g., angiotensin, bradykinin, oxytocin, vasopressin, MSH (melanocyte 
stimulating hormone), TRF (thyroid-releasing factor), gramicidin S, actinomycin, and 
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antamanide (Campbell and Farrell, 2003). Dipeptides containing a proline or a 
hydroxyproline residue, exhibit a marked propensity for intermolecular cyclization. 
Figure 2.7 and Figure 2.8 illustrate the metabolic pathways of phenylalanine and proline 
respectively. 
 
1, transaminase pathway with glutamate; 2, P5C dehydrogenase 
Figure 2.7    Metabolic pathway of phenylalanine (Wang et al., 2001) 
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1, P5C synthase; 2, P5C dehydrogenase; 3, ornithine aminotransferase; 4, spontaneous reaction; 5, urea 
cycle enzymes. 
Figure 2.8    Metabolic pathway of proline (Phanget al., 2008) 
Individual amino acids can be linked together by the formation of a covalent bond 
between them. Water is eliminated during the process and a bond is formed between 
the α-carboxyl group of one amino acid and the α-amino group of the next one (Figure 
2.9). A bond formed this way is called a peptide bond. Peptides are compounds formed 
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by the linking of small numbers of amino acids, ranging from two to several dozen 
(Campbell and Farrell, 2003). 
 
Figure 2.9    Formation of a peptide bond (Campbell and Farrell, 2003)  
Proteins the fundamental building blocks of all life consist of polypeptide chains which 
are usually made up of more than 100 amino acids. The human body contains about 
100 000 different proteins. Proteins are of variable length and structure, which fold upon 
themselves to generate a shape that is characteristic of each protein. The function and 
properties of different peptides and proteins are determined through the sequence of 
amino acids. This sequence is based on the genetic information contained in 
deoxyribonucleic acid (DNA) (Campbell and Farrell, 2003; Mohan, 2001). 
Proteins and peptides control numerous biochemical reactions in the body and may 
represent an unexploited source of new drugs for treating a variety of diseases (Mohan, 
2001). 
Synthesised medicinal peptides represent a broad range of biological substances that 
will exert biological effects for related medicinal conditions. These substances represent 
a broad variety such as hormones, cytokines, enzymes, blood coagulation regulators, 
vaccines, poisons and antibiotics that are integral to the regulation and maintenance of 
biological processes (Frokjaer and Hovgaard, 2000). Table 2.1 illustrates the biological 
substances that are used clinically (Bhattycharyya et al., 2005). Peptides in which 
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amino acids are key precursors include the vasodilators (bradykinin, natriuretic 
peptides, vasoactive intestinal peptides, substance P, neurotension, calcitonin gene 
related peptide) and vasoconstrictors (angiotension II, vasopression, endothelins and 
neuropeptide Y). These hormones and neurotransmitters control and maintain the 
function and integrity of all the body‟s major organ systems. Neurotransmitters function 
in the transmission of nerve impulses and the activation and inactivation of receptors 
and these vital functions will control normal body regulators such as metabolism, 
immune defences, digestion, respiration, reproduction and sensitivity to pain (Katzung, 
2009). Peptides exhibit a very wide structural and functional variation and are therefore 
very important for the regulation and maintenance of biological processes (Frokjaer and 
Hovgaard, 2000). Table 2.1 illustrates the major peptide-and protein-containing drugs 
currently used (Bhattycharyya et al., 2005). 
Table 2.1    Key groups of peptide- and protein-containing drugs (Bhattycharyya et al., 
2005). 
Peptides 
Antibiotics Bacitracin, Bleomycin, Colitimethate sodium, 
Gramicidine 
Hormones Corticotropin, Glucagon, Gonadorelin 
hydrochloride,Lypressin, Oxytocin, Vasopressin, 
Calcitonin, Desmopressin, Leuprolide acetate, 
Demoferin acetate, Goserelin acetate, Teriparatide 
acetate, Sermorelin acetate, Cosyntropin, 
Corticorelin, Histrelin acetate, Protirelin, Secretin  
Others Polymyxin B, Cyclosporin, Eptifibatide 
Non-glycosylated proteins 
Interleukins Aldesleukin (IL-1), Anakinra (IL-2), Denileukindiftitox 
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Interferons Interferon alfa-n1, Interferon alfa-n3, Interferon alfa-
2a, Interferon alfa-2b 
Peginterferon alfa-2b, Interferon alfacon-1, 
Interferon beta-1b, Interferon gamma-1b 
Enzyme /Inhibitors Alpha-1 Proteinase Inhibitor, Anistreplase, 
Asparaginase, Pegaspargase, Rasburicase, 
Reteplase, Tenecteplase, Dornase alpha, 
Chymotrypsin, Hyaluronidase, Prancreatin, 
Pancrelipase, Papain, Trypsin, Urokinase, 
Alglucerase, Chymopapain, 
Deoxyribonuclease,Fibrinolysin, Imiglucerase, 
Pegademase, Streptokinase, Adenosine 
deaminase, Rasburicase, Lactase 
Growth Factors/Hormones Becaplermin, Filgrastim, Pegfilgrastim, menotropins 
Antithrombotic Agents Thrombin, fibrinogen, Fibrin, Hirudin, Hirulog 
 
Others 
 
Insulin, Insulin Lispro, Gelatin, Collagen, Prolactin, 
Digoxin, Immune Fab, Albumin Human, 
Haemoglobin 
Glycosylated proteins 
Interferons Interferon beta-1a 
Antithrombotic Agents Alteplase, Drotrecoginalfa, Antithrombin III 
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Antianaemic Darbopoeitin alfa, Erythropoietin 
Growth Hormones Somatropin, Somatrem, Chorionic Gonadotropin 
Human, follitropin alpha, Follitropin beta, 
Urofollitropin, Thyrotropin 
Immune globulins Normal Immune Globulin, Hepatitis B Immune 
Globulin, Pertussis Immune Globulin, Rabies 
Immune Globulin, Tetanus Immune Globulin, 
VacciniaImmune Globulin, CMV Immune Globulin, 
Varicella-Zoster Immune Globulin, Rho(D) Immune 
globulin, Intravenous Gamma Globulin, Lymphocyte 
Anti-Thymocyte Immune Globulin Equine, 
Lymphocyte Anti-Thymocyte Immune Globulin 
Rabbit 
Coagulation Factors Factor VII, Antihaemophillic factor, Cryoprecipitated 
AHF, Factor IX 
(Factor VIII) Others Etanercept (CSF), Sargramostim (TNF) 
Monoclonal antibodies 
Abciximab, Alemtuzumab, Arcitumomab, Basilximab, Capromab, Declizumab, Ibritumomab, Tiuxetan, 
Imciromab, Infliximab, Nofetumomab, Palivizumab, Rituximab, Trastuzumab, Daclizumab, Satumomab, 
Muromonab-CD3, Gentuzumab 
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2.3 Cyclicdipeptides 
2.3.1 General aspects of cyclic dipeptides 
Cyclic dipeptides are heterocyclic compounds compromising of two amino acid residues 
linked to a central diketopiperazine (DKP) ring structure (Kilian, 2002). The general 
structure of cyclic dipeptides is illustrated in Figure 2.10 where R1 and R2 can be 
substituted with different amino acid side-chain residues, resulting in a number of 
chemical structures of varying chemical and biological properties. 
 
Figure 2.10    General structures of a 2, 5-diketopiperazine, where R1 and R2 represent the substituting 
amino acid residues (Prasad, 1995). 
In 1888 Curtius and Gloebel synthesised the first cyclic dipeptide, cyclo(Gly-Gly), for the 
sole purpose of examining their physiological properties, many simple diketopiperazines 
(DKPs) have been synthesised since then (Prasad, 1995). 
Cyclic dipeptides are divided into two broad classes. Firstly cyclic dipeptides are termed 
homodetic if the linkage that contributes to the formation of the DKP ring is a peptide 
bond and secondly heterodetic if the cyclisation includes other bridges such as disulfide, 
ester (lactone), ether or thioether bridges. Several chemical strategies, including head-
to-tail cyclisation reactions utilising solid- or solution-phase synthetic methods, have 
been developed to convert linear peptides to cyclic structures (Adessi and Soto, 2002).  
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Optimisation of potential drug candidates often precludes the use of peptides because 
of their poor physical and metabolic properties. As a result of the structural similarity of 
DKPs to peptides, their appearance in biologically active natural products has inspired 
medicinal chemists to use DKPs to circumvent the limitations of peptides. Constraining 
the nitrogen atoms of an α-amino amide into a DKP ring alters physical properties, 
reduces susceptibility to metabolic amide bond cleavage reactions and reduces 
conformational mobility. As a result of the change in structural and physical 
characteristics, DKPs can confer more drug-like properties to molecules and enhance 
favourable interactions with macromolecules (Dinsmore and Beshore, 2002). Table 2.2 
lists some of the properties of cyclic dipeptides that make them different from ordinary 
peptides. 
Table 2.2    The difference between cyclic dipeptides and ordinary peptides  
The properties of cyclic dipeptides differ from those of ordinary peptides: 
They do not exist as zwitterions and are often neutral compounds
1
 
The simpler members of this group are water soluble
1 
They have the ability of forming hydrogen bonds with the solvent (via the two cis-amide groups in the 
cyclic dipeptide ring), and give rise to hydrophobic interactions
2
 
 
They are important metabolic intermediates and provoke the destruction of the secondary globular 
protein structure
3,4
, (especially non-ionic polar DKPs exhibit the potential to act as denaturing agents)
2
 
 
They are chirally enriched, easy accessible heterocycles and owing to their constrained nature, do not 
exhibit unwanted physical and metabolic properties
5
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They are sensitive to oxidation, especially when imino acid residues are the building blocks
5
 
 
They may act as powerful hydrolytic catalysts
6
 
 
Their physico-chemical and biological properties are dependent on the spatial arrangement of their 
constituent atoms
7
 
They do not have backbone terminal charged groups
7
 
 
1
(Sammes, 1975), 
2
(Ramani et al., 1977), 
3
(Krejcarek et al., 1968), 
4
(Crescenzi et al., 1973), 
5
(Haüsler et 
al., 1978), 
6
(Imanishi et al., 1975), 
7
(Ovchinnikov and Ivanov, 1975),  
2.3.2 Conformational aspects of cyclic dipeptides 
The DKP backbone is an important cornerstone in peptide research, drug discovery and 
design and for the development of peptidomimetics (Sammes, 1975). The DKP 
backbone is conformationally restrained by a six membered ring with side chains that 
are orientated in a spatially defined manner. The DKP ring contains two hydrogen bond 
accepting centres and two hydrogen bond donating sites which are important for 
potential interactions between the lead compound and receptor sites (Deslauriers et al., 
1975). 
The conformations and molecular structures of cyclic dipeptides containing the DKP ring 
have been studied by a number of physical techniques, including X-ray crystallography, 
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infrared (IR) spectroscopy, nuclear magnetic resonance (NMR), optical rotatory 
dispersion (ORD) and circular dichroism (CD) spectroscopy (Deslauriers et al., 1975). 
A strong link between the physicochemical and biological properties of cyclic dipeptides 
and the spatial arrangements of their constituent atoms has been shown to exist 
(Ovchinnikov and Ivanov, 1975). 
The two major considerations, with respect to conformational analysis of cyclic 
dipeptides, are the degree of planarity of the DKP ring and the degrees of folding or 
extension of the different side-chain substituents (Van der Merwe, 2005). 
Structural models have shown that the six-membered DKP ring of cyclic dipeptides is 
slightly flexible and may thus adopt four main configurations (planar, boat, bowsprit-boat 
and twist–boat), which is strongly influenced by the substituents at the α-carbon atoms 
(Funasaki et al., 1993). Three conformations of the DKP ring have been identified in the 
solid state i.e., chairs, boat and twists (Jankowska and Ciarkowski, 1987). 
 The aromatic side chains of the two phenylalanine-containing rotamers [cyclo(Phe-
Pro); cyclo(Phe-D-Pro)]  can adopt one of three predominant conformations: a folded 
conformation; extended towards the nitrogen (EN); or extended towards the oxygen 
(Young et al., 1976). 
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   Figure 2.11    Side chain conformations of cyclo(Phe-Pro) and cyclo(Phe-D-Pro). (Adapted from Young 
et al., 1976). 
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2.3.3 Physiochemical properties of cyclic dipeptides 
2.3.3.1 Solubility of cyclic dipeptides 
Interactions between water and the hydrophobic or hydrophilic parts of peptides, such 
as amino acid side chains and peptide groups, play a crucial role in their structure and 
stability (Della Gatta et al., 2005). 
As a result of the intramolecular aminolysis reaction, cyclic dipeptides are not capable of 
existing as zwitterions. Simpler members have been shown to exist exclusively as 
neutral compounds (Grant, 2002). Cyclic dipeptides share the capability of establishing 
hydrogen bonds with the solvents via the two cis-amide groups in the DKP ring, and of 
giving rise to hydrophobic interactions, the extent of which is determined by the R1 and 
R2 substituents. The solubility of non-ionic DKPs is limited, to DKPs containing short 
alkyl R substituents (Crescenzi et al., 1973; Sammes, 1975). 
2.3.3.2 Physical stability of cyclic dipeptides 
Cyclic dipeptides exist as fairly stable entities. However, studies have shown that either 
of the two carbonyl groups of the DKP ring of cyclo(Phe-Pro) can undergo hydrolysis, 
thereby producing two different linear dipeptides, i.e., Phe-Pro-OH and Pro-Phe-OH. 
This suggests their possible use as pro-drugs (Goolcharren and Borchardt, 1998).  
Results from studies by Grant (2002) showed that aqueous solutions of some cyclic 
dipeptides, stored at high temperatures for a prolonged period of time, had a high 
degree of thermo stability. The cis-fused diketopiperazines are thermodynamically more 
stable, compared to their trans-fused counterparts, and constitute a predominant class 
of naturally occurring products. This seems logical considering their biosynthetic origin, 
usually from two proteinogenic L-α-amino acids. There are only a few reports on trans-
configured diketopiperazines derived from natural sources (Siwicka et al., 2005).   
Cyclic dipeptides are also more stable between certain pH ranges. For 
example,cyclo(Phe-Pro) exist as a relatively stable entity between pH values 3 and 8, 
23 
 
but hydrolysis of the diketopiperazine nucleus occurs at pH values of less than 3 or 
greater than 8 (Goolcharren and Borchardt, 1998). 
2.3.4 Absorption, transportation and metabolic stability of cyclic dipeptides 
In order to exhibit or exert their pharmacological action, peptide and protein drugs must 
be transported without metabolic degradation to the systemic circulation. Although 
active transport of linear peptides and oligopeptides by intestinal oligopeptide 
transporters has been reported, overall intestinal absorption of peptides is very poor due 
to metabolic degradation by peptidases (Mizuma et al., 2002). 
Peptide transporters are integral plasma membrane proteins that mediate the cellular 
uptake of dipeptides and tripeptides in addition to a variety of peptidomimetics. Peptide 
transporters represent excellent targets for the delivery of pharmacologically active 
compounds, because their substrate binding site accommodates a wide range of 
molecules of differing size, hydrophobicity and charge (Rubio-Aliaga and Daniel, 2002). 
Although intestinal and renal peptide transporters have similar features, such as 
substrate recognition and driving force, it has been suggested that the intestinal and 
renal transport systems are not identical. Molecular cloning studies revealed the 
existence of two homologous peptide transporters, PEPT1 (SLC15A1) and PEPT2 
(SLC15A2) (Terada et al., 1997). 
PEPT1 and PEPT2 actively transport dipeptides and tripeptides, including 
peptidomimetics, across cell membranes in animals, microbes and plants (Rubio-Aliaga 
and Daniel, 2002). PEPT1 is a low-affinity/high-capacity transporter, which is found 
primarily on the brush-border membrane of the small intestine, and to a lesser extend in 
the proximal tubule of the kidney. In contrast, PEPT2 is a high-affinity/low-capacity 
transporter expressed predominantly in the apical membrane of the kidney (Shen et al., 
1999; Smith et al., 1998). Both transporters function electrogenetically, as they are 
driven electrochemically via a gradient of proteins across the intestinal or renal brush-
border membrane in the lumen-to-cytoplasm direction (Nussberger and Hediger, 1995). 
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In addition to amino acid transporters, peptide transporters contribute to the 
homeostasis of amino acids (Palacin et al., 1998).  
Mizuma et al. (2002) studied the uptake of cyclic dipeptides via the PEPT1 peptide 
transporters. They noted that the cellular uptake of cyclic dipeptides was pH dependent, 
and that the uptake was inhibited by the addition of PEPT1 substrates, which indicates 
PEPT1-mediated transport of the cyclic dipeptides. It was concluded that tyrosine had a 
high affinity for PEPT1 and that the phenolic hydroxyl group may enhance this affinity 
for PEPT1. According to Mizuma et al. (2002), cyclo(Ser-Tyr) and other cyclic 
dipeptides were stable enough to be transported in any region of the small intestine, 
while the linear dipeptides including seryltyrosine were too unstable to be transported 
and were degraded by peptidases. 
Certain cyclic dipeptides have the ability to be transported by additional paracellular 
mechanisms, thereby effectively enhancing their transport beyond that of their 
corresponding linear dipeptides (Mizuma et al., 1997). Not only absorptive transport, but 
also excretive transport is observed for certain cyclic dipeptides. That is, the intestinal 
absorption of certain cyclic dipeptides consists of carrier-mediated absorptive transport 
and carrier-mediated excretive transport in addition to passive transport. Absorptive 
transport is mediated by PEPT1, whereas excretive transport is mediated by a 
transporter that is closely linked to adenosine triphosphate (ATP). The concentration 
dependent preference of these absorptive and excretive transport cause atypical 
intestine absorption of certain cyclic dipeptides (Mizuma et al., 2003). 
As far as metabolism is concerned, possible recognition of peptide derivatives by 
hepatic cytochrome P450 3A has been suggested by binding and metabolism of 
numerous pseudopeptidic compounds such as ergot derivatives and cyclosporin. 
Natural linear or cyclic dipeptides containing hydrophobic amino acids produced by 
microorganisms and present in mammals are able to interact with the P450. Some 
cyclic dipeptides are rapidly transformed by cytochrome P450 3A to mono or 
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hydroxylated metabolites. This metabolism of cyclic dipeptides occurs in eight species 
including man (Delaforge et al., 2001). 
2.3.5 Biologically active cyclic dipeptides 
 Amongst the simplest and easiest to obtain peptide derivatives found in nature are 
cyclic dipeptides. They are common to synthetic, spontaneous and biological formation 
pathways. Since their discovery around the turn of the century, more than a hundred 
cyclic dipeptides have been identified from natural origins (Anteunis, 1978), and 
continue to be discovered. They are detected in sponges (Wegerski et al., 2004; De 
Rosa et al., 2003; Fu et al., 1998; Prasad, 1995), microorganisms (Lautru et al., 2002; 
Holden et al., 1999; Kanoh et al., 1997; Prasad, 1995; Park and Stroebel, 1994; 
Sammes, 1975) and mammals (Gudasheva et al., 1997; Walter et al., 1978). 
Although cyclic dipeptides are commonly found in nature, very few of these molecules 
have been tested and only four are known to exhibit biological activity in mammals. 
These include cyclo(His-Pro), cyclo(Leu-Gly), cyclo(Tyr-Arg) and cyclo(Asp-Pro). 
Amongst these four compounds only cyclo(His-Pro) has been shown to be endogenous 
to mammals (Prasad, 1995). 
Milne et al. (1998) studied the effects of cyclo(Phe-Pro), cyclo(Tyr-Pro), cyclo(Trp-Pro) 
and cyclo(Trp-Trp) on ion channel regulation in rat and guinea-pig myocytes, induction 
of differentiation in cultured cancer cell lines as well as the antimicrobial activity of these 
compounds. Results from the study suggest that the compounds could have potential 
as muscle relaxants, anticancer agents and antibiotics, if their solubilities can be 
increased. Evaluation of some cyclic dipeptides by Graz et al. (1999) further supported 
the potential of these compounds as antibacterial agents. Table 2.3 illustrates the 
biological activity of some cyclic dipeptides. 
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Table 2.3    Biological activity of some cyclic dipeptides  
Cyclic Dipeptide Biological activity 
Cyclo(Phe-Pro), Cyclo(Tyr-Pro), Cyclo(Trp-Pro) 
and Cyclo(Trp-Trp)
1, 3, 29 
 Calcium and sodium channel blocking activity 
 Antibacterial activity 
 Anticancer activity 
 Cyclo(Phe-Pro), cyclo(Tyr-Pro) and cyclo(Trp-
Pro) play a role in the induction of 
differentiation in cancer cell lines  
Cyclo(His-Pro)
2, 21, 22, 23, 24, 25, 26, 27, 29 
 Played an important role in the perception of 
pain-induced by physical, mechanical, thermal 
and chemical stimuli 
 Inhibition of prolactin release from the pituitary 
gland 
 Decreased gastric mocussa blood flow 
 Production of hypothermia in mice 
 Suppression of stress induced eating, 
starvation induced eating and spontaneous 
eating over a ten hour period in mice 
 Antagonism of ethanol narcosis in mice 
 Modulation of glucose metabolism 
 Hormonal regulation   
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Cyclo(Leu-Gly)
2 
Caused the blockade of: 
 The development of physical dependence on 
morphine 
 The development of tolerance to the 
pharmacological effects of β-endorphin 
 The development of tolerance to haloperidol-
induced catalepsy and hypothermia 
 Dopaminergic supersensitivity after long-term 
morphine exposure 
 An increase in response latency measured in 
the rat yeast-paw test following oral 
administration of the peptide  
Cyclo(Pro-Phe)
2 
 Blockade of the development of physical 
dependence on morphine 
Cyclo(Tyr-Arg)
2 
 Antinociceptive activity 
Cyclo(Asp-Pro)
2, 29 
 Inhibition of caloric and dietary fat intake  
Cyclo(Tyr-Pro)
2 
 Phytotoxic action 
Cyclo(Pro-Gly)
4 
 Antiamnesia properties 
Cyclo(Tyr-Tyr)
5 
 Voltage dependent calcium channel blocking 
activity 
 Increased heart rate and coronary flow rate of 
isolated rat hearts 
 Mixed agonist and antagonist activity  at µ-
opioid receptors 
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Cyclo(Phe-Tyr)
5 
 Inhibition of HT-29, HeLa and MCF-7 tumor 
cell lines 
 Calcium channel blocking activity 
 Decreased heart rate, coronary flow rate and 
ventricular pressure of isolated rat hearts 
 Agonist activity at µ-opioid receptors 
Cyclo(Phe-Cys) and cyclo(Tyr-Cys)
6 
 Decreased heart rate and coronary flow rate 
and, and increased ventricular pressure of 
isolated rat hearts 
 Inhibition of HT-29 and  HeLa tumor cell lines 
 Cyclo(Tyr-Cys) also inhibited MCF-7 tumor 
cell lines 
 Deceleration of the rate of blood clot formation 
 Concentration dependent acceleration of 
thrombin substrate reaction 
 Concentration dependent change in rate of 
platelet aggregation 
 Deceleration of initial fibrin formation  
Cyclo(Gly-Gly), Cyclo(Gly-Trp), 
Cyclo(Trp-Tyr), Cyclo(Trp-Trp), 
Cyclo(Phe-Trp), Cyclo(Phe-Phe), 
Cyclo(Pro-Gly), Cyclo(Pro-Pro), 
Cyclo(Phe-Pro), Cyclo(Pro-Trp), 
Cyclo(Ala-Pro), Cyclo(Glu-Phe), 
 Antifungal activity 
 
 
 
 
 
29 
 
Cyclo(Tyr-Pro), Cyclo(Trp-Pro)
7, 29 
 Antifungal activity 
Cyclo(Gly-Gly), Cyclo(Trp-Tyr), 
Cyclo(Trp-Trp),Cyclo(Phe-Trp), 
Cyclo(Phe-Phe),Cyclo(Pro-Gly), 
Cyclo(Pro-Pro), Cyclo(Phe-Pro),  
Cyclo(Ser-Ser), Cyclo(Pro-Trp), 
Cyclo(Ala-Pro), Cyclo(Glu-Phe),  
Cyclo(Tyr-Pro), Cyclo(Phe-Leu),  
Cyclo(Trp-Pro)
7, 20, 29 
 Antibacterial activity 
 Cyclo(Pro-Pro) demonstrated anticancer 
activity 
Cyclo(Met-Met) and cyclo(Met-Gly)
7, 8 
 Antifungal and antibacterial activity 
 Inhibition of adenosine diphosphate (ADP) and 
thrombin induced platelet aggregation  
 Calcium and sodium channel blocking activity    
Cyclo(Gly-Tyr) and cyclo(Gly-Phe)
9, 29 
 Antibacterial activity 
 Inhibition of adenosine diphosphate (ADP) and 
thrombin induced platelet aggregation  
 Calcium and sodium channel blocking activity    
 Inhibition of HT-29, HeLa and MCF-7 tumor 
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cell lines 
 Anticonvulsant activity 
Cyclo(Trp-Tyr) and cyclo(D-Trp-L-Tyr)
10 
 Inhibition of adenosine diphosphate (ADP) and 
thrombin induced platelet aggregation 
 Calcium channel agonistic activity 
 Increased coronary flow rate of isolated rat 
hearts 
 
Cyclo(Met-Trp) and cyclo(Met-Tyr)
11 
 Inhibition of adenosine diphosphate (ADP) and 
thrombin induced platelet adhesion 
 Antifungal and antibacterial activity 
 Calcium and sodium channel blocking activity    
 Cyclo(Met-Trp) Inhibited HT-29, HeLa and 
MCF-7 tumour cell lines 
 
Cyclo(His-Gly) and cyclo(His-Ala)
12 
 Antifungal activity 
 Inhibition of MCF-7 tumour cell lines 
 Cyclo(His-Ala) also inhibited  HT-29 and HeLa 
tumor cell lines 
 Decreased coronary flow rate of isolated rat 
hearts 
  Inhibition of adenosine diphosphate (ADP) 
and thrombin induced platelet aggregation 
 Inhibition of thrombin substrate binding 
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Cyclo(His-Phe) and cyclo(His-Tyr)
13 
 Inhibition of WHCO3, HeLa and MCF-7 tumor cell lines 
 Calcium and sodium channel blocking activity and 
opening of inward rectifying potassium ion channels 
 Cyclo(His-Phe) decreased heart rate and  coronary flow 
rate while  increasing ventricular pressure of isolated rat 
hearts 
 Cyclo(His-Tyr) increased heart rate and ventricular 
pressure of isolated rat hearts 
 Cyclo(His-Tyr) prolonged blood clotting time, slowed clot 
lysis and inhibited ADP-induced platelet adhesion and 
aggregation 
 Antifungal activity 
 Cyclo(His-Tyr) also demonstrated antibacterial activity 
 
 
Cyclo(Gly-Gly), Cyclo(Trp-Trp) and  
Cyclo(Gly-Trp)
14 
 Inhibition of HT-29, HeLa and MCF-7 tumor cell lines 
 Inhibition of adenosine diphosphate (ADP)  induced 
platelet adhesion and aggregation 
 Cyclo(Trp-Trp) also inhibited thrombin induced platelet 
aggregation 
 Cyclo(Gly-Gly) and cyclo(Gly-Trp) demonstrated calcium 
channel agonist activity while cyclo(Trp-Trp) showed 
calcium channel blocking activity 
 Cyclo(Trp-Trp) demonstrated antifungal activity 
Cyclo(L-Gly-L-Val) and cyclo(L-Gly-D-Val)  Antifungal and antibacterial activity 
 Inhibition of HT-29, HeLa and MCF-7 tumor cell lines 
 Decreased heart rate, coronary flow rate and ventricular 
pressure of isolated rat hearts 
 Increased the rate and extend of thrombin formation 
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Cyclo(Gly-Leu) and cyclo(Gly-Ile)
17 
 Antifungal and antibacterial activity 
 Inhibition of HT-29, HeLa and MCF-7 tumor cell lines 
 Inhibition of ADP-induced platelet aggregation and 
fibrinolysis  
 Decreased heart rate, coronary flow rate and ventricular 
pressure of isolated rat hearts 
 
Cyclo(L-Trp-L-Pro), Cyclo(L-Trp-D-Pro),  
Cyclo(D-Trp-L-Pro) and Cyclo(D-Trp-D-Pro)
15 
 Cyclo(L-Trp-D-Pro) and cyclo(D-Trp-L-Pro) 
showed anticancer activity 
 Cyclo(L-Trp-L-Pro) and cyclo(D-Trp-L-Pro) 
inhibited Gram-positive bacteria, cyclo(L-Trp-D-
Pro) inhibited Gram-negative bacteria and 
cyclo(D-Trp-D-Pro) inhibited fungi 
 Cyclo(D-Trp-L-Pro) showed calcium channel 
blocking activity;cyclo(L-Trp-L-Pro) ,cyclo(L-Trp-
D-Pro) and cyclo(D-Trp-D-Pro) showed calcium 
channel agonistic activity 
 Cyclo(L-Trp-D-Pro) showed positive 
chronotropic activity, while cyclo(D-Trp-L-Pro) 
showed negative chronotropic activity of 
isolated rat hearts. Cyclo(L-Trp-D-Pro) and 
cyclo(D-Trp-L-Pro) also increased the coronary 
flow rate of isolated rat hearts 
 Cyclo(L-Trp-D-Pro) inhibited thrombin-induced 
platelet aggregation. All the cyclic dipeptides 
increased ADP induced platelet adhesion, yet 
caused reduced adhesion when the platelets 
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were stimulated by thrombin 
Cyclo(Gly-Thr) and cyclo(Gly-Ser)
18 
 Gram-negative antibacterial activity 
 Inhibition of HT-29 and  HeLa tumor cell lines 
 Cyclo(Gly-Ser) also showed cytotoxic activity 
against MCF-7 cell lines 
 Increased fibrin and thrombin formation 
 Enhanced ADP-induced platelet aggregation 
 Decreased heart rate and ventricular pressure 
of isolated rat hearts 
Cyclo(Trp-Pro) and cyclo(Pro-Trp)
19 
 Antifungal activity 
 Cyclo(Pro-Trp) also demonstrated antibacterial 
activity 
 Anticancer activity 
 Cyclo(Trp-Pro) modulated delayed-rectifier 
potassium and calcium channels 
Cyclo(Leu-Ile)
28 
 Antibacterial activity 
Cyclo(Arg-Lys) and Cyclo(Asp-Lys)
29 
 Immunomodulation 
Cyclo(Ala-Phe)
29 
 Anticonvulsive activity 
Cyclo(Phe-Phe)
29 
 Inhibition of cell division 
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2.4 Motivation for the research 
No investigations have yet been undertaken to determine the biological activity of the 
halogenated cyclic dipeptides, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro). Studies 
on these cyclic dipeptides are therefore warranted. Table 2.4 illustrates some other 
proline- and phenylalanine-containing cyclic dipeptides and their effects on some 
biological systems. 
Table 2.4    Some biologically active Phenylalanine- and Proline-containing cyclic 
dipeptides 
Cyclic dipeptide Cyclo(Tyr-Pro) 
Antimicrobial Showed antimicrobial activity against: Eschericia coli
1, 5
, 
Pseudomonas aerugenosa
1
, Klebsiella pneumonia
1, 5
, Bacillus 
subtilis
5
, Staphylococcus areus
5
, Candida albicans
5 
Anticancer Played a role in the induction of differentiation in HT-29 cancer cell 
lines
1 
Cyclic dipeptide Cyclo(Phe-Pro) 
Antimicrobial Showed broad spectrum antibacterial properties
1, 2, 9 
Anticancer Inhibit ed the growth of HT-29, HeLa and MCF-7. Induced apoptosis 
in HT-29 colon cancer cell lines
1, 2, 9 
Cyclic dipeptide Cyclo(Phe-Phe) 
Anticancer Inhibit ed cell division
5, 9 
Antifungal exhibited broad spectrum antifungal properties
5, 9 
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Cyclic dipeptide Cyclo(Phe-Tyr) 
Anticancer Inhibited HeLa , HT-29 and MCF-7 cells
3 
Cyclic dipeptide Cyclo(Phe-Cys) 
Anticancer Significantly reduced the growth of HeLa , HT-29 and MCF-7 cells
4 
Cyclic dipeptide Cyclo(His-Phe) 
Anticancer Inhibited WHCO3, HeLa and MCF-7 tumor cell lines
7 
 
Antifungal Antifungal activity
7 
 
Cyclic dipeptide Cyclo(D-Trp-L-Pro) 
Anticancer Showed anticancer properties against Hepatocyte cell lines
8 
Antimicrobial Showed activity against Streptococcus
8 
Cyclic dipeptide Cyclo(L-Trp-L-Pro) 
Antibacterial Showed activity against Gram-positive bacteria: S. aureus and 
Streptococcus
8 
Cyclic dipeptide Cyclo(L-Trp-D-Pro) 
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Antibacterial Showed activity against E. Coli
8 
Cyclic dipeptide Cyclo(L-Trp-D-Pro) 
Antibacterial Showed activity against C.albicans
8 
Anticancer Caused the inhibition of HeLa cell lines
8 
Cyclic dipeptide Cyclo(Gly-Phe) 
Haematological Caused the inhibition of endogenous agonists (ADP and thrombin) 
induced aggregation of isolated platelets
6, 9 
Antibacterial Showed the activity against B.Subtilis, E.coli, Klebsiella sp., S.aureus, 
P.aeruginosa
6, 9 
Cyclic dipeptide Cyclo(Phe-Cys) 
Haematological Slowed the rate of clot formation
4 
Antibacterial Showed activity against B.Subtilis
4 
1
(Milne et al., 1998), 
2
(Graz et al., 1999), 
3
(Kilian, 2002), 
4
(Van der Merwe, 2005), 
5
(Graz, 2002),
6
(Olivier, 
2002), 
7
(Mcleland, 2003), 
8
(Jamie, 2002), 
9
(Brauns, 2004) 
As indicated in Table 2.4 phenylalanine- and proline-containing cyclic dipeptides have 
shown potentially promising biological activity, and the biological investigation of 
cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) are therefore warranted. 
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CHAPTER 3 
CYCLIC DIPEPTIDE SYNTHESIS 
3.1 Introduction 
Diketopiperazines (DKPs), the smallest cyclic dipeptides, represent an important class 
of biologically active natural products and research into their characteristics has been 
fundamental to many aspects of peptide chemistry. The advent of combinatorial 
chemistry has revived interest in DKPs for two reasons: firstly, they are simple 
heterocyclic scaffolds in which diversity can be introduced and stereochemically 
controlled at up to four positions; secondly, they can be prepared from readily available 
α-amino acids using robust synthetic procedures (Fischer, 2002). 
Peptides are formed by the condensation of two amino acids under the formation of an 
amide group with the release of water. However, when a carboxylic acid and an amine 
are mixed, an acid-base reaction takes place instead of a covalent bond formation. 
Thus the formation of an amide bond has to overcome unfavourable thermodynamics. 
Therefore the carboxylic acid has to be activated, in order for the amino to attack. A 
range of methods and reagents are used to facilitate the formation of amino bonds 
(Montalbetti and Falque, 2005). Some of the most common methods involve the use of 
carbodiimides, pentaflurophenyl or succinimide esters, uronium or phosphonium 
reagents, symmetrical or asymmetrical anhydrides and acyl chlorides as coupling 
reagents (Montalbetti and Falque, 2005).     
Several methods have been reported for the synthesis of cyclic dipeptides. These 
include (i) heating linear dipeptides in β-napthol (Lichtenstein, 1938), (ii) solid phase 
synthesis (Gisin and Merrifield, 1972), (iii) acetic acid catalysed synthesis (Suzuki et al., 
1998), (iv) boiling the formate salts of dipeptide methyl esters in a neutral solvent for 3 
hours (Nitecki et al., 1968) and (v) heating linear dipeptides in phenol (Kopple and 
Ghazarian, 1968). 
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The formation of the DKP rings, like any other cyclisation procedure, requires the 
generation of mutually reactive chain-ends and the reaction of these ends under 
conditions favouring intramolecular processes. The mutually reactive ends are 
commonly free amino acids groups that are not reduced in nucleophilicity by protonation 
or substitution, and carboxyl groups that are activated to be susceptible to nucleophilic 
attack (Bodanszky, 1993; Bodanszky, 1988). 
Although many novel approaches have been developed to accomplish the head-to-tail 
synthesis of peptides, one of the most commonly used methods is still the solution-
phase synthesis using peptide-coupling reagents. A rational selection of coupling 
reagents can effectively improve the results of peptide cyclisation (Peng and Roller, 
2002; Loughlin et al., 2000). Solution-phase cyclisation of dipeptides can be achieved 
by utilising unprotected linear dipeptides or protected linear dipeptide esters (Lambert et 
al., 2001).  
DKP rings may be produced without great difficulty and may also form without particular 
activation of the carboxyl groups of linear dipeptide precursors (Bodanszky, 1993). 
Kopple and Ghazarian (1968) reported an efficient method for the cyclisation of linear 
dipeptides without particular activation of their carbonyl groups. They described the 
formation of cyclic dipeptides by heating the unprotected linear dipeptide in phenol. This 
relatively fast three hour procedure produced high yields of cyclic dipeptides, with little 
racemisation. It is however necessary for at least one of the amino acid residues of the 
free linear dipeptide to be sensitive to phenol for the cyclisation procedure to occur 
(Kopple and Ghazarian, 1968). 
Cyclisation of some linear dipeptides may be an inherently improbable and slow 
process, and the exposure to reagents necessary for the cyclisation may lead to 
extensive racemisation when optically pure linear dipeptide precursors are utilised 
(Nitecki et al., 1968). This racemisation can be avoided by protecting the amino and 
carboxyl terminals of the dipeptide precursors with blocking groups, which are capable 
of being selectively removed when necessary (Kopple, 1972). Among other blocking 
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groups (Han and Kim, 2004), tert-butyloxycarbonyl (t-Boc) has been used to protect the 
amino groups of linear dipeptide precursors (Nitecki et al., 1968). Nitecki et al. (1968) 
reported a method for the cyclisation of the formate salts of dipeptide methyl esters. The 
formate salts were formed as a result of successful deblocking t-Boc dipeptides with 
formic acid (98%) at room temperature for three hours. Subsequent heating of the 
deblocked dipeptides in a neutral medium resulted in the formation of sterically pure 
cyclic dipeptides. The procedure decreased racemisation and improved the yields of 
acetic sensitive amino acids (Nitecki et al., 1968).    
3.2 Methodology   
The cyclic dipeptides were synthesised according to a modified method as developed 
by Milne et al. (1992). The tert- butyloxycarbonyl group (t-Boc) is the most common 
amino protecting group and is distinguished from the other amino protecting groups 
(e.g., Trityl) in its ability to show selectivity of the removal by trifluoroacetic acid 
(Jakubke and Jeschkeit, 1997). According to Milne et al. (1992), the t-Boc group of the 
ester can be removed by dissolving the compound in formic acid (20 ml) and anisole 
(0.2 ml) which is then stirred for three hours at room temperature and dried in vacuo 
leading to the formation of a formate ester. Both cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-
4Cl-Pro) will be synthesised using phenylalanine as the primary amino acid component 
(amino component protected by N-t-butyloxycarbonyl (t-Boc)) and proline as the 
secondary amino acid component (carbonyl component protected by methyl ester), 
resulting in the protected linear dipeptides. The t-Boc group was then removed followed 
by boiling in a neutral medium (Sec-butanol and toluene 4:1) giving rise to cyclo(Phe-
4Cl-Pro) and cyclo(D-Phe-4Cl-Pro).    
High performance liquid chromatography (HPLC) (Shimadzu, Japan) and thin layer 
chromatography (TLC) (Rf values for each compound was calculated) was performed to 
confirm the purity of the compounds. HPLC, like other forms of chromatography, is 
essentially a technique for the separation of chemical compounds in mixtures by a 
continuous distribution of the components between two phases: a mobile phase and a 
stationary phase. The simplicity and rapidity of TLC makes it a useful tool to monitor the 
40 
 
progress of organic reactions and to check the purity of the products (Skoog et al., 
2001). 
3.2.1 Synthesis of the linear dipeptides 
All reagents used were of reagent grade. Starting amino acids (Indicated in Figure 3.1) 
(FLUKA (PTY) LTD, SA) were tert-butyloxycarbonyl phenylalanine (N-t-boc-L-Phe-4Cl 
or N-t-boc-D-Phe-4Cl) (Molecular weight = 299.75) and proline methyl ester (L-Pro-
OMe) (Molecular weight = 165.62). 
N
H
OMe
O
Proline methyl ester
Cl
O
OHNH
O
O
CH3
CH3
CH3
Boc
 
Figure 3.1    Protective groups used in the synthesis of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
(Method according to Milne et al., 1992). 
According to the method of Milne et al. (1992): 
N-t-Boc-L-Phe/ N-t-Boc-D-Phe (2 g, 6.57 mmol) and 1.10 g of L-Pro-OMe (6.67 mmol) 
were dissolved in 40 ml of 1,2-dimethoxyethane at 0 ˚C.  
DEPC (diethylphosphoryl cyanide) (1.11 ml, 7.60 mmol) and triethylamine (1.91 ml, 
13.71 mmol) were added drop wise to the above mixture and stirred for 1 hour at 0 ˚C, 
after which it was allowed to reach room temperature.  
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The entire reaction was carried out in a positive inert atmosphere (N2) and complete 
dipeptide formation was observed after a further 4 hours stirring at room temperature. 
The reaction mixture was then diluted to 250 ml with chloroform and successively 
washed with 50 ml of a 5% hydrochloric acid solution, 50 ml of aqueous sodium 
hydrogen carbonate and 50 ml of saturated brine solution. 
Removal of the solvent phase with the aid of vacuum yielded the protected dipeptide as 
a colourless viscous liquid of a syrup consistency. Figure 3.2 illustrates the mechanism 
of the reaction. 
Cl
O
OHNHBoc
N OMe
O
H
Cl
O
-
OHNHBoc N OMe
O
H
N-t-Boc-Phe
Pro-OMe
N-t-Boc-Phe-Pro-OMe
Cl
NH
BOC
O
N
O
OMe
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Figure 3.2    Synthesis of the protected linear dipeptide ester (Adapted from Milne et al., 1992). 
3.2.2 Removal of the protective Boc group  
The N-t-Boc dipeptide ester was dissolved in formic acid (20 ml) containing anisole (0.2 
ml) and stirred for 3 hours at room temperature. The reaction mixture was then dried in 
vacuo. The removal of the Boc group led to the formation of a formate ester product 
(Figure 3.3). 
Cl
HCOO 
-
 NH3
+ O
N
O
OMe
 
Figure 3.3    Formate ester product (Adapted from Milne et al., 1992). 
3.2.3 Cyclisation 
A volume of 40 ml sec-butanol and toluene mixture (4:1, V/ V) was added to the residue 
containing the crude dipeptide formate ester and the solution was refluxed in a oil bath 
for 3 hours at 120 ˚C. After 3 hours the solvent was evaporated off until about 8 ml were 
left. This concentrated solution was then cooled to 0 ˚C. This resulted in the 
precipitation of the cyclic dipeptide which was then filtered out and washed with ether. 
Recrystallisation from MeOH/ether gave rise to crystals for both cyclo(Phe-4Cl-Pro) and 
cyclo(D-Phe-4Cl-Pro). Figure 3.4 mechanistically illustrates the cyclizsation of the linear 
L-or D-Phe-4Cl-Pro formate esters to the respective cyclic compounds.  
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Figure 3.4    Mechanism of cyclisation of the linear dipeptide formate ester to cyclo(Phe-4Cl-Pro)  
(Adapted from Capasso et al., 1998). 
3.3 Results and Discussion 
The yields obtained after the cyclisation of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-
Pro) are summarised in Table 3.1 
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Table 3.1    Relative yields for (Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
Compound Percentage yield (neutral medium cyclisation)  
Cyclo(Phe-4Cl-Pro) 54% 
Cyclo(D-Phe-4Cl-Pro). 62% 
 
3.4 Thin layer chromatography 
Purity of the compounds was assessed by thin layer chromatography (TLC) in two 
different solvent systems. Table 3.2 lists the mobile phase ratio compositions and the Rf 
values obtained. 
Table 3.2    Mobile phase ratio compositions and the R f  values obtained for (Phe-4Cl-Pro) 
and cyclo(D-Phe-4Cl-Pro) 
Compound Mobile phase Ratios Rf 
cyclo(Phe-4Cl-
Pro) 
Chloroform/MeOH 
Chloroform/MeOH/AcOH 
32%      
7/3 
14/2/1 
0.81 
0.91 
cyclo(D-Phe-4Cl-
Pro). 
Chloroform/MeOH 
Chloroform/MeOH/AcOH 
32%      
7/3 
14/2/1 
0.75 
0.76 
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No signs of unwanted by-products were visualised by way of TLC, with only a single 
spot being recorded consistently. The cyclisation method produced high yields of both 
cyclic dipeptides. 
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3.5 High-performance liquid chromatography 
3.5.1 Introduction 
Today high-performance liquid chromatography (HPLC) is the most versatile and widely 
used type of elution chromatography. It is a broadly applicable and valuable analytical 
tool for scientist in a number of diverse fields. This can mainly be attributed to its 
sensitivity, its high resolution and speed of analysis, its ready adaptability to accurate 
quantitative determinations, its ease of automation, its suitability for separating 
nonvolatile species or thermally fragile ones, HPLC columns can also be reused without 
repacking or regeneration and reproducibility is greatly improved as the parameters 
affecting the efficiency of the separation can be closely controlled. HPLC is ideally 
suited for the separation and identification of amino acids, carbohydrates, lipids, nucleic 
acids, proteins, pigments, steroids, pharmaceuticals, and many other biological active 
molecules (Skoog et al., 2004). 
HPLC is used in analytical development to quantify the active pharmaceutical ingredient 
(API) and to evaluate impurity and degradation products profile of drug substances and 
drug products. Additional uses of HPLC include the determination of content uniformity 
of dosage forms, monitoring of dissolution profiles, determination of antioxidant and 
microbial preservative content, and to support cleaning evaluations (Ahuja and Dong, 
2005). 
Column chromatography methods can generally be classified into Gas chromatography 
(GC) and Liquid chromatography (LG). In liquid chromatography, the mobile phase is a 
liquid solvent containing the sample as a mixture of solutes. HPLC can be classified by 
the separation mechanism or by the type of stationary phase. These include: partition or 
liquid-liquid chromatography, adsorption or liquid-solid chromatography, ion-exchange 
or ion chromatography, size-exclusion chromatography, affinity chromatography and 
chiral chromatography (Skoog et al., 2004). 
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The rapid advancement in peptide research over the past 25 years must be attributed, 
in part, to the effectiveness of HPLC, particularly reversed-phase chromatography 
(RPC) (Gazes, 2001). Normal phase separations (adsorption) are performed on a 
adsorbent (silica Gel; Alumina) column and a non-polar mobile phase, where as 
reversed phase separations are done on a non-polar column with a polar mobile phase. 
If the components to be separated are soluble in relatively polar solvents say 
H2O/MeOH systems RPC method can be utilised by selecting a polar mobile phase e.g., 
H2O/MeOH and a non-polar stationary phase e.g., μ BONDPAK C18. Conversely, if the 
solutes are insoluble in polar solvents, a non-polar mobile phase with a polar column 
packing is selected e.g., n-Hexane/THF/CHCl3 and μ Porasil. RPC has found both 
analytical and preparative applications in the area of biochemical separation and 
purification. Molecules that possess some degree of hydrophobic character, such as 
proteins, peptides and nucleic acids, can be separated by RPC with excellent recovery 
and resolution (Ahuja and Dong, 2005). 
In normal-phase chromatography the least polar component is eluted first, thus 
increasing the polarity of the mobile phase and decreasing the elution time. Conversely 
in reversed-phase chromatography the most polar component elutes first, increasing the 
mobile-phase polarity and elution time. Other advantages of reverse-phase 
chromatography are that water, an inexpensive, nontoxic, UV-transparent solvent 
compatible with many biological solutes, can be used as the mobile phase, the ability to 
change the composition of the mobile phase to accommodate a wide variety of solutes. 
Increased mass transfer speed and solvent equilibration is also reached more rapidly 
(Skoog et al., 2004). 
In order to fully understand the fundamentals of HPLC we must first look at what 
chromatography entails. Chromatography can be defined as a separation process in 
which the sample mixture is distributed between two phases in the chromatographic bed 
(column or plane). One phase is stationary whilst the other passes through the 
chromatographic bed. The stationary phase is either a solid, porous, surface-active 
material in small-particle form or a thin film of liquid coated on a solid support or column 
48 
 
wall. The mobile phase is a gas or liquid. If a gas is used, the process is known as gas 
chromatography (GC); the mobile phase is always liquid in all types of liquid 
chromatography (LC) (Meyer, 2004). 
Martin and Synge, The inventors of modern chromatography, were aware as far back as 
1941 that, in theory, the stationary phase requires very small particles and hence a high 
pressure is essential for forcing the mobile phase through the column. As a result, 
HPLC is sometimes referred to as high-pressure liquid chromatography (Meyer, 2004). 
HPLC differs from the classical LC in that many aspects of the separation system have 
been optimised to provide increased speed, resolution and sensitivity (Pieper and 
Rutledge, 1989). These advantages of HPLC are the result of two major advances. 
Firstly, the development of stationary supports with very small particle sizes and large 
surface areas, and secondly, the improvement of elution rate by applying high pressure 
to solvent flow. A combination of the application of high pressure and adsorbents of 
small particle size leads to high resolving power and a short period of time is needed for 
analysis. Pumping pressures of several hundred atmospheres are required to achieve 
reasonable flow rates with packaging, of adsorbents, in the 3 to 10 μm size range. 
HPLC is thus a separation technique conducted in the liquid phase in which a sample is 
separated into its constituent components (or analytes) by distributing between the 
mobile phase (i.e., a flowing liquid) and a stationary phase (i.e., adsorbents packed 
inside a column). An online detector monitors the concentration of each separated 
component (or contaminant) in the column effluent and generates a chromatogram 
(Ahuja and Dong, 2005). 
3.5.2 Methodology 
3.5.2.1 Preparation of solutions 
Stock solutions containing 2 mM of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) were 
prepared. All chemicals used were either of analytical or HPLC grade. All water 
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containing solutions required for analysis were prepared by utilising analytical grade 
water (AGW) obtained from an ultra clear TWF UF TM Reverse Osmotic water 
purification system SG®. Acetonitrile, for the preparation of the mobile phase, were 
obtained from Sigma Chemicals Co., USA. The mobile phases for the respective cyclic 
dipeptides were prepared according to the formulae indicated in Table 3.3. The mobile 
phase and cyclic dipeptide solutions were filtered through 0.45 µm (Millipore™, USA) 
and 0.22 µm Millipore™, USA), filters respectively, prior to use. 
Table 3.3    Formulas for the preparation of the mobile phases  
Cyclic dipeptide % Acetonitrile % Water 
Cyclo(Phe-4Cl-Pro) 31% 69% 
Cyclo(D-Phe-4Cl-
Pro) 
28% 72% 
The Mobile phases were prepared with boiled, carbondioxide-free, AGW water  
3.5.2.2 HPLC analysis of the cyclic dipeptides  
HPLC analysis of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) were carried out on a 
Shimadzu LC2020 analytical liquid chromatography system fitted with a photoiodide 
array (PDA) detector (Shimadzu, Tokyo, Japan). As this analysis was performed using a 
PDA detector, purity of the peak could also have been determined using the peak purity 
curve, which the software generated automatically. The analyses were performed using 
a 4.6 x 150 mm, 5 µm reverse phase Atlantis® dC18 column (Waters®, Ireland). To 
standardise sample delivery, analyses were performed by initial injection of a 20 µl 
sample solution and using a constant flow rate of 1.0 ml/min for optimal resolution. 
UV detection was at 220 nm (Gazes, 2001) for cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-
4Cl-Pro). 
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3.5.2.3 Results and discussion 
The detectability of peptides varies greatly, depending on their amino acid composition. 
The aromatic amino acids (eg., tyrosine, tryptophan, and phenylalanine) offer selective 
detection by UV light at 280 nm and 254 nm. In the absence of these amino acids, low 
wavelength (< 220 nm), which also detected many other substances, including 
components of the mobile phase, must be used (Gazes, 2001). UV detection of 
cyclo(Phe-4Cl-Pro) and  cyclo(D-Phe-4Cl-Pro) was at 220 nm. 
The observed HPLC chromatograms, indicating the retention times (tR), for cyclo(Phe-
4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) are illustrated in Figures 3.5 and 3.6, respectively. 
The HPLC chromatograms for both cyclic dipeptides show single peaks with high 
resolution, indicating that the cyclic dipeptides were free from impurities. Further 
structural elucidation studies, including infrared spectroscopy, mass spectrometry, 
molecular modeling and nuclear magnetic resonance spectroscopy are, however, 
necessary to ultimately confirm the structure and presence of the cyclic dipeptides. The 
peaks observed at ± 2.1 are the void volume.  
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Figure 3.5    The HPLC chromatogram of cyclo(D-Phe-4Cl-Pro) (tR = 5.40 minutes) at UV detection 
wavelength of 220 nm  
 
Figure 3.6    The HPLC chromatogram of  cyclo(Phe-4Cl-Pro) (tR = 5.39 minutes) at UV detection 
wavelength of 220 nm  
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CHAPTER 4 
QUALITATIVE PHYSIOCHEMICAL ANALYSIS 
Qualitative analysis and evaluation of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
was performed using scanning electron microscopy, thermal analysis and X-ray powder 
diffraction. 
4.1 Scanning electron microscopy 
4.1.1 Introduction 
Physical characterisation of pharmaceutical solids is fundamental in the drug 
development process. Surface topography of drugs is of significant interest to science, 
technology and industry (Castle and Zhdan, 1997; Laitinen, 2003). 
Optical microscopy used to be the conventional method for obtaining detailed 
information about the physical nature of surfaces, it is still an important technique. 
However the resolution of optical microscopy is limited by diffraction effects to about the 
wavelength of light. Much higher resolution information is obtainable by using one of the 
electron microscopic methods (scanning electron microscopy (SEM) or transmission 
electron microscopy). SEM provides images of external morphology, similar to those 
accessed by the human eye (Skoog et al., 2004). 
SEM can reveal topographical details of a surface with clarity and detail, which cannot 
be obtained by any other means. It can also detect surface potential distributions, 
subsurface conductivity, surface luminescence, surface composition and 
crystallography (Hayat, 1974).   
In obtaining an SEM image, the interaction of the primary electron beam with the 
sample surface is accompanied by the formation of a flux of secondary and back-
scattered electrons that are collected by detectors. Secondary electrons formed near 
the impact area of the primary electron beam are used to produce images with a spatial 
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resolution closely related to the cross-sectional area of the scanning beam of electrons. 
The intensity of the emitted electrons in a material of a given homogeneous composition 
depends on the local angle of the surface to the scanning beam moderated by the 
probability of them reaching the detector. The three dimensionality of a typical scanning 
electron micrograph is subjective, but can be used for obtaining topographic information 
of surfaces (Skoog et al., 2004). 
The major advantages of scanning electron microscopy (SEM) characterisation of 
materials are the presence of several modes that can provide important complimentary 
information on various properties of materials, and in most cases its ability to examine 
macroscopic specimens with no special sample preparation steps (Yacobi et al., 1994).  
4.1.2 Methodology 
The scanning electronmicrographs of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
were recorded on a Philips® XL30 Scanning Electron Microscope (Philips®, UK). A 
portion of each respective cyclic dipeptide was mounted on carbon tags on a sample 
stub using conductive adhesive glue. The mounted specimens were then sputter coated 
with a thin layer of gold using a Novotech® SEM prep 2-sputter coater (Novotech®, 
Germany). Electronmicrographs were then recorded, showing the typical shape and the 
surface topography of the crystals (Skoog et al., 2004; Van der Merwe, 2005). 
4.1.3 Results and discussion 
The electronmicrographs for cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) are 
illustrated in Figures 4.1 to 4.4. The electronmicrographs show the shape and surface 
topography of the cyclic dipeptides. Six crystal systems are known, which are commonly 
referred to as cubic, tetragonal, orthorhombic, monoclinic, triclinic, and hexagonal. 
Crystal morphology occurs as a result of molecular arrangement. The molecular 
arrangements are predetermined for a specific polymorphic form, and cannot be 
changed provided that there are no changes in the polymorphic form. Five types of 
crystal habits are recognized, which can occur in any crystal system. The crystal habits 
are referred to as tubular (moderate expansion of two parallel faces), platy (plates), 
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prismatic (columns), acicular (needle-like) and bladed (flat acicular) (Aulton, 2002). The 
crystal habit is the macromolecular appearance of a crystal. It depends on conditions of 
crystallisation and can change without change in physical characteristics. The crystals 
of both cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) were obtained via identical 
synthetic pathways. Cyclo(Phe-4Cl-Pro) (Figures 4.1 and 4.2) appears to form a platy 
(plates) crystal habit predominantly, whereas cyclo(D-Phe-4Cl-Pro) (Figures 4.3 and 
4.4) form an prismatic (columns) crystal habit. The surface area of undissoloved solid 
paricles is influenced by the size of the solid particles. The surface area is universily 
proportional to particle size. The particle shape may influence pharmaceutical 
processes such as powder flow and compressability. Fine particles with with very high 
surface to mass ratios are more cohesive compared to coarser particles, which are 
influenced more by gravitational forces. Particles larger than 250 µm are relatively free 
flowing, but sizes below 100 µm powders become cohesive and flow problems tend to 
occur. Powders with similar partile sizes, but dissimilar shapes can have slightly diffirent 
flow properties, due to diffirences in interpartile contact areas (Skoog et al., 2004). 
      
Figure 4.1    Electronmicrograph of cyclo(Phe-4Cl-Pro) with a magnification of 250x 
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Figure 4.2    Electronmicrograph of cyclo(Phe-4Cl-Pro) with a magnification of 2000x 
 
.  
Figure 4.3    Electronmicrograph of cyclo(D-Phe-4Cl-Pro) with a magnification of 250x 
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Figure 4.4    Electronmicrograph of cyclo(D-Phe-4Cl-Pro) with a magnification of 2000x 
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4.2 Thermal analysis 
Thermal analyses compromise a family of techniques whereby a physical property (i.e. 
heat flow, weight loss) is measured as a function of temperature or time. It is a general 
term covering a group of related techniques whereby the dependence of the parameters 
of any physical property of a substance on temperature is measured. The physical 
parameter is determined as a dynamic function of temperature. Measurements made at 
fixed or isothermal temperatures are normally not included. Using the definition, the 
principal thermal analysis techniques are thermogravimetry and differential thermal 
analysis (Sichina, 2001). 
The development and manufacturing of drugs requires that close attention to be paid to 
purity, quality, stability and safety in order to assure that the drug performs as intended. 
Pharmaceuticals or organic compounds have a propensity to exist in different structural 
or morphological forms and this gives rise to concerns over processing, long-term 
stability, aging and biodelivery. Due to the complexity of the formulation of 
pharmaceutical material, it becomes important to have a complete understanding of the 
properties of pharmaceutical materials. One of the best analytical techniques for 
characterisation of pharmaceutical material is thermal analysis. Two most widely used 
thermal analytical techniques for the characterisation of pharmaceuticals are differential 
scanning calorimetry and thermogravimetric analysis (Sichina, 2001).  
4.2.1 Thermogravimetric analysis and derivative thermogravimetry 
4.2.1.1 Introduction  
The thermal analysis technique of thermogravimetry (TG) is one where the change in 
sample mass (loss or gain) in a controlled atmosphere, is determined as a function of 
temperature or time (Skoog et al., 2004). Derivative thermogravimetry (DTG) is a 
method of expressing the results of TG by giving the first derivative curve as a function 
of temperature or time (Dodd and Tonge, 1987). This provides quantitative information 
on weight change processes, and enables the stereochemistry of a reaction to be 
followed directly, e.g., reactant (solid) → product (solid) + gas (Leung and Grant, 1997; 
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Dodd and Tonge, 1987). It is also easier to compare the shape or overlap of DTG 
curves with other differential measurements such as DSC. The use of DTG improves 
the resolution of complex or overlapping TG curves, thus providing additional 
information about decomposition or mass loss phenomena of compounds (Sichina, 
2001).  
In Thermogravimetric analysis (TGA) a sample is placed into a tared TGA sample pan 
which is attached to a sensitive microbalance assembly. The sample holder portion of 
the TGA balance is subsequently placed into a high temperature furnace. The balance 
assembly measures the initial sample weight at room temperature and then 
continuously monitors changes in sample weight as heat is applied to the sample. TGA 
tests may be run in a heating mode at a controlled heating rate, or isothermally. 
Dynamic TG, in which the sample is heated in an environment whose temperature, is 
changing in a predetermined manner, preferably linear, is a common mode of TG 
(Brown, 1998; Wendlandt, 1986). 
The resulting mass change versus temperature curve, also known as a thermogram, 
provide information concerning the thermal stability and composition of the initial 
sample, the  thermal stability and composition of any intermediate compounds that may 
be formed, and the composition of the residue, if any ( Wendlandt, 1986). Typical weight 
loss profiles could therefore be analysed to determine the amount or percent of weight 
loss at any given temperature, the amount or percent of non-combusted residue at 
some final temperatures, and the temperatures of various sample degradation 
processes (Brown, 1998). 
4.2.2 Differential scanning calorimetry 
4.2.2.1 Introduction 
DSC is a thermal analysis technique which has been used for more than two decades to 
measure the temperatures and heat flows associated with transitions in materials as a 
function of time and temperature. Such measurements provide quantitative and 
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qualitative information about physical and chemical changes that involve endothermic or 
exothermic processes, or changes in heat capacity (TA211, 2002). 
DSC is one of the most widely used thermal analysis techniques for the characterisation 
of pharmaceutical solids. Thermal events such as melting, recrystallisation, 
decomposition, and glass transitions can be measured with it. Additionally, quantitative 
mixture analysis (e.g., to establish the presence of different polymorphs) can be 
performed utilising DSC. The use of modulated DSC expands the capabilities of DSC 
and allows one to measure heat capacities and characterise reversible and non-
reversible thermal transitions (Sichina, 2001).        
DSC records the energy necessary to establish a zero temperature difference between 
a substance and a reference material against either time or temperature, as the two 
specimens are subject to identical temperature regimes in an environment heated or 
cooled at a controlled rate (Pope and Judd, 1977). 
When a thermal transition occurs in a sample, thermal energy is added to either the 
sample or the reference containers in order to maintain both the sample and reference 
at the same temperature. The balancing of energy yields a calorimetric measurement of 
the transition energy, because the energy transferred is exactly equivalent to the energy 
absorbed or evolved in the transition (Dodd and Tonge, 1987). 
Thermal transition events in the sample thus appear as deviations from the DSC 
baseline, in either a endothermic or exothermic direction, depending upon whether more 
or less energy has to be supplied to the sample relative to the reference material 
(Brown, 1998). 
4.2.3 Methodology 
The TGA and DSC thermograms for cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) were 
obtained by heating the samples in a TA Instruments Q600 SDT (simultaneous DSC-
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TGA) V8.3 (TA Instruments, USA). The TA Instruments Q600 SDT was calibrated for 
temperature using the melting points of indium and tin. Cyclo(Phe-4Cl-Pro) (2.710 mg) 
and cyclo(D-Phe-4Cl-Pro) (2.472 mg) were heated in open aluminium crucibles at a 
heating rate of 5 °C per minute, over a temperature range of 50 to 400 °C, with nitrogen 
as the purging gas (flow rate of 50 ml per minute). 
4.2.4 Results and discussion 
In all TGA thermograms the region x (as shown in the thermograms below) indicates a 
loss of weight. This could be free water, waters of hydration, or loss of solvent. This is 
followed by a weight loss portion (region y), indicating a melt. The inflection (region Z) 
indicates a change in the rate of decomposition. 
In the TGA thermogram (Figure 4.5) the plateau of constant weight (region x) indicated 
free water or waters of hydration, coming of above 100 ˚C. A small decrease in the TGA 
curve is seen at 100 ˚C. The corresponding DSC peak relates to this enthalpy of 
hydration. The onset of the narrow endotherm starts at 172.71 ˚C, corresponding to the 
melting point of cyclo(Phe-4Cl-Pro) . The dipeptide started to decompose soon after the 
melting point.    
A loss of mass in the TGA thermogram (Figure 4.6) at around 50 ˚C is observed. This 
can be associated to the presence of acetone, an indication that the compound was not 
dried properly. The onset point of the narrow endotherm starts at 174.06 ˚C, 
corresponding to the melting point of cyclo(D-Phe-4Cl-Pro) . From the spectrum it is 
very clear that the dipeptide started to decompose soon after the melting point.   
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Figure 4.5    Simultaneous DSC-TGA thermogram of cyclo(Phe-4Cl-Pro) 
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Figure 4.6    Simultaneous DSC-TGA thermogram of cyclo(D-Phe-4Cl-Pro) 
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structure of materials (Pecharsky and Zavalij, 2005). 
Much of what is known about the arrangement and the spacing of atoms in crystalline 
materials has been determined directly from diffraction studies. XRPD provides a 
convenient and practical means for the qualitative identification of crystalline 
54.80°C 
37.44°C 
89.14J/g 
176.74°C 
174.06°C 
149.7J/g 
-2 
-1 
0 
1 
2 
Heat Flow (W/g) 
-20 
0 
20 
40 
60 
80 
100 
Weight (%) 
0 50 100 150 200 250 300 350 400 
Temperature (°C) 
Sample: Cyclo(D-phe-4Cl-pro) 
Size:  2.2260 mg 
Method: Temperature 
DSC-TGA 
File: H:...\Cyclo(D-phe-4Cl-pro).001 
Operator: Teboho/Thabo 
Run Date: 18-Aug-2010 11:45 
Instrument: SDT Q600 V8.3 Build 101 
Exo Up Universal V4.2E TA Instruments 
Y 
Z 
         X 
63 
 
compounds. It is the only analytical method that is capable of providing qualitative and 
quantitative information about the compounds present in a solid sample (Skoog et al., 
2004).    
 XRPD materials analysis involves characterisation of the sample by means of atomic 
arrangements in the crystal lattice. XRPD uses single or multiphase specimens, 
comprising of a random orientation of small crystallites, each of the order of 1-50 µm in 
diameter. Each crystallite, in turn, is made up of a regular, ordered array of atoms. An 
ordered arrangement of atoms (the crystal lattice) contains planes of high atomic 
density which in turn means planes of high electron density. A monochromatic beam of 
X-ray photons will be scattered by these atomic electrons and if the scattered photons 
interfere with each other, diffraction maxima may occur. A diffraction pattern is typically 
in the form of a graph of diffraction angle (or inter planar spacing) against diffracted line 
intensity. The pattern is made up of a series of super-imposed diffractograms, one for 
each unique phase in the specimen. Each of the unique patterns can act as an 
empirical “fingerprint” for the identification of various phases (Meyers, 2000). 
Although powder data usually lack the three dimensionality of a diffraction image, the 
fundamental nature of the method is easily appreciated from the fact that each powder 
diffraction pattern represents a one-dimensional snapshot of the three-dimensional 
reciprocal lattice. The quality of the powder diffraction pattern is usually limited by the 
nature and the energy of the available radiation, by the resolution of the instrument and 
by the physical and chemical conditions of the specimen (Pecharsky and Zavalij, 2005). 
Of all the methods available to the analytical chemist, only X-ray diffraction is capable of 
providing general purpose qualitative and quantitative information on the presence of 
phases in an unknown mixture. A diffraction pattern contains a good deal of information 
of which three parameters are of special interest: 
 The position of the diffraction maxima. 
 The peak intensities. 
64 
 
 The intensity distribution as a function of diffraction angle. 
These three species of information can, in principle, be used to identify and quantify the 
contents of the sample, as well as to calculate the material‟s crystallite size and 
distribution, crystallinity, stress and strain (Meyers, 2000). 
The role of XRPD for identification of unknown chemicals is limited in the 
pharmaceutical industry, since there are numerous techniques available for determining 
molecular structure of organic molecules. The techniques of mass spectrometry and 
nuclear magnetic resonance are predominant in this role. On the other hand, due to its 
speed of data acquisition and sensitivity XRPD exists as the primarily tool for phase 
identification (Stephenson, 2005; Beckers, 2004). While it does serve as a means for 
identification of primarily inorganic unknowns, by non-destructively determining the 
crystallographic constitution of samples, XRPD is used to: 
 Determine crystal structures. 
 Screen for polymorphs or hydrates. 
 Detect changes in morphology or crystalline state of active ingredients (e.g., 
during processing or at non-ambient conditions).  
 Detect and quantify crystalline impurities (in some cases down to 0.05%). 
 Determine the crystallinity or the crystallite size of a compound. 
 Analyse and optimise final dosage forms. 
XRPD data on a compound or drug is also required for new product registration and 
patent application/protection (Litteer and Beckers, 2005).  
4.3.2 Methodology 
XRPD patterns for cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) were obtained by 
using an Bruker Advanced Solutions XRD Commander (Diffracplus Version 2.3) 
diffractometer (Bruker Advanced Solutions, Germany), and the resultant diffraction 
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patterns were interpreted using Bruker Advanced X-ray Solutions Eva Software 
(Diffracplus Version 10.0 Rev.1). n-Hexane (BD Laboratory Supplies, England) was used 
as a wetting agent, which enabled small samples of the cyclic dipeptide to adhere to 
silicon plates, without causing dissolution of the compounds. The silicone plates were 
then placed within the X-ray powder diffractometer and scanned for 1 hour. 
4.3.3 Results and discussion  
The diffraction patterns obtained from powdered samples can only be identified when 
compared alongside the diagrams of known substances until a match is obtained 
(Willard et al., 1998).  
The XRPD patterns of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) are illustrated in 
Figures 4.7 and Figures 4.8, respectively. Determining the phase composition of the 
cyclic dipeptides was not possible, since none of the powder diffraction databases 
available included experimental diffraction patterns to which the compounds could be 
compared. Since the obtained Bragg angles and intensities of the cyclo(Phe-4Cl-Pro) 
and cyclo(D-Phe-4Cl-Pro) have no known match, the collected data can potentially be 
used as a “fingerprint” to identify new crystalline substances. The identity of the cyclic 
dipeptides should, however, firstly be confirmed through structural elucidation to ensure 
that it is not a mixture of compounds. 
From the diffraction patterns of both cyclic dipeptides it can be seen that they are 
crystalline solids, since the curve of scattered intensity versus 2θ for crystalline solids is 
zero everywhere except at certain angles where sharp maxima occur. 
Both morphous solids and liquids have structures characterised by an almost complete 
lack of periodicity and tendency to order. The atoms in amorphous structures also show 
preference for a particular interatomic distance, resulting in x-ray diffractograms 
exhibiting only one or two broad maxima.   
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Figure 4.7    X-ray powder diffraction pattern of cyclo(Phe-4Cl-Pro)    
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Figure 4.8    X-ray powder diffraction pattern of cyclo(D-Phe-4Cl-Pro)    
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CHAPTER 5 
STRUCTURAL AND CONFORMATIONAL ANALYSIS 
Structural and conformational analysis of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
was performed using infrared spectroscopy, mass spectrometry, molecular modelling 
and nuclear magnetic resonance spectroscopy. 
5.1 Infrared spectroscopy  
5.1.1 Introduction 
Infrared spectroscopy (IR) is a technique based on the vibrations of the atoms of a 
molecule. It involves the examination of the twisting, bending, rotating and irrational 
motions of atoms in a molecule. IR spectroscopy has been extensively used in both 
qualitative and quantitative pharmaceutical analysis. All molecular species, with the 
exception of O2, N2, CL2 and H2 absorb infrared radiation (Skoog et al., 2004). Many 
functional groups in organic molecules show characteristic molecular vibrations and 
rotations, which correspond to absorption bands in defined regions of the infrared 
spectrum. These molecular vibrations are localised within the functional groups and do 
not extend over the rest of the molecule. Thus such functional groups can be identified 
by their absorption bands (Stuart, 2004). 
An IR spectrum is commonly obtained by passing IR radiation through a sample and 
determining what fraction of the incidence radiation is absorbed at a particular energy. 
The energy at which any peak in an absorption spectrum appears corresponds to the 
frequency of a vibration of a part of a sample molecule (Stuart, 2004).The wave 
number, expressed in centimeter units (cm-1), is the reciprocal of the wavelength in 
centimeters, i.e., Wave number = 1/λ (cm) (McMurry, 2008). Polar bonds are associated 
with strong IR absorption while symmetrical bonds may not absorb at all. The vibrational 
frequency, i.e., the position of the IR bands in the spectrum, depends on the nature of 
the bond. Shorter and stronger bonds have their stretching vibrations at the higher 
energy end (shorter wavelength) of the IR spectrum than the longer and weaker bonds. 
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Similarly, bonds to lighter atoms, e.g., hydrogen, vibrate at higher energy than bonds to 
heavier atoms (Field et al., 2001).    
Fourier-transform infrared (FTIR) spectroscopy is based on the interference of radiation 
between two beams to yield an interferogram. The latter is a signal produced as a 
function of the change of pathlength between the two beams. The two domains of 
distance and frequency are interconvertable by the mathematical method of Fourier-
transformation. The radiation emerging from a source is passed through an 
interferometer to the sample before reaching a detector. Upon amplification of the 
signal, in which high-frequency contributions have been eliminated by a filter, the data 
are converted to digital form by an analogue-to-digital converter and transferred to the 
computer for Fourier-transformation (Stuart, 2004). 
The infrared spectrum can be divided into three main regions: the far-infrared (< 400 
cm-1), the mid-infrared (400 – 4000 cm-1) and the near-infrared (4000 – 13000 cm-1). 
Many infrared applications employ the mid-infrared region, but the near- and far- 
infrared regions also provide important information about certain materials. Generally 
there are less infrared bands in the 1800 – 4000 cm-1 region with many bands between 
400 cm-1 and 1800 cm-1 (Stuart, 2004). 
5.1.2 Methodology 
The infrared spectra of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) were recorded on 
a Shimadzu 1600 spectrophotometer (Shimadzu, Tokyo, Japan). Approximately 1 mg of 
each cyclic dipeptide, dried in a dessicator, was mixed with approximately 100 mg of 
dry, powdered, spectral grade potassium bromide (KBr) (Merck, SA). Potassium 
bromide is suitable for use since it is transparent over the whole IR range, i.e., it has no 
IR bands of its own (Field et al., 2001). Potassium bromide is however hygroscopic, so 
that traces of water can rarely be totally excluded during the grinding and pressing of 
the KBr disc. Therefore a weak band is usually observed at 3450 cm-1 (Field et al., 
2001). The mixture was then ground using an agate mortar and pestle. A Perkin Elmer® 
Bench Press set at a pressure of 1 x 104 kg. cm-2, was then used to press the powdered 
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mixture into a thin transparent disc. The disc was transferred to the KBr sample cell of 
the IR spectrophotometer and the spectra recorded after 16 scans. The infrared spectra 
of the two cyclic dipeptides were then recorded within the frequency range of 4000 cm-1 
to 400 cm-1. 
5.1.3 Results and discussion 
The IR spectra for cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) are illustrated in 
Figures 5.1 and 5.2, respectively. The main functional groups found in cyclo(Phe-4Cl-
Pro) and cyclo(D-Phe-4Cl-Pro) were identified by comparing the peaks obtained from 
the IR spectra with the observed reference values from literature, shown in Table 5.1. 
Table 5.1    Frequencies/absorption bands (cm -1) of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-
4Cl-Pro) 
Description of  band Cis-amide 
absorption bands 
Trans-amide 
absorption bands 
Cyclo(Phe-4Cl-
Pro) 
Cyclo(D-Phe-
4Cl-Pro) 
Amide I band (CO 
stretch) 
1670-1690
1 
1650 1658.84 1647.26 
Amide II band (NH-
in plane vibration) 
1440-1450
 
1420-1460
2 
 
1550 1454.38 
 
1425.44 
1491.02 
Amide III (cis 
CONH) 
1300-1350
3 
Not present 1294.28 - 
NH bending  1450
1 
1450 1454.38 1458.23 
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CN stretching 1350
1 
1350 1365.65 1332.86 
NH stretching 3180-3195
4 
3350 3149.86 3344.68 
Combination band 
of CO stretching 
and NH bending 
vibrations of the 
cisCONH group 
3100, 3200
1 
3100, 3300 3101.64, 
3267.52 
3119.00, 
3344.68 
CH2 twisting 1249
1 
 1234.48 1251.84 
CH2 bending 1468
1 
 1454.38 1458.23 
CH2 wagging 1340
1 
 1365.65 1332.86 
CH2 rocking  998
1 
 1045.45 1003.02 
CO in-plane 
bending 
806
1 
 810.13 813.99 
Skeletal stretching 
(NMe stretching) 
1075
1 
 1078.24 1070.53 
C-Me stretching 910
1 
 1045.45 920.08 
Free NH groups 3420-3480
4 
 - - 
Hydrogen bonded 3300-3380
4 
 3340.00 3344.68 
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NH groups 
1
(Miyazawa, 1960), 
2
(Ovchinnikov and Ivanov, 1975), 
3
(Bláhaet al., 1966), 
4
(Sammes, 1975), 
5
(Stuart, 
2004) 
The presence of secondary amide and carbonyl groups together with the absence of 
carboxylic acid groups was necessary to confirm that the diketopiperazine (DKP) rings 
were present in the structure of the cyclic dipeptides. 
According to literature, secondary amide functional groups will show N-H stretching 
absorption bands between 3180 – 3195 cm-1 (cis) and 3350 cm-1 (trans), with carbonyl 
stretching (Amide I) absorption bands being observed between 1650 cm-1 (trans) and 
1670 – 1690 cm-1 (cis) (Stuart, 2004; Sammes, 1975; Miyazawa, 1960). The amide II for 
secondary amide groups is due to the coupling of N-H bending and C-N stretching and 
appears between 1420 – 1460 cm-1 (cis) (Ovchinnikov and Ivanov, 1975). A weak band 
which is an overtone of the amide II band also appears at 650 cm-1 (Stuart, 2004). 
For cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) the presence of secondary amide 
groups were confirmed by the presence of N-H stretching absorption bands at 3149.86 
cm-1for cyclo(Phe-4Cl-Pro) and  3344.60 cm-1for cyclo(D-Phe-4Cl-Pro), carbonyl 
stretching was observed at 1658.84 cm-1  for cyclo(Phe-4Cl-Pro) and at 1647.26 cm-1 for  
cyclo(D-Phe-4Cl-Pro), the amide II bands occurring at 1467.6 cm-1 for cyclo(Phe-4Cl-
Pro) and 1467.6 cm-1 for cyclo(D-Phe-4Cl-Pro) and weak bands representing the 
overtones of the amide II occurring at 751.8 cm-1 and 732.0 cm-1 for cyclo(Phe-4Cl-Pro) 
and cyclo(D-Phe-4Cl-Pro), respectively. 
The absence of carboxylic acid groups is also necessary to confirm that the cyclisation 
of the linear dipeptides had occurred. Carboxylic acid groups show a strong broad O-H 
stretching band in the 2500 cm-1 to 3300 cm-1 range. The C=O stretching band of the 
free acid band is observed at 1760 cm-1 Carboxylic acids also show characteristic C-O 
stretching and in-plane and out-plane O-H bending at 930 cm-1 and 1430 cm-1, 
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respectively (Stuart, 2004). The absence of these characteristic bands, for both cyclic 
dipeptides, indicated the absence of carboxyl (COOH) end groups. 
The presence of secondary amide functional groups, together with the absence of any 
carboxylic acid functional groups for cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
therefore suggested that a DKP ring is present in the structures of the cyclic dipeptides 
and that cyclisation therefore had occurred during the synthesis of these compounds. 
Infrared spectroscopy also reliably discriminates between cis and trans secondary 
amides (Ovchinnikov and Ivanov, 1975; Miyazawa, 1960). As a consequence of their 
biosynthetic origin from the two L-α-amino acids, most naturally occurring DKPs are cis-
configured (Bull et al., 1998). 
The cis-amide bond nature of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) was 
revealed through the values of the C=O stretching mode (amide I), which produced a 
peak at approximately 1670 cm-1 to 1690 cm-1 (Miyazawa, 1960). Strong peaks 
appeared at 1680.3 cm-1 for cyclo(Phe-4Cl-Pro) and at 1666.0 cm-1 for cyclo (D-Phe-
4Cl-Pro), confirming the presence of cis-amide configuration. Further evidence for cis-
amide configuration was given by the absence of trans-peaks at 1650 cm-1 for the cyclic 
dipeptides (Miyazawa, 1960).  
Amide II vibrations are present due to interactions of the N-H bending and C-N 
stretching modes. The difference in frequencies between these two modes is 
approximately 100 cm-1, which is due to negligible interactions between them. A 
difference of approximately 100 cm-1 exists between the N-H bending and the C-N 
stretching modes of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) , and according to 
(Miyazawa, 1960), this is only apparent in the cis-CONH configuration which further 
confirmed the cis-amide configuration of the cyclic dipeptides. 
The amide type II mode is represented by a single absorption band within the 1420 cm-1 
to 1460 cm-1region (Ovchinnikov and Ivanov, 1975). N-H bonding contributes the most 
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to amide II vibrations, whereas the C-N stretching vibration contributed more to the 
amide III band. The amide II vibrations occurred at 1467.6 cm-1  for cyclo(Phe-4Cl-Pro) 
and at 1467.1 cm-1 for  cyclo(D-Phe-4Cl-Pro), confirming cis-amide configuration. Once 
again the absence of the trans-peaks between 1480 cm-1 and 1575 cm-1 (Ovchinnikov 
and Ivanov, 1975), provided further evidence of the cis-amide configuration of the cyclic 
dipeptides. 
The cis-amide type III mode is represented by absorption bands within the 1300 cm-1 to 
1350 cm-1 region (Bláha et al., 1966). Amide III vibrations occurred at 1327.6 cm-1 for 
cyclo(Phe-4Cl-Pro) and at 1345.0 cm-1 for  cyclo(D-Phe-4Cl-Pro), which confirmed the 
cis-amide configuration. 
The N-H stretching mode of the cis-bond is represented by absorption band within the 
3180 cm-1 to 3195 cm-1 region (Sammes, 1975). N-H stretching vibrations occurred at 
3240.3 cm-1 for cyclo(Phe-4Cl-Pro) and  at 3185.6 cm-1 cyclo(D-Phe-4Cl-Pro), 
confirming the cis-amide configuration. The absence of trans-peaks at 3350 cm-1 
provided further evidence of the cis-amide configuration. 
The CH2 bending vibration is also present within the amide II mode, and since only a 
single absorption band appears in this range, it is difficult to determine the presence of 
each mode. Similarly the CH2 wagging vibration is overlapped by the C-N stretching 
mode, and is therefore not clearly defined. CH2 twisting and rocking was observed at 
1234.2 cm-1 and 976.8 cm-1 for  cyclo(Phe-4Cl-Pro) and at 1223.6 cm-1 for cyclo(D-Phe-
4Cl-Pro). 
Figure 5.1 and figure 5.2 Illustrates the overlay of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-
4Cl-Pro) respectively. The spectrum of cyclo(Phe-4Cl-Pro), however, shows absorption 
bands at 1520.6 cm-1and at 1620.1 cm-1. These absorption bands, which are not seen in 
the spectrum of cyclo(Phe-4Cl-Pro), are due to aromatic C=C stretching caused by the 
aromatic tyrosine side-chain. 
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Figure 5.1    Infrared spectrum of cyclo(Phe-4Cl-Pro) 
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Figure 5.2    Infrared spectrum of cyclo(D-Phe-4Cl-Pro) 
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5.2 Fast atom bombardment mass spectrometry 
5.2.1 Introduction 
The objective of drug screening is to detect and quantify active molecules, metabolites 
and toxic compounds. Fast atom bombardment (FAB) mass spectrometry is the 
preferred ionization technique for the collision-induced dissociation (CID) spectra of 
[M+H] + ions of simple cyclic dipeptides generated by FAB ionization with a tandem 
mass spectrometer (Siuzdak, 2005). 
Mass spectrometry (MS) is a technique for measuring the mass, and therefore the 
molecular weight (MW), of a molecule. In addition it is often possible to gain structural 
information about a molecule by measuring the masses of the fragments produced 
when molecules are broken apart (McMurry, 2008). MS can also provide a method for 
characterising impurities in drugs and formulation excipients (Watson, 2005). FAB is an 
ionisation source that uses a matrix and a highly energetic beam of particles to desorp 
ions from a surface. FAB is a soft ionisation source that requires the use of a direct 
insertion probe for sample introduction and a beam of xenon neutral atoms or cesium 
ions to sputter the sample and matrix from the direct insertion probe surface. It is 
common to detect matrix ions in the FAB spectrum as well as the protonated or 
cationised molecular ion of the analyte of interest. The FAB matrix is typically a non-
volatile liquid material that serves to constantly replenish the surface with new sample 
as it is bombarded by the continuous incident ion beam. By absorbing most of the 
incident energy the matrix also minimises sample degradation from the high-energy 
particle beam. Two of the most common matrices used with FAB are m-nitrobenzyl 
alcohol and glycerol. The fast atoms or ions impinge on or collide with the matrix 
causing the matrix and analyte to be desorbed into the gas phase. The sample may 
already be charged and get transferred into the gas phase by FAB, or it may become 
charged during FAB desorption through reactions with surrounding molecules or ions. 
Once in the gas phase, the charged molecules can be propelled electrostatically to the 
mass analyzer (Siuzdak, 2005). 
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5.2.2 Methodology 
The FAB mass spectra for cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) were recorded 
on a VG-7070E spectrometer (Biotech, UK) equipped with a VG2035 data system. All 
samples were run under positive ion operating conditions. 3 Nitro-benzylalcohol was 
used as the sample matrix and the solvent was deuterated dimethyl sulphoxide (DMSO-
d6). A small amount of each cyclic dipeptide was mixed on the probe tip with the 
sample. The spectra obtained were subsequently analysed in order to determine the 
molecular mass and possible fragments of the cyclic dipeptides. 
5.2.3 Results and discussion 
Possible fragmentation pathways of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) are 
illustrated in Figure 5.3 
The mass spectra of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) are illustrated in 
Figures 5.4 and 5.5, respectively. 
The mass spectra of both cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) indicated a 
peak at m/e 154, which corresponds to the base peak for DKPs. The mass spectra of 
the cyclic dipeptides also had other important similarities. The common peaks found at 
105, 107, 115, 120, 136, 152 and 165 are all characteristic of DKPs. 
The mass spectrum of cyclo(Phe-4Cl-Pro) indicated a parent peak at m/e 279, which 
corresponds to the molecular mass of the protonated form of the cyclic dipeptide i.e., 
[C14H16O2N2 ]
+. This ion has a saturation index of 8, which confirms it to be the parent 
peak. The saturation index, which is an indicator of the number of rings and/or double 
bonds present in a molecule, is calculated from the formula CXHYNZON, were the total 
number of rings and/or bonds = X – ½ Y + ½ Z + 1, where x represents the number of 
carbons, y the number of hydrogens and z the number of nitrogens. The saturation 
index will therefore equal 14 – ½ (16) + ½ (2) + 1, which equals 8 and corresponds to 
the total number of rings and double bonds in the structure. The number of oxygens 
79 
 
does not play a role in the calculation (Lee, 1998). The mass spectra of cyclo(Phe-4Cl-
Pro) also indicates the principle fragmentations of the cyclic dipeptide. A positive ion 
peak at m/e115, indicates the fragmentation of the cyclic dipeptide to form the DKP ring 
[C4H4O2N2]
+. In analysing mass spectra of simple cyclic dipeptides, certain 
fragmentation patterns are evident. 
The parent ion dominates the following fragmentations: 
a) loss of CO or CHO; 
b) amine fragmentation (R2CH=
+NH2); and 
c) elimination of cyanuric acid (HNCO) (Sammes, 1975). 
When proline is present, in some cyclic dipeptides, there is a two mass shift to the left of 
some characteristic peaks (Svec and Junk, 1964). The following ions usually indicate 
the existence of a cyclic dipeptide ring: m/e 114; m/e 113; and m/e 85 (Szafranek et al., 
1976). 
With reference to the molecular mass of the cyclic dipeptides, the following m/e ratios 
corresponding to the positive ion of the following fragmentations were of importance: 
a) the positive ion, relating to the cleavage of the aromatic side chain (m/e 155) 
b) cyclic dipeptide pyrrolidine fragment (m/e 154) 
c) loss of the CO group (m/e 251) 
d) amine fragmentation (m/e 125) 
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Figure 5.3    Possible fragmentation pathways of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
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Figure 5.4    Mass spectrum of cyclo(Phe-4Cl-Pro) 
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Figure 5.5    Mass spectrum of cyclo(D-Phe-4Cl-Pro) 
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5.3 Nuclear magnetic resonance spectroscopy 
5.3.1 Introduction 
Nuclear magnetic resonance (NMR) spectroscopy has for many decades been an 
important tool in the pharmaceutical sciences. Its initial role was to identify and 
characterise chemically synthesised drugs, or biologically active compounds derived 
from a variety of natural sources. Today, NMR remains a premier method for the 
structural characterisation of pharmaceutical compounds. The development for 
methodology for assigning and determining the structures of peptides and proteins by 
two-dimensional NMR has made possible, a variety of new applications in the field of 
drug design (Abraham and Mobli, 2004). 
Nuclear magnetic resonance spectroscopy (NMR) provides a “map” of the carbon-
hydrogen framework of an organic molecule. NMR, infrared spectroscopy and mass 
spectrometry are used together to determine the complete structure of a molecule 
(McMurry, 2008). 
The nuclei of certain isotopes e.g., 1H and 13C (12C has no nuclear spin and cannot be 
observed by NMR) have an intrinsic spinning motion around their axes. The spinning of 
the positive charged particles will generate magnetic moment around and along their 
axes of spin. When the nuclei (1H and 13C) are placed in an external magnetic field, the 
magnetic field of the isotopes can either align with (parallel to) or against (antiparallel to) 
the external magnetic field (Willard et al., 1998). The parallel orientation is lower in 
energy than the antiparallel orientation. If the nuclei (parallel or antiparallel orientation) 
are irradiated with electromagnetic radiation energy absorption will occur and the lower 
energy states will “spin-flip” to a higher energy state (McMurry, 2008). NMR has various 
applications in pharmaceutical analysis: 
 It is used as a powerful technique for the characterisation of the exact structure 
of raw materials and finished products. 
 It can determine impurities, including enantiomeric impurities. 
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 It can potentially be used for finger printing mixtures. 
 It is also a good agent for quantitative analysis of drugs in formulations without 
prior separation (Watson, 2005). 
1H NMR spectra offer three important parameters which can be extracted, the 1H 
chemical shift (δ), the 1H, 1H coupling constants (nJHH; n= number of intervening bonds, 
generally 2-4), and the signal intensity (integral) (Bechmann et al., 2004). 
The COSY (Correlation spectroscopy) spectrum is a symmetrical spectrum which has 
the 1H NMR spectrum of the substance at both of the two chemical shift axes. The 
COSY shows which pairs of nuclei in a molecule are coupled (Ozaki et al., 1999). 
13C DEPT (distortionless enhancement by polarization transfer) contains only signals 
arising from protonated carbons and gives information about the number of protons 
bonded to each carbon (McMurry, 2008). 
HMBCGP (Heteronuclear multiple bond correlation experiment) gives information about 
weak proton-carbon J-couplings. A weak proton-carbon J-coupling indicates that the 
proton is two, three or four bonds away from the carbon. HMBCGP also gives 
information about which protons are near to (but not directly bonded to) different 
carbons.  HMBCGP together with HMQC (Hetronuclear Multiple Quantum Correlation 
experiment) provides an enormous amount of information about the molecular structure, 
since the long range proton-carbon correlations can include quaternary carbons, in 
addition to protonated carbons (Würtzet al., 2008). 
HSQC (Heteronuclear Single Quantum Coherence) is a two-dimensional spectrum with 
one axis for the1H protons and the other for a heteronucleus (atomic nucleus other than 
a proton i.e 13C). The spectrum contains a peak for each unique proton attached to the 
heteronucleus being considered. If the chemical shift of a specific proton is known, the 
chemical shift of the coupled heteronucleus can be determined (Samuel et al., 2011).  
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5.3.2 Methodology 
The 1H (300.13 MHZ) and 13C (75.48 MHZ) spectra for cyclo(Phe-4Cl-Pro) and cyclo(D-
Phe-4Cl-Pro) were recorded on a Bruker AMS 300 (Bruker, Germany). COSY, HSQC, 
HMBCGP, was also recorded for the assignment of the proton to proton, and proton to 
carbon couplings within the respective cyclic dipeptides. Cyclic dipeptide solutions were 
prepared using DMSO-d6 (Merck, Germany) as the solvent. TMS was used as the 
internal standard, specified at 0 parts per million (ppm), for the determination of the 
chemical shifts. 
5.3.3 Results and discussion  
All recorded NMR spectra are shown in Figures 5.6 to 5.16 with NMR results recorded 
as shifts in parts per million (ppm). The 1H and 13C assignments of cyclo(Phe-4Cl-Pro) 
and cyclo(D-Phe-4Cl-Pro)  are given in Tables 5.2 and 5.3.   
Table 5.2    NMR data of cyclo(Phe-4Cl-Pro) (DMSO-d6) 
1
H-NMR  δ-values (ppm) 
13
C-NMR  δ-values (ppm) 
 1.481 (1H; m) Pro-β 22.34 (t ) Pro-γ 
1.752 (2H; m ) Pro-γ  28.31 (t ) Pro-β 
 2.045 (1H; m) Pro-β 34.90 (t ) Phe-β 
3.040 (2H; m ) Phe-β ( distorted triplet) 45.07 (t ) Pro-δ 
3.287 (1H; m) Pro-δ 55.95 (d)Phe-α 
3.313 (1H; m) Pro-δ  58.86 (d) Pro-α 
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4.092 (1H; distorted t) Pro- α 128.31 (d) Phe-Ar 
4.376 (1H; t) Phe-α 131.53 (m) Phe-Ar 
7.314 (4H; m) Phe-Ar 132.20 (q) Phe-Ar 
8.150 (1H; s) Phe-NH) 136.74 (q) Phe-Ar 
 165.39 (s) Phe-C=O 
 169.67 (s) Pro-C=O 
s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet 
The Pro-β and Pro-δ protons of cyclo(Phe-4Cl-Pro) are non-equivalent as they 
resonated at 1.481 ppm and 2.045 ppm , 3.287 ppm and 3.313 ppm respectively 
indicating that the one β-proton and one δ-proton are more shielded. The Pro-γ and 
Phe-β protons resonated at 1.752 ppm and 3.040 ppm respectively. The Pro-α proton 
resonated upfield (4.092 ppm) compared with the Phe-α proton which resonated at 
4.376 ppm, indicating greater deshielding of the Phe-α proton. The aromatic protons 
and Phe-NH resonated far downfield at 7.314 ppm and 8.150 ppm respectively. 
From the 13C-NMR spectrum it can be seen that the Pro-α carbon resonated downfield 
at 58.86 ppm compared with the Phe-α carbon which resonated at 55.95 ppm. The Pro-
γ, Pro-β, Phe-β and Pro-δ carbons resonated at 22.34 ppm, 28.31 ppm, 34.90 ppm and 
45.07 ppm respectively. 
The carboxyl groups resonated far downfield at 165.39 ppm and 169.67 ppm 
respectively, while the aromatic carbons resonated downfield between 128.31 ppm and 
136.74 ppm 
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Table 5.3    NMR data of cyclo(D-Phe-4Cl-Pro) (DMSO-d6) 
1
H-NMR  δ-values (ppm) 
13
C-NMR  δ-values (ppm) 
1.639 (2H; m) Pro-β, Pro-γ 21.87 (t ) Pro-γ 
1.806 (1H; m) Pro-γ  29.01 (t ) Pro-β 
 2.020 (1H; m) Pro-β 38.94 (t ) Phe-β 
2.907 (1H; dd) Phe-β 45.29 (t ) Pro-δ 
2.994 (1H, dd) Phe-β 57.80 (d) Phe-α  
3.236 (1H; m ) Pro-δ  58.26 (d) Pro-α  
3.775 (1H; m) Pro-δ 128.69 (d) Phe-Ar 
3.954 (2H; q) Pro-α, Phe-α 132.05 (m) Phe-Ar 
7.165 (2H; d ) Phe-Ar 135.71 (m) Phe-Ar 
7.353 (2H; d ) Phe-Ar 165.22 (s) Phe-C=O 
8.183 (1H; d) Phe-NH) 168.89 (s) Pro-C=O 
  
s = singlet, d = doublet, t = triplet, q = quartet, m = multipletdd = doublet of doublets 
The Pro-β and Pro-γ protons of cyclo(D-Phe-4Cl-Pro) are non-equivalent as they 
resonated at 1.639 ppm, 1.806 ppm and 2.020 ppm indicating that the one β-proton and 
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one γ-proton are more shielded. The Pro-δ protons are also non-equivalent as they 
resonated at 3.236 ppm and 3.775 ppm indicating that the one δ-proton is more 
shielded. The Phe-β protons resonated at 2.907 ppm and 2.994 ppm. The Pro-α proton 
and Phe-α proton resonated at 3.954 ppm. The aromatic protons and Phe-NH 
resonated far downfield at 7.165 ppm, 7.353 ppm and 8.183 ppm respectively. 
From the 13C-NMR spectrum it can be seen that the Pro-α carbon resonated down field 
at 58.26 ppm compared with the Phe-α carbon which resonated at 57.80 ppm. The Pro-
γ, Pro-β, Phe-β and Pro-δ carbons resonated at 21.87 ppm, 29.01 ppm, 38.94 ppm and 
45.29 ppm respectively. 
The carboxyl groups resonated far downfield at 165.22 ppm and 168.89 ppm 
respectively, while the aromatic carbons resonated downfield between 128.69 ppm and 
135.71 ppm 
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Figure 5.6    1H NMR spectrum of cyclo(Phe-4CL-Pro) 
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Figure 5.7    13C NMR spectrum of cyclo(Phe-4CL-Pro) 
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Figure 5.8    13C COUPLED spectrum of cyclo(Phe-4CL-Pro) 
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Figure 5.9    COSY spectrum of cyclo(Phe-4CL-Pro) 
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Figure 5.10    HMBCGP spectrum of cyclo(Phe-4CL-Pro)      
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Figure 5.11    HSQC spectrum of cyclo(Phe-4CL-Pro) 
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Figure 5.12    1H NMR spectrum of cyclo(D-Phe-4CL-Pro) 
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Figure 5.13    13C NMR spectrum of cyclo(D-Phe-4CL-Pro) 
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Figure 5.14    13C GD spectrum of cyclo(D-Phe-4CL-Pro) 
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Figure 5.15    COSY spectrum of cyclo(D-Phe-4CL-Pro) 
99 
 
Figure 5.16    HMBCGP spectrum of cyclo(D-Phe-4CL-Pro) 
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Figure 5.17    HSQC spectrum of cyclo(D-Phe-4CL-Pro) 
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5.4 Molecular modelling 
5.4.1 Introduction 
Pharmaceutical chemists today are facing numerous intricate challenges. The most 
demanding and rewarding one is the rational design of new therapeutic agents for 
treating human diseases (Cohen, 2007). 
 Recent scientific developments have changed the way pharmaceutical research 
produces new bio-active molecules. The traditional “trial and error” drug discovery 
processes are now slowly being replaced by structure based rational drug design. This 
includes the use of X-ray crystallography and NMR for the determination of the 3-
dimensional structure of a target protein followed by various modelling techniques for 
the design of ligands that could interact with the target structure (Zsoldos et al., 2003). 
Active conformation can be defined as the conformation, which a drug molecule adopts 
when bonding to either an enzyme or a receptor. This conformation is not necessarily 
the most energetically preferred one, but rather contains the correct spatial arrangement 
of all essential binding groups. Knowledge of the preferred conformation is nevertheless 
valuable as a means of explaining activity profiles and for the design of new analogues 
(Lucietto, 2004). The main challenge of structure based rational drug design is finding 
small molecular structures that bind strongly to a given protein due to steric and 
electrostatic complementarity and is readily available or easy to synthesise (Zsoldos et 
al., 2003). 
The difficulty lies in keeping equal focus on both the above-mentioned criteria. Two 
main approaches are used to overcome this problem, each prioritising one of the criteria 
over the other: 
 Flexible docking of potential ligands from a database of 3-D structures of 
known compounds. Here the availability criterion is a given, since the 
considered structures are all available (or synthesisable). 
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 Build up complimentary structures from scratch-de novo design focused on 
generating the best possible fit to the constraints (Zsoldos et al., 2003). 
5.4.2 Methodology  
The energetically favourable conformation distributions of cyclo(Phe-4Cl-Pro) and 
cyclo(D-Phe-4Cl-Pro) were elucidated by using Spartan‟10® (Professional Version 1.10) 
computer molecular modelling software. Local minima conformations were obtained for 
each cyclic dipeptide by the use of molecular mechanics (AMBER force field) 
optimisation methods, due to the fact that it does not consider hydrogens explicitly 
(Wishart and Case, 2001). 
The cyclic dipeptides cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) were initially built by 
using the amino acid database included in the Spartan‟10® software. A step-wise 
approach to energy minimisation was then followed. Geometrical optimisation was 
achieved by an initial steepest-descent run, which was run for at least 200 cycles or 
until the root mean square (RMS) of 0.1 kcal.mol-1Å-1 was achieved. Geometrical 
optimisation of the cyclic dipeptides was then followed by a PolakRibiere (Conjugated 
gradient) minimisation, which was done in repeated runs of 32560 cycles, until suitable 
low energy conformations with RMS of less than 0.001 kcal.mol-1Å-1 was obtained. The 
conformational search was executed in order to identify the three lowest energy 
conformations, which could then be analysed to produce conclusions on the 
conformations of the cyclic dipeptides. 
5.4.3 Results and discussion 
The data for the three lowest energy conformers for each cyclic dipeptide are reported 
in Tables 5.4, 5.5, 5.6 and 5.7 respectively. The lower the heat of formation, or energy 
of the conformer, E (kJ/mol), the greater the stability of the conformer and thus the most 
likely to be found in nature, under standard conditions. The relative energy, Rel. E 
(kJ/mol), is calculated relative to the lowest energy conformer which is assigned a 
energy of 0 kJ/mol.     
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Table 5.4    Conformational search results calculated for cyclo(Phe-4Cl-Pro) in the gas 
phase 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann 
Distribution 
1 360.77 0 0.924 
2 368.03 7.26 0.049 
3 369.53 8.76 0.027 
Figure 5.18    Conformation 1 of cyclo(Phe-4Cl-Pro) in the gas phase     
Figure 5.19    Conformation 2 of cyclo(Phe-4Cl-Pro) in the gas phase      
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Figure 5.20    Conformation 3 of cyclo(Phe-4Cl-Pro) in the gas phase 
Figure 5.21    Overlay of conformation 1 and 2 of cyclo(Phe-4Cl-Pro) in the gas phase 
Figure 5.22    Overlay of conformation 1 and 3 of cyclo(Phe-4Cl-Pro) in the gas phase 
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Figure 5.23    Overlay of conformation 2 and 3 of cyclo(Phe-4Cl-Pro) in the gas phase 
 
 
 
 
Figure 5.24    Overlay of conformation 1, 2 and 3 of cyclo(Phe-4Cl-Pro) in the gas phase 
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Table 5.5    Conformational search results calculated for cyclo(D-Phe-4Cl-Pro) in the gas 
phase 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann 
Distribution 
1 0 365.03 0.814 
2 3.88 368.91 0.17 
3 9.76 374.8 0.016 
Figure 5.25    Conformation 1 of cyclo(D-Phe-4Cl-Pro) in the gas phase 
Figure 5.26    Conformation 2 of cyclo(D-Phe-4Cl-Pro) in the gas phase 
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Figure 5.27    Conformation 3 of cyclo(D-Phe-4Cl-Pro) in the gas phase 
Figure 5.28    Overlay of conformation 1 and 2 of cyclo(D-Phe-4Cl-Pro) in the gas phase 
Figure 5.29    Overlay of conformation 1 and 3 of cyclo(D-Phe-4Cl-Pro) in the gas phase 
 
   
 
 
 
108 
 
   
Figure 5.30    Overlay of Conformation 2 and 3 of cyclo(D-Phe-4Cl-Pro) in the gas phase 
 
 
 
 
Figure 5.31    Overlay of conformation 1, 2 and 3 of cyclo(D-Phe-4Cl-Pro) in the gas phase 
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Table 5.6    Conformational search results calculated for cyclo(Phe-4Cl-Pro) in the 
solvated (water) phase 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann 
Distribution 
1 287.86 0 0.942 
2 296.19 8.33 0.033 
3 296.84 8.98 0.025 
Figure 5.32    Conformation 1 of cyclo(Phe-4Cl-Pro) in the solvated (water) phase 
Figure 5.33    Conformation 2 of cyclo(Phe-4Cl-Pro) in the solvated (water) phase 
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Figure 5.34    Conformation 3 of cyclo(Phe-4Cl-Pro) in the solvated (water) phase 
 
 
  
Figure 5.35    Overlay of conformation 1 and 2 of cyclo(Phe-4Cl-Pro) in the solvated (water) phase 
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Figure 5.36    Overlay of conformation 1 and 3 of cyclo(Phe-4Cl-Pro) in the solvated (water) phase 
 
 
 
 
Figure 5.37    Overlay of Conformation 2 and 3 of cyclo(Phe-4Cl-Pro) in the solvated (water) phase 
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Figure 5.38    Overlay of Conformation 1, 2 and 3 of cyclo(Phe-4Cl-Pro) in the solvated (water) phase 
Table 5.7    Conformational search results calculated for cyclo(D-Phe-4Cl-Pro) in the 
solvated (water) phase 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann 
Distribution 
1 291.37 0 0.791 
2 294.83 3.46 0.916 
3 301.54 10.16 0.013 
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Figure 5.39    Conformation 1 of cyclo(D-Phe-4Cl-Pro) in the solvated (water) phase 
 
   
Figure 5.40    Conformation 2 of cyclo(D-Phe-4Cl-Pro) in the solvated (water) phase 
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Figure 5.41    Conformation 3 of cyclo(D-Phe-4Cl-Pro) in the solvated (water) phase 
Figure 5.42    Overlay of conformation 1 and 2 of cyclo(D-Phe-4Cl-Pro) in the solvated (water) phase 
Figure 5.43    Overlay of Conformation 1 and 3 of cyclo(D-Phe-4Cl-Pro) in the solvated (water) phase 
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Figure 5.44    Overlay of Conformation 2 and 3 of cyclo(D-Phe-4Cl-Pro) in the solvated (water) phase 
 
 
 
 
Figure 5.45    Overlay of Conformation 1, 2 and 3 of cyclo(D-Phe-4Cl-Pro) in the solvated (water) phase 
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Table 5.8    Conformational search results calculated for cyclo(Phe-4Cl-Pro) in dimethyl 
sulphoxide (DMSO) 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann Distribution 
1 -3315302.5 
 
0 0.648 
 
2 -3315300.02 
 
2.49 0.238 
 
3 -3315298.2 
 
4.3 0.114 
 
 
 
 
 
Figure 5.46    Conformation 1 of cyclo(Phe-4Cl-Pro) in DMSO 
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Figure 5.47    Conformation 2 of cyclo(Phe-4Cl-Pro) in DMSO 
 
  
 
Figure 5.48    Conformation 3 of cyclo(Phe-4Cl-Pro) in DMSO 
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Figure 5.49    Overlay of conformation 1 and 2 of cyclo(Phe-4Cl-Pro) in DMSO 
 
 
 
 
Figure 5.50    Overlay of conformation 1 and 3 of cyclo(Phe-4Cl-Pro) in DMSO 
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Figure 5.51    Overlay of conformation 2 and 3 of cyclo(Phe-4Cl-Pro) in DMSO 
 
 
 
 
Figure 5.52    Overlay of conformation1, 2 and 3 of cyclo(Phe-4Cl-Pro) in DMSO 
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Table 5.9    Conformational search results calculated for cyclo(D-Phe-4Cl-Pro) in DMSO 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann 
Distribution 
1 -3315307 
 
 
0 0.673 
 
2 -3315304 
 
 
2.05 0.295 
 
3 -3315299 
 
 
7.54 0.032 
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Figure 5.53    Conformation 1 of cyclo(D-Phe-4Cl-Pro) in DMSO 
 
   
Figure 5.54    Conformation 2 of cyclo(D-Phe-4Cl-Pro) in DMSO 
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Figure 5.55    Conformation 3 of cyclo(D-Phe-4Cl-Pro) in DMSO 
 
  
 
Figure 5.56    Overlay of conformation 1 and 2 of cyclo(D-Phe-4Cl-Pro) in DMSO 
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Figure 5.57    Overlay of conformation 1 and 3 of cyclo(D-Phe-4Cl-Pro) in DMSO 
 
 
 
 
Figure 5.58    Overlay of conformation 2 and 3 of cyclo(D-Phe-4Cl-Pro) in DMSO 
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Figure 5.59    Overlay of conformation1, 2 and 3 of cyclo(D-Phe-4Cl-Pro) in DMSO 
The aromatic cyclic side chain is extended and not folded onto the cyclic dipeptide ring 
due to steric hindrance caused by the halogen atom. This is a possible indication that 
the keto-groups are free to bind to a complimentary receptor.   
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CHAPTER 6 
ANTICANCER STUDIES 
6.1 Introduction 
The term cancer can be defined as an unregulated growth of cells arising from one 
abnormal cell. The clinical term malignant neoplasm, is defined as a relatively 
autonomous growth of tissue not subject to the rules and regulations of normal growing 
cells. Tumour is a general term indicating any abnormal mass or growth of tissue. The 
main characteristics of benign tumours can be summarised as encapsulation, slow 
growth, and non-invasive growth into surrounding tissue, in other words lack of the 
ability to metastasise. Malignant tumours grow rapidly, are not encapsulated and 
incomplete if present, invade surrounding tissues and metastasise. Benign growths 
generally have a normal complement of chromosomes, exhibit good differentiation, and 
have limited cell division whereas the opposite is characteristic of malignant neoplasms 
(Warshawsky and Landolph, 2006). Table 6.1 illustrates the main type of cancers. 
Table 6.1    Main types of cancers (Warshawsky and Landolph, 2006).  
Tissue Benign Malignant  
Epithelial 
Glands or ducts (e.g., gut, 
breast, lung, uterus) 
Adenoma 
Carcinoma-in-situ 
Adenocarcinoma 
Stratified squamous tissue (e.g., 
skin, lung) 
Squamous cell papilloma Squamous cell or epidermoid 
carcinoma 
Basal cells (skin) - Basal cell carcinoma 
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Melanocytes (skin) Nevus Malignant melanoma 
Renal epithelium Renal tubular adenoma Renal cell carcinoma 
Liver cells Liver cell carcinoma Hepatocellular carcinoma 
Connective tissue and derivatives 
Fibroblast Fibroma Fibrosarcoma 
Cartilage Chondroma Chondrosarcoma 
Bone Osteoma Osteogenic sarcoma 
Striated muscle Rhabdomyoma Rhabdomyosarcoma 
Blood vessels Haemangioma Angiosarcoma 
Bone marrow, spleen 
Haematopoietic (blood-forming) 
cells 
- Leukemias, erythroleukemia, 
myeloma, lymphomas 
Nerves 
Peripheral nervous system - Neuroblastomas 
Central nervous system - Gliomas, Astrocytomas, 
Medullablastomas 
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Cancer is either inherited or results from mutations caused by an accumulation of 
environmental factors. About 5 to 10 percent of cancers are hereditary. The remaining 
cancers result from damage to genes that occur throughout our lifetime either due to 
internal (e.g., inherited mutations, hormones, immune conditions and mutations that 
occur from metabolism) or external (e.g., tobacco, infectious organisms, chemicals and 
radiation) factors. Statistics reveal that about 80 percent of all human cancers deaths 
are related to external factors that can be controlled or prevented (Warshawsky and 
Landolph, 2006).  
6.1.1 Cell growth cycle 
Figure 6.1 illustrates the cell growth cycle. A cell cycle is the period from formation of a 
new somatic cell to the time at which that new cell divides. It is an orderly sequence of 
events by which the somatic cell duplicates its contents and divides into two. Cancer 
cells, like normal cells, proceed through a specific and orderly set of events during 
cellular replication referred to as the cell cycle (Koda-Kimble et al., 2008). The rate of 
cellular proliferation within any population of cells depends on three parameters: the 
rate of cell division, the fraction of cells within the population undergoing cell division 
(growth fraction), and the rate of cell loss from the population due to terminal 
differentiation or cell death (Tortora and Grabowski, 2009). 
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Figure 6.1    Diagram of the cell cycle specifying the four phases-G1, G2, M, S and G0-and indicating the 
main sites of action of most anticancer agents (Koda-Kimble et al., 2008). 
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The cell division cycle can be divided into the interphase period, in which a cell is not 
dividing and the mitotic period, in which the cell is actively dividing. Two functional 
phases, the S and M, and two preparatory phases, the G1 and G2 can be distinguished. 
During the interphase the cell replicates its deoxyribonucleic acid (DNA). It also 
produces additional organelles and cytostolic components. The interphase is the state 
of high metabolic activity, and during this time the cell does most of its growing and 
performs its metabolic and physiological functions. The interphase consists of three 
phases: G1, S and G2. The S phase occurs between G1 and G2 and is defined as the 
phase in which DNA is replicated. Under normal circumstances, the time it takes a 
typical human cell to complete the S phase is about eight hours and is invariant. The M 
phase consists of nuclear division, or mitosis and cytoplasmic division, or cytokinesis. 
The M phase can be divided into four stages; prophase, metaphase, anaphase and 
telophase (Tortora and Grabowski, 2009). Fully replicated chromosomes are 
segregated to each of the two daughter nuclei by the process of mitosis during the M 
phase (Koda-kimble et al., 2008; Andreeff et al., 2000; Prosser et al., 2006). The length 
of the M phase is about 1 hour and is also normally invariant. The cells that complete 
mitosis may either continue to proceed through the cell cycle to divide again, 
differentiate or mature into specialised cells and eventually die or enter a third resting 
phase called the G0 phase (Koda-Kimble et al., 2008). The G1 and G2 phases have key 
regulating functions and are required for the synthesis of cellular constituents needed to 
support further phases, which is ultimately necessary to complete cell division (Koda-
Kimble et al., 2008). The G1 phase precedes the S phase, whereas the G2 phase 
precedes the M phase. In mammalian cells, the length of the G2 phase is about 2 hours. 
The length of the G1 phase is highly variable and can range from about 6 hours to 
several days or longer. The varying length of the G1 phase accounts for most of the 
differences seen in the rate of cell division, between different cell types or between cells 
growing under different conditions (Andreeff et al., 2000; Prosser et al., 2006). The G0 
phase is a period within the G1 phase of the cell cycle in which cells exist in a stable 
resting state. 
130 
 
Proliferation of normal cells (or cell renewal) is under fine control to balance the loss of 
mature functional cells with the production of new cells. Proto-oncogenes and tumour-
suppressor genes provide the stimulatory and inhibitory signals respectively, which 
regulate the cell cycle (Koda-Kimble et al., 2008). The messages are conveyed to the 
cell by the cell cycle “clock” (Dipiro et al., 2011). In a normal cell, the clock collects the 
inhibitory signals to determine whether the cell should undergo division. The clock 
consists of interacting proteins found in the nucleus, including cyclins and cyclin-
dependant kinases (CDKs). The cyclins combine with the CDKs to form complexes that 
act as a molecular switch. The molecular switch allows the cell to move through the 
restriction point that occurs late in the G1 phase to the S phase. If insufficient amounts 
of cyclins and CDKs are present during the G1 phase, the cell will not enter the S phase 
to start cell division. The complexes release phosphate groups from molecules of 
adenosine triphosphate (ATP) and transfer them to a protein called a retinoblastoma 
protein (pRB). If the pRB acquires enough phosphate groups, the protein will release 
the transcription factors needed by the cell to make proteins, which are essential for cell 
division. New evidence suggests that the function of cyclins, CDKs and inhibitory 
proteins may be disrupted by a malignant transformation, or these proteins could 
undergo changes that cause a malignant transformation (Koda-Kimble et al., 2008). 
The cell cycle clock further regulates cell division by interpreting the inhibitory and 
stimulatory signals it receives from surrounding cells (Rang et al., 2011). Stimulatory 
growth factors interact with complementary receptors on the cell surface and modify the 
signalling pathways that affect the cell cycle clock. Inhibitory growth factors can also 
interact with complementary receptors and modify signalling pathways. The presence of 
excess stimulatory (i.e., cyclins and CKDs) or the absence of inhibitory proteins can 
cause excessive proliferation. Stimulatory growth factors trigger the molecular switch, 
whereas inhibitory growth factors turn the switch off. Two inhibitory proteins, lost or 
muted in 50% of human cancers, include pRB and p53. Altered inhibitory signals can 
lead to a malignant transformation (Koda-Kimble et al., 2008; Rang et al., 2011). 
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If the stimulatory and inhibitory signals do not program the cell to stop dividing, other 
mechanisms, including apoptosis (a normal mechanism of cell death required for tissue 
homeostasis) and senescence (aging), can help control excessive cell division (Rang et 
al., 2011). Unfortunately, proto-oncogenes and tumour-suppressor genes regulate these 
processes. Any gene mutation or deletion can disrupt normal cellular turnover. New 
research is under way to target these genes, proteins, and receptors in an attempt to 
discover new cancer treatments and the prevention of cancer (Dipiro et al., 2011; Koda-
Kimble et al., 2008). 
In cancer cells, cell cycle control is disrupted by (1) abnormal growth factor function 
and/or (2) abnormal cyclin /CKDs function and/or (3) abnormal DNA synthesis as a 
result of oncogene activity and/or (4) abnormal decrease in negative regulatory forces 
owing to mutation of tumour-suppressor genes. Carcinogenesis can activate tumour-
suppressor genes, resulting in the initiation and promotion of carcinogenesis (Rang et 
al., 2011; Heath, 2001). 
Anticancer agents fall into two specific groups: cell cycle specific groups (CCS), which 
exert their action on cells passing through the cell cycle (phases G1 to M); and cell cycle 
non-specific drugs (CCNS), which acts on cells irrespective of whether they are resting 
in the G0 phase or passing through the cell cycle (Dipiro et al., 2011). 
6.1.2 Carcinogenesis 
A cancer, or neoplasm, is thought to develop from a cell in which the normal 
mechanisms for control of growth and proliferation are altered (Heath, 2001). Current 
evidence supports the concept of carcinogenesis as a multistage process consisting of 
initiation, promotion and progression (Dipiro et al., 2011). 
The first process of carcinogenesis is initiation, which involves the exposure of normal 
cells to carcinogenic substances. The general classes include: physical agents 
(radiation), viruses, chemicals (Warshawsky and Landolph, 2006). Ionising and 
ultraviolet radiation have been shown to cause cancers in humans and experimental 
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animals. The possible role of viruses in the etiology of human cancers is not yet clear. 
There have however, been positive correlations between human cancers and viruses. 
These viruses include the: Hepatitis B virus, Epstein-Barr virus, Humanpapilloma virus, 
human immunodeficiency virus (HIV), and the Human T-Cell lymphotropic virus type 1 
(Warshawsky and Landolph, 2006). Chemical carcinogens are classified into two 
groups, according to their mode of action: firstly, direct-acting alkylation agents and 
secondly chemicals requiring activation. Direct-acting carcinogens are chemically and 
biologically reactive by virtue of their structure and are electrophilic in character. The 
majorities of chemical carcinogens, however, are chemically and biologically inert and 
are termed procarcinogens. Specific, spontaneous or biochemical activation reactions 
convert procarcinogens to either proximal or intermediate carcinogens and to ultimate 
electrophilic carcinogens. The exposure to carcinogens may cause a change in DNA, 
ribonucleic acid (RNA), or protein that, if not repaired, results in irreversible cellular 
mutations (Warshawsky and Landolph, 2006). 
The second phase of carcinogenesis, termed the promotion phase, results in the 
formation of latent tumour cells, which leads to a neoplastic growth and eventually 
tumour formation. This phase is considered to be reversible up to a certain point 
(Warshawsky and Landolph, 2006; Coussens and Werb, 2002). During the promotion 
phase carcinogens and the other factors (such as species, strain, age, sex, diet, 
intestinal flora condition, health status, chronic irritation and inflammation) alter the 
environment to favour growth of the mutated cell population over normal cells. 
Depending on the type of cancer, months to years may elapse between the two 
carcinogenic phases and the development of clinically detectable cancer, a process 
which is called conversion (Dipiro et al., 2011). 
The final stage of neoplastic growth, called progression, involves further genetic 
changes leading to increased cell proliferation. The critical elements of this phase 
include tumour invasion into local tissues and the development of metastasis, in which 
malignant cells detach from the primary tumour and invade a body cavity or enter the 
blood or lymphatic system. If these cells survive secondary tumours may be 
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established, becoming vascularised to provide nutrients for further growth (Dipiro et al., 
2011).  
6.1.3 Invasion and metastasis  
Invasion and metastasis are the most dangerous and life-threatening aspects of cancer. 
The capacity for invasion may not initially be expressed or occur in all tumours. 
However, most cancers develop invasive potential, thus progressing to malignancy from 
pre-existing carcinoma in situ, adenomas, or disorders of epithelial proliferation. Once 
the neoplasm becomes invasive, it can disseminate readily through whatever means 
available to it: via the lymphatic and/or vascular channels (Liotta and Kohn, 2000; 
Prosser et al., 2006). Invasion and metastasis kill host cells through two processes: 
firstly local invasion and secondly distant organ injury. Local invasion can compromise 
the function of involved tissue by local compression, local destruction, or prevention of 
normal organ functioning. The most significant turning point in the disease, however, is 
the establishment of metastasis. At this stage, the patient can no longer be cured by 
local therapy alone. The patient with metastatic disease most commonly succumbs to 
injury caused by cancer dissemination or less often to complications associated with 
cytotoxic therapies (Liotta and Kohn, 2000; Prosser et al., 2006). 
Tumours of comparable size and histology can have widely divergent metastatic 
potential, depending on their genotype and local environmental influences. Metastatic 
potential is influenced by the local microenvironment, angiogenesis, stroma-tumour 
interactions, and elaboration of cytokines by the local tissue, and more significantly by 
its molecular phenotype. The malignant phenotype is the culmination of a series of 
genetic changes in the primary tumour and its metastasis, through which the 
investigation of activation, regulation, and the manipulation of regulatory elements can 
be exploited as a new frontier for metastasis research (Liotta and Kohn, 2000; Prosser 
et al., 2006). 
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6.1.4 Cancer therapy  
Treatment of cancer involves three main treatment modalities, namely (1) radiation 
therapy, (2) surgical removal of the tumour, and (3) chemotherapy (Katzung, 2009). 
Successful therapy must be focused on the primary tumour and its metastasis, whether 
clinically apparent or microscopic. Thus local and regional therapy, surgery, or radiation 
must be integrated with systemic therapy, i.e., drugs. The ideal antineoplastic drug 
would destroy cancer cells, without adverse effects or toxicities on normal cells 
(Sartoreli, 2001). 
6.1.4.1 Radiation therapy 
Radiation therapy, or radiotherapy, involves the use of ionising radiation to eradicate 
localised tumour masses (Koda-Kimble et al., 2008). Ionising radiation may be delivered 
by X-ray beams, beams of ionising particles e.g., electrons or by beta or gamma 
irradiation produced in the decay of radioactive isotopes (Koda-Kimble et al., 2008). Not 
all cancers are sensitive to the lethal effects of radiation, so this modality has limited 
application in the treatment of only some cancers (Koda-Kimble et al., 2008). 
Unfortunately, the usefulness of radiation therapy can be limited by its toxic effects on 
normal tissues surrounding the tumour, or heat damage to the skin that develops as 
radiation passes through it to reach an underlying tumour (Koda-Kimble et al., 2008). 
Many complex and sophisticated techniques, however, have been developed and used 
to maximise the dose reaching the tumour while minimising the destructive effects on 
normal tissues (Dipiro et al., 2011). 
6.1.4.2 Surgery   
Surgery is the oldest modality of cancer therapy and still forms the mainstay of 
treatment in solid tumours (Pollock and Morton, 2000). The surgical approach to therapy 
is simple and direct. It seeks to physically remove the tumour mass and thus eliminate 
the problem. However, the nature of tumour growth and metastasis presents certain and 
often major, difficulties (Nowak and Handford, 2004). The type of surgery required is 
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normally determined by the type of tumour and the anatomical site, and may thus 
include any of the following: 
 Wide local excision of the tumour mass, e.g., local excision of a breast lump. 
 Removal of part of an organ and surrounding tissue, e.g., partial glossectomy 
and neck dissection for a carcinoma of the tongue. 
 Removal of an entire organ, e.g., laryngectomy, cystectomy, or hysterectomy 
(Nowak and Handford, 2004). 
6.1.4.3 Chemotherapeutic agents 
Almost all chemotherapeutic agents currently available kill cancer cells by affecting DNA 
synthesis or function, a process that occurs during each cell cycle. Each drug varies in 
the way this occurs within the cycle. Drugs used in cancer chemotherapy can be divided 
into three different groups: cytotoxic (antineoplastic) agents, hormones and 
miscellaneous agents (Rang et al., 2011). Table 6.2 summarises the currently available 
chemotherapeutic agents, their mechanism of action, main indication and side effects. 
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Table 6.2    Currently available antineoplastic agents  (Rang et al., 2011). 
Cass Mechanism of action Tumours commonly 
responsive 
Adverse effects 
Alkylating agents 
Mechlorethamine 
Chlorambucil 
Cyclophosphamide 
Melphalan 
Ifosfamide 
 
Alkylation of DNA with 
restriction of strands 
uncoiling and replication 
Hodgkin‟s, malignant 
lymphoma, small cell 
lung carcinoma, 
carcinoma of the breast 
and testis 
Alopecia, nausea and 
vomiting, 
myelosuppression, 
permanent sterility  
Antimetabolites 
Folate antagonist e.g., 
Methotrexate 
 
Purine antagonist e.g.,                         
6-Mercaptopurine 
 
Pyrimidine antagonist 
Binds to dehydrofolate 
reductase, interfering 
with pyrimidine 
synthesis 
Blocks de novo purine 
synthesis 
 
 
Interferes with 
Carcinoma of the head, 
neck, ovary, malignant 
lymphoma, Osteogenic 
sarcoma 
 
Acute leukaemia 
 
 
Mucosal ulceration, bone 
marrow suppression, 
myelosuppression, 
alopecia, mucositis, 
diarrhoea and vomiting, 
hyperpigmentation, skin 
rash 
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e.g.,        5-Fluorouracil 
 
 
Cytarabine 
thymidylatesynthetase 
to reduce thymidine 
production 
 
DNA polymerase 
inhibition 
 
Gastrointestinal 
neoplasms, carcinoma 
of the breast  
 
Acute leukaemia, 
malignant lymphoma 
Plant alkaloids 
Vincas e.g., Vincristine 
Podophyllotoxins e.g., 
Etoposide 
Mitotic arrest by 
alterations of 
microtubular proteins 
 
Inhibition of mitosis 
Lymphomas, 
leukaemias, carcinoma 
of the breast and testis 
Lymphoma, Hodgkin‟s, 
carcinoma of the testis 
and lung, acute 
leukaemia  
Peripheral neuropathy, 
alopecia, nausea and 
vomiting, 
myelosuppression 
Antibiotics 
Doxorubicin 
 
 
Bleomycin 
 
 
Inhibit DNA uncoiling 
 
 
Incision of DNA strands 
 
 
Acute leukaemia, 
Hodgkin‟s, carcinoma 
of thebreast and lung 
Squamous cell 
carcinoma, lymphoma, 
carcinoma of testis and 
lung 
Carcinoma of colon 
breast and lung 
Nausea and vomiting, 
myelosuppression, 
alopecia, cardiac toxicity, 
anaphylaxis, chills and 
fever, skin rash, 
leucopaenia, alopecia, 
thrombocytopaenia 
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Mitomycin 
 
Inhibit DNA synthesis 
 
 
 
 
 
 
 
 
Nitrosoureas 
Carmustine 
 
Lomustine 
 
 
Alkylating of DNA 
restricting uncoiling and 
replication 
Carbamylation of amino 
acids in proteins 
 
Brain tumours, 
lymphoma 
 
Brain tumours, 
lymphoma 
 
 
Myelosuppression, 
pulmonary and renal 
toxicity 
Pulmonary and renal 
toxicity 
 
Inorganic ions 
Cisplatin 
Inhibits DNA uncoiling Carcinoma of the lung, 
testis, breast and 
stomach 
Anaemia, Ototoxicity, 
Peripheral neuropathy 
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Biological response 
modification  
Interferon 
Antiproliferative effect Lymphomas, renal cell 
carcinoma, melanoma 
Fatigue, fever, myalgias, 
arthralgias, 
Myelosuppression  
Enzymes 
Asparaginase 
Depletion of asparagine Acute lymphocytic 
leukaemia 
Acute anaphylaxis, 
hyperthermia, 
hyperglycaemia 
Hormones 
Tamoxifen 
Flutamide 
 
Anti-oestrogen 
Anti-androgen 
Carcinoma of the 
breast 
Carcinoma of the 
prostate 
Hot flashes, deep vein 
thrombosis 
Hot flashes, 
gynaecomastia 
(Beers and Berkow, 2004; McCleland, 2003; Dipiro et al., 2011) 
6.1.5 Agents utilised as controls for the assays 
Melphalan is currently one of the most widely used anticancer drugs in the world 
(Katzung, 2009). 
Melphalan was first synthesized in 1953 by Bergel and Stock, and was found to have 
significant antitumor activity against multiple myeloma, melanoma, ovarian and breast 
cancer (Katzung, 2009). 
Melphalan is classified as a bifunctional alkylating agent. It is thus able to react with two 
groups, causing intra- or interchain cross-linking. Melphalan is thus able to interfere with 
both transcription and replication. Other effects of alkylation at guanine N7 includes 
excision of the guanine base with main chain scission, or pairing of the alkylated 
guanine with thymine instead of cytosine and ultimately substitution of the guanine (G) 
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cytosine (C) (GC) pair by anadenine (A) thymine (T)(AT) pair. The main action occurs 
during replication, when some parts of the DNA are unpaired and more susceptible to 
alkylation. In other words the effects take place during the S phase of the cell cycle, 
resulting in a block at G2 and ultimately apoptotic cell death. Alkylating agents are most 
active in the resting phase of the cell. These drugs are cell cycle non-specific. 
Melphalan is a phenylalanine derivative of nitrogen mustard. Nitrogen mustards are 
related to sulphur mustard, the “mustard gas” used during the First World War, with a 
basic formula RN-bis-(2-chloroethyl). In the body the 2-chloroethyl side-chain 
undergoes an intermolecular cyclisation with the release of a Cl- ion. The highly reactive 
ethylene immonium derivative can thus interact with the DNA and other molecules 
(Rang et al., 2011). 
6.2 Methodology 
Methods employed by Huq et al. (2004) and Cunningham (2006) were adapted to 
develop a method to test the anticancer activity of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-
4Cl-Pro). 
6.2.1 Cell cultures 
Three human cancerous cell lines, namely HeLa, HT-29 and MCF-7, were used in the 
experiments. Primary cell cultures were obtained from Highveld Biological, South Africa 
(SA), and were stored in liquid nitrogen until needed. Table 6.3 illustrates the 
characteristics of the respective cancerous cell cultures. 
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Table 6.3    Characteristics of cell cultures uti l ised for experiments 
Characteristic HeLa HT-29 MCF-7 
Morphology Epithelial Epithelial Epithelial 
Origin Cervix Colon Pleural effusion from 
breast tissue 
Species Human Human Human 
Age Adult Adult Adult 
Ploidy Aneuploid Aneuploid Aneuploid 
Characteristics Continuous cell line 
from neoplastic tissue 
Continuous cell line 
from neoplastic tissue 
Continuous cell line from 
neoplastic tissue; 
oestrogen receptor 
positive 
Adherent/Suspension 
culture 
Adherent Adherent Adherent 
(Jones, 2002; Pitchen 2002) 
6.2.2 Cell line maintenance and routine culture 
All procedures for experiments were carried out using sterile culture techniques. The 
cells were sub-cultured and maintained using standard procedures (Freshney, 2001). 
HeLa, HT-29 and MCF-7 cell cultures were routinely maintained in 25 cm3 culture flasks 
(Corningware, Cambridge, USA) in RPMI 1640 growth medium (pH 7.4) (Highveld 
Biological, SA), containing 10% heat-inactivated foetal calf serum (FCS) (Adcock 
Ingram, SA). Conventional culture conditions were maintained, namely 37 °C with 5% 
CO2 humidification in a Labtec® humidified carbon dioxide incubator (Labtec® 
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ThermoForma®, SA). Growth medium was replaced every 48 hours. Cell lines were 
sub-cultured at a seeding density of 2.5 x 104 cells/ml in 10 ml. For sub-culturing, the 
respective cell line was rinsed with phosphate buffered saline (PBS). This was followed 
by removing the cells from the culture substrate. The cells were dissociated by the 
addition of 1 ml of 0.25% trypsin in ethylenediaminetetraacetic acid (EDTA), pre-
warmed at 37 °C (Roche Diagnostics GmbH, Mannheim). This initial wash with trypsin/ 
EDTA was removed immediately, and 1 ml trypsin/ EDTA were added to the cells for 
approximately 5 minutes at 37°C. This was removed along with disaggregation by 
pipetting of the detaching cells into growth medium (final density of 1/10 in the medium). 
The dish and any residual cells were washed with more medium and added to the first 
cell suspension. The cells were incubated in a Labtec® humidified carbon dioxide 
incubator (Labcon®, SA) for 10 minutes, before being resuspended in 9 ml of growth 
medium. Sub-culturing allows for the expansion of the culture, providing large amounts 
of consistent material suitable for prolonged use (Freshney, 2001). 
6.2.3 Preparation of solutions 
6.2.3.1 Negative control  
The negative control was utilised to indicate 100% viability of cell line growth and 
consisted of untreated cells. The positive control anti-cancer agent Melphalan was 
dissolved in 1% ethanol. Therefore vehicle controls consisting of 0.5% or 0.25% DMSO 
or 1% ethanol made up to a final volume in RPMI medium containing 10% FCS pre-
warmed to 37 °C to control for any effect the DMSO or ethanol might have on the cell 
growth. Vehicle controls consisted of dimethyl sulphoxide (DMSO), made up to a final 
volume of 0.5% or 0.25% with RPMI medium containing 10% FCS pre-warmed to 37 
°C. to control for any effect the DMSO might have upon the cell growth. DMSO was 
used to aid the solubilisation of the relevant cyclic dipeptides to be tested. Labrofil, was 
also tested as a potential agent, but was found to be too toxic to the cells, so this was 
not used. All test and control solutions were filter-sterilised through a sterile 0.22 µm 
acrodisc and added using a Falcon® serological pipette (Falcon®, USA). 
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6.2.3.2 Polyethylene glycol (PEG) 
Polyethylene glycol (PEG) is a polyether compound. PEG 300 was added at a 
concentration of 0.05% to increase the effectiveness of uptake of the cyclic dipeptides. 
Concentrations of PEG higher than 0.05% was found to be toxic to the cells. This was 
added to the DMSO or ethanol as a vehicle in one set of experiments. 
6.2.3.3 Positive control  
 The positive control, consisting of melphalan (Adcock Ingram, SA) at a concentration of 
100 µM, was utilised to test the susceptibility of the cancerous cell cultures. Melphalan 
was dissolved in 1% ethanol (final concentration) together with vortex agitation (Vortex 
Mixer BM300, Laboratory supplies (Pty) Ltd, SA) to aid in the solubilisation of 
melphalan. The positive control was then made up to concentration with RPMI medium 
containing 10% FCS, which was pre-warmed to 37°C. The positive control was filter-
sterilised through a 0.22 µm acrodisc (seperations) and added to all cell cultures using a 
sterile Falcon® serological pipette (Falcon®, USA). 
6.2.3.4 Cyclic dipeptide solutions   
Cyclo(Phe-4Cl-Pro) (A) and cyclo(D-Phe-4Cl-Pro) (B) were aseptically prepared in 
0.25%, or 0.5% DMSO (final concentration) which together with vortex agitation initially 
aided in the solubilisation of the cyclic dipeptides. The cyclic dipeptides were then made 
up to concentration with RPMI medium containing 10% FCS, which was pre-warmed to 
37°C. The cyclic dipeptides were filter-sterilised through a 0.22 µm sterile acrodisc 
(seperations) and added to all cell cultures using a Falcon® serological pipette (Falcon®, 
USA). 
6.2.3.5 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye solution  
Tetrazolium salts have been used extensively to demonstrate the reductive capacity of 
tissues. Tetrazolium salts are a large group of heterocyclic organic compounds that 
form highly coloured and often insoluble formazans after reduction. First prepared in 
1894, these compounds have been used widely as indicators of both biological redox 
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systems and viability. MTT is a monotetrazolium salt, the reduction of which is one of 
the most frequently used methods for measuring cell proliferation and cytotoxicity. MTT 
is water soluble yielding a yellowish solution when prepared in media or salt solutions 
lacking phenol red. Dissolved MTT is converted to an insoluble purple formazan by 
cleavage of the tetrazolium ring by dehydrogenase enzymes. Only active mitochondrial 
dehydrogenases of living cells, and not dead cells, will cause this conversion. The water 
insoluble formazan can then be dissolved using DMSO or other solvents and the 
dissolved material is measured spectrophotometrically yielding absorbance as a 
function of concentration of the converted dye. Absorbance of the converted dye is 
measured at a wavelength of 540 nm (Liu et al., 1997; Mosmann, 1983). 
MTT (Sigma Chemicals Co., USA) was dissolved in 0.1 M PBS (pH 7.4) to give a stock 
concentration of 1 mg/ml. The solution was then filter-sterilised through a 0.22 µm 
acetate filter and stored, for not more than two weeks, in a sterile Schott bottle at 4 °C 
and away from light until needed. 
6.3. Cytotoxity assays utilizing MTT 
HeLa, HT-29 and MCF-7 cell lines (Section 6.2.1) in exponential growth, showing 70-
80% confluence, were trypsinised with 0.25% trypsin to enable the detachment of cells 
(Section 6.2.2). Cell numbers were then determined by haemocytometer counts using 
an improved neubauer chamber (Bright-line Superior, Germany), and diluted with 
growth medium (Section 6.2.2) to a concentration of 6000 cells/200 µl prior to use. Each 
cell line was tested in separate 96-well flat-bottom microtitre plates (Costar, Corning). 
200 µl of each cell suspension was transferred to the wells of 96-well flat-bottom 
microtitre, plates leaving a control set of 4 replicate wells that contained the medium 
alone (blanks for MTT) assay. This was incubated at 37 °C with 5% CO2 humidification 
for 24 hours. After incubation the cells had attached to the bottom of the wells, which 
enabled the growth medium to be aspirated off. The negative controls (Section 6.2.3.1), 
positive control (Section 6.2.3.3) and cyclic dipeptide solutions (Section 6.2.3.4) were 
then added to the wells in aliquots of 200 µl at appropriate final concentration in culture 
medium, such that each treatment yielded results in quadruplicate. The microtitre plates 
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were subsequently incubated at 37 °C with 5% CO2 humidification for a further 48 
hours. Incubation allowed for the drug compounds to interact with the respective cell 
lines. After 48 hours of incubation the growth medium was aspirated off and discarded 
from each well. 200 µl aliquots of MTT solution (Section 6.2.3.4) were then added to 
each well of the microtitre plates. The MTT containing microtitre plates were then 
incubated at 37 °C with 5% CO2 humidification for three hours to allow for the metabolic 
reduction of the MTT. This resulted in the formation of insoluble formazan precipitates. 
The MTT supernatant was aspirated off and discarded, and replaced with 200 µl 
aliquots of DMSO, which were required to dissolve the formazan precipitate. Each 
microtitre plate was then placed on a plate shaker for 5 minutes and the absorbance 
read immediately at 540 nm on a multiscan MS® (version 4.0) Labsystem® type 352 
microtitre plate spectrophotometer (Multiscan MS®, England) (Huq et al., 2004; 
Cunningham, 2006). Experiments were conducted in quadruplicate. Results were 
reported as the percentage inhibition of growth for each cell culture, after 48 hours of 
exposure to the cyclic dipeptides or the positive control, relative to the appropriate 
negative vehicle control culture. 
6.4 Statistical analysis  
Results were obtained as quadruplicate values and the blank (no cell) subtracted from 
each of the values. Data was represented as a mean ± standard deviation (SD). 
Percentage growth inhibition, after 48 hours of exposure to the cyclic dipeptides, was 
calculated with reference to the appropriate vehicle and compared to the positive 
controls.  
Percentage growth inhibition was calculated as follows: 
% inhibition = 100 – [
                       
                                 
] x 100 
0.25% DMSO was the vehicle for the 1 mM concentrations, 0.5% DMSO was the 
vehicle for the 2 mM concentrations and 1% ethanol was the vehicle for Melphalan. 
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Data were represented graphically with the aid of statistical software packages, 
Microsoft Excel® (Version 2007) and Graph Pad Prism® (Version 5). In order to 
determine whether the cyclic dipeptides under investigation caused statistically 
significant reduction in cell viability relative to the negative control, Student‟s t-tests 
were performed on the raw data for each concentration of cyclic dipeptide. Calculated p-
values of less than 0.05 were defined as an indication of statistical significance. 
6.5 Results and discussion 
The inhibitory effects produced by the different concentrations of cyclo(Phe-4Cl-Pro) 
and cyclo(D-Phe-4Cl-Pro) and melphalan on HeLa, MCF-7 and HT-29 cell growth after 
48 hours of exposure to the compounds are illustrated in Figures 6.2, 6.3, 6.4, 6.5, 6.6 
and 6.7 respectively. The inhibitory effects produced by all concentrations of cyclic 
dipeptides were compared to that of melphalan (Tables 6.4, 6.5, 6.6, 6.7, 6.8, and 6.9). 
The effects of PEG to aid entry/uptake of the compounds were tested by omitting PEG 
from the treatments. 
6.5.1 HeLa cell line 
The percentage growth inhibition produced by all screening concentrations of 
cyclo(Phe-4Cl-Pro)  and cyclo(D-Phe-4Cl-Pro) was found to be notably less than that 
produced by melphalan. Melphalan at a concentration (in 1% ethanol and with 0.05% 
PEG 300) of 100 μM exhibited a percentage growth inhibition of 86.88% ± 5.869 (P < 
0.0001). Cyclo(Phe-4Cl-Pro) (in 0.5% or 0.25% DMSO with 0.05% PEG 300) at 
concentrations of 2000 μM and 1000 μM exhibited percentage growth inhibitions of only 
55.28% ± 0.4332 (P < 0.0001) and – 1.747% ± 2.355 (P < 0.0001), respectively. 
Similarly, cyclo(D-Phe-4Cl-Pro) (in 0.5% or 0.25% DMSO with 0.05% PEG 300) at 
concentrations of 2000 μM and 1000 μM exhibited percentage growth inhibitions of 
32.86% ± 2.144 (P < 0.0001) and 11.75% ± 2.697 (P = 0.0460), respectively.  
Melphalan (in 1% ethanol without PEG 300) at a concentration of 100 µM exhibited a 
growth inhibition of 14.47% ± 6.606 (P < 0.0001). Cyclo(Phe-4Cl-Pro) (in 0.5% or 0.25% 
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DMSO without 0.05% PEG 300) at concentrations of 2000 μM and 1000 μM exhibited 
growth inhibitions of only 34.61% ± 1.14519 (P = 0.0402) and 26.29% ± 1.4287 (P < 
0.0001), respectively. Cyclo(D-Phe-4Cl-Pro) (in 0.5%  or 0.25% DMSO without 0.05% 
PEG 300) at concentrations of 2000 μM and 1000 μM exhibited growth inhibitions of 
45.86% ± 7.706 (P < 0.0001) and 32.13% ± 19.779 (P < 0.0001), respectively. 
Percentage growth inhibition of HeLa cells produced by cyclo(Phe-4Cl-Pro) and 
cyclo(D-Phe-4Cl-Pro) was found to be concentration-dependant, with increasing 
concentrations causing enhanced inhibition. Although cyclo(Phe-4Cl-Pro) and cyclo(D-
Phe-4Cl-Pro) produced statistically significant inhibition of growth relative to the 
negative control, it is evident that their clinical cytotoxic potential against HeLa cell 
growth is fairly limited, since melphalan at 100 µM concentration is more than twice as 
effective in inhibiting the cell growth. The effects produced by cyclo(Phe-4Cl-Pro), 
cyclo(D-Phe-4Cl-Pro) and melphalan compared to the negative control, are represented 
in Table 6.4. 
 
Figure 6.2    Percentage growth inhibition of HeLa cell line after 48 hour exposure to cyclo(Phe-4Cl-Pro) 
(A) and cyclo(D-Phe-4Cl-Pro) (B) and melphalan (n =4)  (vehicle with PEG) 
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Table 6.4    Percentage growth inhibit ion of HeLa cell l ine after 48 hour exposure to 
cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) and melphalan (n =4)  (vehicle with PEG) 
Agent Concentration % Inhibition P-value 
Melphalan 100 µM 86.88 ± 5.869 
 
 
< 0.0001 
 
Cyclo(Phe-4Cl-Pro)  2000 µM 55.28 ± 0.4332 
 
<0.0001 
1000 µM -1.747 ± 2.355 
 
< 0.0001 
 
Cyclo(D-Phe-4Cl-Pro)  2000 µM 32.86 ± 2.144 
 
< 0.0001 
 
1000 µM 11.75 ± 2.697 
 
< 0.0001 
 
Results are reported as percentage inhibition relative to the negative control cell lines 
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Figure 6.3    Percentage growth inhibition of HeLa cell line after 48 hour exposure to cyclo(Phe-4Cl-Pro) 
(A) and cyclo(D-Phe-4Cl-Pro) (B) and melphalan (n =4)  (vehicle without PEG) 
Table 6.5    Percentage growth inhibit ion of HeLa cell l ine  after 48 hour exposure to 
cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) and melphalan (n =4)  (vehicle without PEG) 
Agent Concentration % Inhibition P-value 
Melphalan 100 µM 14.47 ± 6.606 
 
< 0.0001 
 
 
Cyclo(Phe-4Cl-Pro)  2000 µM 34.61 ± 1.4519 
 
0.0402 
 
1000 µM 26.29 ± 1.4287 
 
< 0.0001 
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Cyclo(D-Phe-4Cl-Pro)  2000 µM 45.86 ± 7.706 
 
< 0.0001 
 
1000 µM 32.13 ± 19.779 
 
< 0.0001 
 
Results are reported as percentage inhibition relative to the negative control cell lines 
6.5.2 MCF-7 cell line 
The inhibitory effects produced by the different screening concentrations of cyclo(Phe-
4Cl-Pro), cyclo(D-Phe-4Cl-Pro) and melphalan on MCF-7 cell growth after 48 hours of 
exposure to the compounds are illustrated in Figure 6.4. Percentage growth inhibition 
produced by all screening concentrations of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-
Pro) was found to be notably less than that produced at a 100 µM concentration for 
melphalan. Melphalan (in 1% ethanol with 0.05% PEG 300) at a concentration of 100 
μM exhibited percentage growth inhibition of 82.39% ± 2.058 (P < 0.0001). Cyclo(Phe-
4Cl-Pro) (in 0.5% or 0.25% DMSO with 0.05% PEG 300) at concentrations of 2000 μM 
and 1000 μM exhibited percentage growth inhibitions of 71.62% ± 0.1252 (P < 0.0001) 
and 31.66% ± 1.127 (P < 0.0001), respectively. Cyclo(D-Phe-4Cl-Pro) (in 0.5% or 
0.25% DMSO with 0.05% PEG 300) at concentrations of 2000 μM and 1000 μM 
exhibited percentage growth inhibitions of 50.84% ± 0.5489 (P < 0.0001) and 29.79% ± 
0.9773 (P < 0.0001), respectively.  
Melphalan (in 1% ethanol without 0.05% PEG 300) at a concentration of 100 µM 
exhibited a growth inhibition of 86.06% ± 1.632 (P < 0.0001). Cyclo(Phe-4-Cl-Pro) (in 
0.5% or 0.25% DMSO without 0.05% PEG 300) at concentrations of 2000 µM and 1000 
µM exhibited percentage growth inhibitions of 18.56% ± 1.972 (P < 0.0001) and  -
5.499% ± 0.5015 (P < 0.0001). Cyclo(D-Phe-4Cl-Pro) (in 0.5% or 0.25% DMSO without 
PEG) at concentrations of 2000 μM and 1000 μM exhibited percentage growth 
inhibitions of 21.98091% ± 4.750 (P = 0.0340) and 19.77% ± 2.382 (P < 0.0001). 
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Although cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) at concentrations of 2000 μM 
and 1000 μM produced statistically significant inhibition of growth relative to the 
negative control, their clinical relevance against MCF-7 cell growth is questionable, 
since melphalan at 100 µM is more than three times as effective in inhibiting the cell 
growth. The effects produced by cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) and 
melphalan compared to the negative control, are represented in Table 6.6. 
 
Figure 6.4    Percentage growth inhibition of MCF-7 cell line after 48 hour exposure to cyclo(Phe-4Cl-
Pro) (A) and cyclo(D-Phe-4Cl-Pro) (B) and melphalan (n =4)  (vehicle with PEG) 
Table 6.6    Percentage growth inhibit ion of MCF-7 cell l ine after 48 hour exposure to 
cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) and Melphalan (n =4)  (vehicle with PEG) 
Agent Concentration % Inhibition P-value 
Melphalan 100 µM 82.39 ± 2.058 
 
 
 
< 0.0001 
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Cyclo(Phe-4Cl-Pro)  2000 µM 
71.62 ± 0.1252 <0.0001 
 1000 µM 31.66 ± 1.127 
 
 
<0.0001 
Cyclo(D-Phe-4Cl-Pro)  2000 µM 50.84 ± 0.5489 
 
 
< 0.0001 
 1000 µM 29.79 ± 0.9773 
 
 
<0.0001 
Results are reported as percentage inhibition relative to the negative control cell lines 
 
Figure 6.5    Percentage growth inhibition of MCF-7 cell line after 48 hour exposure to cyclo(Phe-4Cl-Pro) 
(A) and cyclo(D-Phe-4Cl-Pro) (B) and Melphalan (n =4)  (vehicle without PEG) 
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Table 6.7    Percentage growth inhibit ion of MCF-7 cell l ine after 48 hour exposure to 
cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) and melphalan (n =4)  (vehicle without PEG) 
Agent Concentration % Inhibition P-value 
Melphalan 100 µM 86.06 ± 1.632 
 
 
< 0.0001 
 
 
Cyclo(Phe-4Cl-Pro)  2000 µM 18.56 ± 0.5015 
 
< 0.0001 
 
1000 µM -5.499 ± 1.972 
 
< 0.0001 
 
Cyclo(D-Phe-4Cl-Pro)  2000 µM 21.98091± 2.382 
 
0.0340 
 
1000 µM 19.77 ± 4.750 
 
< 0.0001 
 
Results are reported as percentage inhibition relative to the negative control cell lines 
6.5.3 HT-29 cell line 
The inhibitory effects produced by the different screening concentrations cyclo(Phe-4Cl-
Pro), cyclo(D-Phe-4Cl-Pro) and melphalan on HT-29 cell growth after 48 hours of 
exposure to the compounds are illustrated in Figure 6.6. Again percentage growth 
inhibition produced by all screening concentrations of cyclo(Phe-4Cl-Pro) and cyclo(D-
Phe-4Cl-Pro) was found to be notably less than that produced for melphalan. Melphalan 
at a concentration (in 1% ethanol with 0.05% PEG 300) of 100 μM exhibited percentage 
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growth inhibition of 71.30% ± 1.035 (P = 0.0006). Cyclo(Phe-4Cl-Pro) (in 0.5% or 0.25% 
DMSO with 0.05% PEG 300) at a concentration of 2000 μM exhibited a percentage 
growth inhibition of 56.65% ± 0.3647 (P = 0.0006) and at 1000 µM 35.73% ± 2.645 (P < 
0.0001). Cyclo(D-Phe-4Cl-Pro) (in 0.5% or 0.25% DMSO with 0.05% PEG 300) at a 
concentration of 2000 μM exhibited  percentage growth inhibition of 47.63% ± 1.583 (P 
< 0.0001), and at 1000 µM 32.54% ± 3.261 (p < 0.0001).  
Melphalan (in 1% ethanol without 0.05% PEG 300) at a concentration of 100 µM 
exhibited a growth inhibition of 44.45% ± 3.370 (P < 0.0001). Cyclo(Phe-4Cl-Pro) (in 
0.5% or 0.25% DMSO without 0.05% PEG 300) at a concentration of 2000 μM exhibited 
a percentage growth inhibition of 25.66% ± 1.525 (P = 0.0007) and at 1000 µM 19.77% 
± 4.750 (P < 0.0001). Cyclo(D-Phe-4Cl-Pro) (0.5% or 0.25% DMSO without PEG 300) 
at a concentration of 2000 μM exhibited a percentage growth inhibition of 24.60% ± 
2.4200 (P = 0.0002) and at a 1000 µM 21.61% ± 2.3300 (P < 0.0001). Percentage 
inhibition of HT-29 cell growth produced by cyclo(Phe-4Cl-Pro),cyclo(D-Phe-4Cl-Pro) 
and melphalan was found to also be concentration-dependant. Although cyclo(Phe-4Cl-
Pro) and cyclo(D-Phe-4Cl-Pro) produced statistically significant inhibition of growth 
relative to the negative control, it is evident that both cyclic dipeptides‟ cytotoxic 
potential against HT-29 cell growth is very limited, since melphalan at 100 µM is more 
than ten times as effective in inhibiting the cell growth. The effects produced by 
cyclo(Phe-4Cl-Pro), cyclo(D-Phe-4Cl-Pro) and melphalan compared to the negative 
control, are represented in Table 6.8. 
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Figure 6.6    Percentage growth inhibition of HT-29 cell line after 48 hour exposure to cyclo(Phe-4Cl-
Pro) (A) and cyclo(D-Phe-4Cl-Pro) (B) and melphalan (n =4)  (vehicle with PEG) 
Table 6.8    Percentage growth inhibit ion of HT-29 cell l ine after 48 hour exposure to 
cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) and melphalan (n =4)  (vehicle with PEG) 
Agent Concentration % Inhibition P-value 
Melphalan 100 µM                             
 
71.30 ± 1.035  
 
0.0006 
 
Cyclo(Phe-4Cl-Pro)  2000 µM 56.65 ± 0.3647 
 
0.0006 
 
1000 µM 35.73 ± 2.645 
 
< 0.0001 
 
Cyclo(D-Phe-4Cl-Pro)  2000 µM 47.63 ± 1.583 
 
< 0.0001 
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1000 µM 32.54 ± 3.261 
 
< 0.0001 
 
Results are reported as percentage inhibition relative to the negative control cell lines 
 
Figure 6.7    Percentage growth inhibition of HT-29 cell line after 48 hour exposure to cyclo(Phe-4Cl-
Pro) (A) and cyclo(D-Phe-4Cl-Pro) (B) and Melphalan (n =4)  (vehicle without PEG) 
Table 6.9    Percentage growth inhibit ion of HT-29 cell l ine after 48 hour exposure to 
cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) and melphalan(n =4)  (vehicle without PEG) 
Agent Concentration % Inhibition P-value 
Melphalan 100 µM                             
 
44.45 ± 3.370 
 
 
< 0.0001 
 
Cyclo(Phe-4Cl-Pro)  2000 µM 25.66 ± 1.525 
 
0.0007 
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1000 µM 17.83 ± 0.992 
 
< 0.0001 
Cyclo(D-Phe-4Cl-Pro) 2000 µM 24.60 ± 2.4200 
 
0.0002 
 
1000 µM 21.61 ± 2.3300 
 
< 0.0001 
 
Results are reported as percentage inhibition relative to the negative control cell lines 
6.6 Conclusion 
Natural and synthetic peptides have been shown to exhibit therapeutic anticancer 
activity against human tumours (Lee et al., 2005). 
Table 6.10 and Table 6.11 summerises the percentage inhibition of the negative control, 
positive control, Cyclo(Phe-4Cl-Pro) and Cyclo(D-Phe-4Cl-Pro) on HeLa, HT-29 and 
MCF-7 cell lines (vehicle with and without 0.05% PEG 300), respectively. 
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Table 6.10    the percentage inhibition of the negative control, posit ive control, Cyclo(Phe -
4Cl-Pro) and Cyclo(D-Phe-4Cl-Pro) on HeLa, HT-29 and MCF-7 cell l ines (vehicle with 
0.05% PEG 300) 
Cell line Negative 
0.25% 
Negativ
e 0.5% 
Positive 
  
Cyclo(Phe-
4Cl-Pro) 
1mM 
Cyclo(Phe-
4Cl-Pro) 
2 mM 
Cyclo(D-
Phe-4Cl-
Pro) 
1 mM 
 
Cyclo(D-
Phe-4Cl-
Pro) 
2 mM 
 
HeLa -4.533% 10.86% 86.88% -1.74% 55.28% 11.75% 32.86% 
HT-29 7.90% 
 
3.74% 
 
71.30% 
 
35.73% 
 
56.65% 
 
32.54% 
 
47.63% 
 
MCF-7 -11.27% 
 
-14.91% 
 
82.38% 
 
31.65% 
 
71.62% 
 
31.65% 
 
50.84% 
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Table 6.11    the percentage inhibition of the negative control, posit ive control, Cyclo(Phe -
4Cl-Pro) and Cyclo(D-Phe-4Cl-Pro) on HeLa, HT-29 and MCF-7 cell l ines (vehicle without 
0.05% PEG 300) 
Cell line Negative 
0.25% 
Negativ
e 0.5% 
Positive Cyclo(Phe-
4Cl-Pro)   
1 mM 
Cyclo(Phe-
4Cl-Pro) 
2 mM 
Cyclo(D-
Phe-4Cl-
Pro) 
1 mM 
 
Cyclo(D-
Phe-4Cl-
Pro) 
2 mM 
 
HeLa -16.05% 
 
-10.76% 
 
14.47% 
 
26.28% 
 
34.61% 
 
32.12% 
 
45.86% 
 
HT-29 -25.18% 
 
-14.13% 
 
44.45% 
 
17.82% 
 
25.66% 
 
21.60% 
 
24.59% 
 
MCF-7 5.8635% 
 
4.16% 
 
86.05% 
 
-5.49% 
 
18.56% 
 
19.76% 
 
21.98% 
 
The results with 0.05 %PEG 300 showed more inhibition than the results withoutout 
0.05% PEG 300. Cyclo(Phe-4Cl-Pro) at a concentration of 2000 µM, showed the 
greatest inhibition for the HeLa, MCF-7 and HT-29 cell lines, with a inhibitions of 
55.28% ± 0.4332, 71.62% ± 0.1252 and 56.65% ±0.3647, respectively. Cyclo(Phe-4Cl-
Pro) at a concentration of 1000 µM produced unexpected results for the HeLa (vehicle 
with 0.05% PEG 300) cell line of -1.747% ±2.355 inhibition and at a concentration of 
100 µM for MCF-7 (Vehicle without 0.05% PEG 300) of -5.499% ±0.5015 inhibition. This 
requires further investigation.    
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A study conducted by (Brauns, 2004) on the effects of cyclo(Phe-Pro) on HT-29, HeLa 
and MCF-7 cell lines showed that cyclo(Phe-Pro) exhibited more than 50% growth 
inhibition (p < 0.01) in the three cell lines. Cyclo(Phe-Pro) exhibited significant growth 
inhibition at concentrations of 5 mM (p < 0.01) and 10 mM (p < 0.01) in all three cell 
lines. The IC50 values for cyclo(Phe-Pro) were 5.24 ± 1.25 mM in HT-29, 3.85 ± 1.26 
mM in HeLa and 5.07 ± 1.32 mM in MCF-7 cells. 
Cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) exhibited limited potential as anticancer 
agents against HeLa, HT-29, MCF-7 cell lines when compared to melphalan. They are 
only effective at very high concentration (1mM and 2 mM), yielding better results at 2 
mM. It has been suggested that the hydrophobicity of peptides, rather than the number 
of hydrophobic amino acids, may play an important role in anticancer activity or 
membrane transport (Lee et al., 2005). The limited anticancer activity demonstrated by 
both cyclic dipeptides may therefore be as a result of poor solubility, which hinders their 
ability to cross the cell membranes and steric hindrance. Future studies could possibly 
include, investigating the toxicity with normal cells and ways of optimising the delivery or 
uptake of the cyclic dipeptides into the cells. 
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CHAPTER 7 
ANTIMICROBIAL STUDIES 
7.1 Introduction 
The continuous use of antibiotics has resulted in the emergence of multi-resistant 
bacterial strains all over the world and as expected, hospitals have become breeding 
grounds for human associated microorganisms. It‟s widely accepted among clinicians, 
medical researchers, microbiologist and pharmacologists, that antibiotic resistance will, 
in the very near future, leave healthcare professionals without effective therapies for 
bacterial infections. Antibiotics rank the most important medical advancements of the 
20th century (Lipsitch 2001). It is now estimated that about half of all S. aureus strains 
found in many medical institutions are resistant to antibiotics such as methicillin. The 
emerging resistance of enterococci to another useful and widely effective antibiotic, 
vancomycin might accelerate the spread of vancomycin-resistant genes, eventually 
limiting the efficacy of this drug. Consequently, the priority for the next decades should 
be focused on the development of alternative drugs and/or the recovery of natural 
molecules that will allow the consistent and proper control of pathogen-caused 
diseases. Ideally, these molecules should be as natural as possible, with a wide range 
of action over several pathogens, easy to produce, and not prone to introduce 
resistance (Marshall and Arenas, 2003). 
It is important to differentiate between those bacteria that are pathogenic, non-
pathogenic and opportunistically pathogenic. The choice of antimicrobial agent is 
essential to ensure that only the pathogenic organism is eliminated, and not colonising 
flora, which are crucial for normal body function (Dipiro et al., 2011). 
Microorganisms are said to be opportunistically pathogenic, when the growth of 
colonising flora are unopposed by normal other bacterial flora. Commonly an 
opportunistic infection can occur as a result of yeast overgrowth, when bacterial flora is 
eradicated by antibacterial therapy intended to eradicate pathogenic organisms. The 
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ideal antimicrobial agent would be specific for pathogenic bacteria, without disrupting 
the normal colonising bacteria (Dipiro et al., 2011). Table 7.1 lists those bacteria that 
are naturally occurring flora, while Table 7.2 list commonly occurring pathogenic 
bacteria. 
Table 7.1    Normal colonising flora (Dipiro et al., 2011). 
Skin 
Staphylococci (coagulase-negative) 
Streptococci 
Diphtheroids (corynebacterium sp.) 
Propionibacteria 
Upper respiratory tract 
Bacteroides sp. 
Haemophilus sp. 
Streptococci 
Neisseria sp. 
Gastrointestinal tract 
Bacteroides sp. 
Anaerobic streptococci 
Fusobacterium sp. 
Enterobacteriaceae 
Diphtheroids 
Clostridium sp. 
Genital tract 
Staphylococci 
Streptococci 
Enterobacteriaceae 
Corynebacterium sp. 
Mycoplasma sp. 
Lactobacillus sp. 
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Table 7.2    Commonly occurring pathogenic bacteria (Dipiro et al., 2011). 
Gram-positive cocci 
Staphylococci 
Coagulase positive 
S. aereus 
Coagulase negative 
S. Epidermidis 
Streptococci 
Anaerobes 
Peptostreptococcus 
Streptococcus pneumoniae 
Group A, β-haemolytic 
Streptococcus pyogenes 
Group B 
Streptococcus agalactiae 
Group D 
Enterococcal species 
Gram-negative bacilli 
Anaerobes 
Bacteroides fragilis 
Enterobacteriaceae 
Citrobacter sp. 
Enterobacter sp. 
Escherichia coli 
Klebsiella sp. 
Serratia sp. 
Proteus sp. 
Salmonella sp. 
Pseudomonas sp. 
P. aeruginosa 
P. cepacia 
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E. raffinosus 
E. faecalis 
Non-enterococcal species 
Streptococcus bovis 
Viridans group 
Streptococcus mutans 
Gram-positive bacilli 
Bacillus sp. 
Bacillus cereus 
Clostridium sp. 
Clostridium difficile 
Clostridium perfringens 
Clostridium tetani 
Diphtheroids 
Corynebacterium diphtheriae 
Xanthomonas maltophilia 
Gram-negative cocci 
Moraxella caterrhalis 
Neisseria gonorrhoeae 
Neisseria meningitidis 
 
Mycobacteria (acid-fast bacilli) 
Mycobacterium tuberculosis 
Mycobacterium bovis 
165 
 
Fungi 
Yeasts 
Candida sp. 
Cryptococcus neoformans 
Aspergillus sp. 
Aspergillus fumigatus 
 
7.1.1 Current modes of antimicrobial therapy  
Figure 7.1 summarises the classes of antimicrobial agents by their mechanism of 
action. There are five major processes, namely, inhibition of cell wall synthesis, folate 
metabolism, DNA and RNA synthesis, protein synthesis and interfering with the 
bacterial cell membrane, through which currently available antimicrobial agents exhibit 
their mechanism of action (Katzung, 2009).  
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Figure 7.1    Sites of action of antimicrobial agents (Page et al., 1997). 
7.1.2 Inhibitors of bacterial cell wall synthesis 
Sub-classes within this class include the β-lactams (penicillins, cephalosporins, 
monobactams, β-lactamase inhibitors and carbapenems), vancomycin, teicoplanin, 
fosfomycin, bacitracin and cycloserine. Inhibitors of cell wall synthesis exhibit their 
action through interfering with the synthesis of peptidoglycan, a major component of the 
bacterial cell wall, which is exclusive to bacteria. This enables the antibacterial agent to 
destroy the bacterial cell with little or no effect on normal human cells. Initiation of 
peptidoglycan synthesis (Figure 7.2) begins with the conversion of glucose-6-phosphate 
(Glc-6-p) to N-acetylglucosamine (NAcGlc or G) which complexes with uridine 
diphosphate (UDP). The N-acetylglucosamine portion of the UDP–G molecule is then 
converted by enolpyruvate transferase with the addition of phosphoenolpyruvate to 
UDP–N-acetylmuramic acid (UDP-M). Fosfomycin inhibits enolpyruvate transferase and 
thus inhibits the formation of peptidoglycan at a very early stage of its synthesis. Once 
UDP-M is formed, five amino acids are incorporated into the molecule namely L-Ala-D-
Glu-L-Lys-D-Ala-D-Ala. Cycloserine is a structural analogue of alanine and blocks the 
enzyme alanine racemase, which converts L-Ala into D-ala to be incorporated into the 
pentapeptide unit. The M-pentapeptide unit is then transferred from its UDP carrier to a 
lipid membrane carrier, bactropenol (BP). BP requires dephosphorylation in order to 
bind to the pentapeptide sub-unit. Bacitracin interferes with the dephosphorylation of BP 
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and therefore prevents the transmembrane transport of peptidoglycan sub-units. A 
molecule of N-acetylglucosamine is then bonded to the N-acetylmuramic acid portion of 
the peptidoglycan sub-unit, after which a [Gly]5 pentapeptide is bonded to the lysine 
residue. BP then transports this molecule to the extracellular surface, where it binds, 
with the aid of the enzyme transglycosylase, to a growing peptidoglycan chain. 
Vancomycin inhibits the actions of transglycosylase by firmly binding to the D-Ala-D-Ala 
portion of the peptidoglycan sub-unit. Chains are then cross-linked by the removal of the 
terminal D-Ala and binding to an adjacent peptide. Penicillin-binding proteins (PBP) 
catalyse this transpeptidase reaction. PBP also bind β-lactams, which then inhibit the 
cross-linking of peptidoglycan strands and reduces the rigidity, resulting in breakdown of 
the bacterial cell wall (Dipiro et al., 2011; Katzung, 2009). 
 
Figure 7.2    Peptidoglycan synthesis (Katzung, 2009).  
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The biosynthesis of a Peptidoglycan cell wall showing sites of action of fosfomycin (1), cycloserine (2), 
bacitracins (3), vancomycin (4), β-lactam antibiotics (5). 
β-lactams are the most favourable agents to use of the cell wall synthesis inhibitors and 
consists of five main groups, the penicillin, cephalosporins, monobactams, β-lactamase 
inhibitors and carbapenems. Penicillins, (see general structure of penicillins Figure 7.3), 
consist of the β-lactamase sensitive (benzylpenicillin, phenoxymethylpenicillin), β-
lactamase resistant (cloxacillin, flucloxacillin) and the extended spectrum penicillins 
(amoxillin, ampicillin) (Katzung, 2009). Incorporation of clavulanic acid into preparations 
containing broad-spectrum penicillins decreases the inactivation of the penicillin by β-
lactamase. Clavulanic acid is a structural analogue to penicillin with low antibacterial 
activity, but which has a far greater affinity for the β-lactamase binding site than other 
active penicillins. Clavulanic acid is thus preferentially broken down, while the penicillins 
are capable of producing their effect unharmed (Katzung, 2009). 
 
Figure 7.3    General structure of the penicillins (Katzung, 2009). 
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Cephalosporins: 
Cephalosporins, (see general structure of cephalosporins Figure 7.4), are similar to 
penicillins, with respect to chemistry, mechanism of action and toxicity. Cross sensitivity 
between cephalosporins and penicillins are common. Cephalosporins are classed as 
first, second, third and fourth generations. First generations cephalosporins include 
cephalexin and cefazolin. This class are more effective against Gram-positive cocci. 
Second generation cephalosporins include cefamandole, cefaclor and cefoxitin. These 
agents are active against the same bacteria as the first generation agents, but have an 
added spectrum covering some Gram-negative bacteria. Cefoxitin are also active 
against anaerobic bacteria. The third generation encompasses cefotaxime, ceftriaxone 
and cefpodoxime. They have a greater activity against Gram-negative bacteria. They 
also have the ability to cross the blood brain barrier (BBB), which is beneficial in the 
treatment of bacterial meningitidis and other central nervous system infections. The 
fourth generation cephalosporins (cefepime) are very similar to the third generation with 
respect to antibacterial activity, but are more resistant to hydrolysis from β-lactamase 
(Katzung, 2009). 
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Figure 7.4    General structure of cephalosporins (Katzung, 2009). 
Other β-lactam agents: 
Other β-lactam agents include the monobactams, β-lactamase inhibitors and 
carbapenems. Aztreonam is an example of the monobactams and are most active 
against Gram-negative rods. β-Lactamase inhibitors include clavulanic acid, sulbactam 
and tazobactam, and while these agents have very little antibacterial activity 
themselves, they are structurally related to the β-lactams and inhibit β-lactamase by 
being preferentially broken down by the enzyme instead of the active β-lactam agent. 
For this reason they are co-administered with other β-lactams such as amoxillin. 
Carbapenems are structurally related to β-lactams and have a wide spectrum of activity. 
Meropenem and imipenem are some examples of this class (Katzung, 2009). 
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Vancomycin: 
Vancomycin is a glycopeptide molecule, which inhibits bacterial cell wall synthesis by 
binding to the D-Ala-D-Ala portion of the peptidoglycan sub-unit and inhibiting 
elongation of the structure (Figure 7.2) (Katzung, 2009). 
Fosfomycin: 
Fosfomycin inhibits the early stages of peptidoglycan synthesis (Figure 7.2). It is 
structurally unrelated to any other antimicrobial agent and appears to be related in 
structure to phosphoenolpyruvate, a precursor of N-acetylmuramic acid. Fosfomycin is 
active against both Gram-positive and Gram-negative bacteria and is used frequently 
for urinary tract infections (Katzung, 2009). 
Bacitracin: 
Bacitracin originates from the bacterium Bacillus subtilus and is a cyclic peptide 
“mixture” which inhibits the dephosphorylation of the peptidoglycan transporter 
bactoprenol. It thus inhibits the transfer of the peptidoglycan sub-units across the 
bacterial cell membrane (Figure 7.2). Bacitracin is active against Gram-positive 
organisms, but with limited systemic use, due to it being extremely nephrotoxic. It is 
however still used topically, limiting its systemic absorption and systemic side-effects 
(Katzung, 2009). 
7.1.3 Inhibitors of cell membrane functioning  
The polymyxins are a group of peptides displaying good inhibition of Gram-negative 
bacteria. Their mechanism is similar to cationic detergents, as they attach to the 
bacterial lipid membrane, disrupting it, leading to cell death. They are more active 
against Gram-negative bacteria as they have thinner peptidoglycan cell walls, which 
enable access of the polymyxins to the cell membrane (Katzung, 2009). 
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7.1.4 Inhibitors of protein synthesis 
Ribosomes, the intracellular organelles responsible for protein synthesis, are found in 
two sub-units, a smaller and a larger sub-unit, both of which must be associated in order 
to „translate‟ messenger RNA (mRNA) into proteins. In eukaryotic cells such as those 
found in humans, ribosomes consist of a 40S and a 60S sub-unit. In prokaryotic cells, 
such as bacteria, the ribosomes comprise a 30S and a 50S sub-unit. Due to the 
difference in ribosomal sub-units between human and bacterial cells, it is possible to 
selectively inhibit bacterial protein synthesis by inhibiting the functions of the 30S and 
50S bacterial ribosomal sub-units (Dipiro et al., 2011). 
Agents that inhibit bacterial ribosomal function, and ultimately protein synthesis, include 
the aminoglycosides, macrolides, lincosamides, streptogramins, amphenicols, and 
tetracyclines. These agents require entry into the bacterial cell in order to elicit a 
response, which often results in the formation of mutant resistant bacteria, which alter 
their permeability to the antibacterial agents. This is often a problem, but inclusion of 
cell wall synthesis inhibitors into the regime, results in breakdown of the cell wall and 
easy access of the inhibitors of protein synthesis. This synergistic effect is frequently 
exploited by prescribing of agents such as penicillin G and gentamycin together (Dipiro 
et al., 2011). 
Figure 7.5 represents a brief summary of the mechanisms of the individual classes of 
bacterial protein synthesis inhibitors. Aminoglycosides such as gentamycin, tobramycin 
and amikacin bind to the 30S ribosomal sub-unit, changing its shape, resulting in 
incorrect coding of mRNA to transfer RNA (tRNA), which carry the amino acids for 
peptide bond formation (Dipiro et al., 2011). 
Macrolides which include the prototype erythromycin as well as azithromycin and 
clarithromycin, bind to the 50S sub-unit, preventing movement of the ribosome along 
the mRNA strand (Katzung, 2009). Tetracycline, including doxycycline, minocycline and 
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tetracycline, bind to the 30S ribosomal sub-unit, interfering with the attachment of tRNA 
to the mRNA-ribosome complex, inhibiting protein synthesis (Dipiro et al., 2011). 
The amphenicols, chloramphenicol and thiamphenicol, are primarily bacteriostatic. They 
bind to the 50S ribosomal sub-unit, preventing the amino acid bound portion of the 
tRNA from binding to the growing peptide chain (Dipiro et al., 2011). 
 
Figure 7.5    Inhibitors of protein synthesis (Page et al., 1997). 
7.1.5 Inhibitors of folate metabolism 
Folates are precursors to the formation of purine basis in DNA, and although human 
cells have uptake mechanisms which enable the cell to utilise pre-formed folate for 
dietary intake, bacterial cells must synthesise their own from p-aminobenzoic acid 
(PABA). Thus, if the enzymes involved in folate synthesis are inhibited, the production 
of DNA will also be inhibited. Sulphonamides, (including sulphanilamide, 
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sulphamethoxazole and sulfadiazine), are structurally related to PABA (Figure 7.6), and 
compete with PABA binding preferentially to the enzyme, dihydropteroate synthase, 
which converts PABA into dihydrofolic acid (Figure 7.7). Trimethoprim also inhibits 
folate synthetase, by inhibiting the enzyme dehydrofolate reductase (Figure 7.7) in 
bacteria, with about 50000 times greater selectivity than the mammalian enzyme. This 
ultimately results in the inhibition of tetrahydrofolic acid synthesis, which is the precursor 
to purines (Katzung, 2009).  
 
Figure 7.6    Structure of sulphonamides in comparison to p-aminobenzoic acid (PABA) (Katzung, 2009).  
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Although these agents result in impaired DNA synthesis, resistance develops rapidly, 
enabling bacteria to utilise other pathways to produce folates. This justifies the clinical 
use of a sulphonamide with trimethoprim in order to effectively inhibit folate synthesis. 
This results in the effects of these agents to move from being bacteriostatic individually 
to being bactericidal in combination (Katzung, 2009). Together these agents are 
effective against most Gram-negative and Gram-positive bacteria as well as Chlamydia 
trachomatis and some protozoa (Dipiro et al., 2011). 
 
Figure 7.7    Folate metabolism (Katzung, 2009). 
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 7.1.6 Inhibitors of DNA and RNA synthesis 
DNA Gyrase inhibitors: 
DNA gyrase inhibitors inhibit bacterial topoisomerase II (DNA gyrase). These agents 
include the quinolones, nalidixic acid, and the fluoroquinolones, (norfloxacin, 
ciprofloxacin, ofloxacin, levofloxacin and enoxacin) (Katzung, 2009). 
RNA synthesis inhibitors: 
Inhibitors of RNA synthesis block DNA-dependant RNA polymerase and include the 
rifamycins that result in the inhibition of RNA production and ultimately cell division and 
protein synthesis. Two agents fall within this class, Rifampicin and rifabutin. These 
agents are active against some conventional bacteria such as streptococci, N. 
meningitidis, H. Influenzae type B and S. aureus, but their primarily indication is for the 
treatment of tuberculosis as well as other non-tubercular mycobacteria (Katzung, 2009). 
7.1.7 Bacterial resistance 
An increasingly alarming problem in clinical practice today, is bacterial resistance, 
where bacteria become or are inherently resistant to the effects of antibacterial agents 
resulting in severe uncontrollable infection. 
7.1.8 Mechanisms of bacterial resistance 
Two classifications of bacterial resistance can be identified, namely, innate and 
acquired. Innate refers to the intrinsic resistance a bacterium has based on the 
mechanisms of the drug, for example, if entry of the antibiotic into the cell required the 
presence of a specific transport mechanism which a certain bacteria does not possess, 
the resistance which the bacterium has for the drug is said to be innate. If however, the 
bacterium was susceptible, it acquires a gene that alters the pathways utilised by the 
drug in order to elicit its response, the resistance referred to be acquired. All antibiotics 
known have at least one strain of bacteria that is able to acquire resistance. Acquired 
resistance genes result in resistance by three main mechanisms, firstly, reduction in 
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permeability of the cell membrane, secondly preventing the entry of the antibiotic; and 
the production of bacterial enzymes which break down the drug and thirdly, mutations 
resulting in alteration of the drug‟s target site. Reduced permeability of bacterial 
membranes usually occurs in Gram-negative bacteria and alters the effects of 
antibiotics whose target site is inside the bacterial cell (Dipiro et al., 2011). 
 7.1.9 Implications 
The production of enzymes which breakdown or alter drug molecules into an inactive 
form, has become a significant problem with β-lactam antibiotics. Some strains of 
staphylococci have developed genes for the production of β-lactamase, which 
breakdown the β-lactam ring of penicillins and cephalosporins, resulting in resistance. 
This problem is of growing concern, as resistance to these agents due to β-lactamase 
production is becoming an enormous problem (Livermore, 2000).   
The need for newer antibiotics acting by alternative mechanisms is of utmost 
importance in order to solve the problem of multi-drug resistant bacterial infection. The 
use of these agents must be prescribed under complete control and monitored carefully 
to ensure patients are effectively completing courses and eradicating all pathogenic 
bacteria, so that none survive to develop resistance.  
Antimicrobial peptides have a great potential to be the next breakthrough class of 
antimicrobials (Hancock and Lehrer, 1998). Hundreds of peptide antibiotics have been 
described in the past half-century. They fall into two major classes: non-ribosomally 
synthesised peptides, such as the gramicidins, polymyxins, bacitracins, glycopeptides 
and ribosomally synthesised peptides. Non-ribosomally synthesised peptides are often 
drastically modified and are largely produced by bacteria, whereas the ribosomally 
synthesised peptides are produced by all species of life, including bacteria, as a major 
component of the natural host defence molecules of these species (Hancock and 
Chapple, 1999). 
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Many different types of organisms use antimicrobial peptides typically 20 to 40 amino 
acids in length, for defence against infection. Most are capable of rapidly killing a wide 
range of microbial cells. Epand and Vogel (1999) have classified antimicrobial peptides 
according to their structure into six extensive groups. The groups are classified as: 
amphipathic and hydrophobic helices; β-sheet peptides and small proteins; peptides 
with irregular amino acid composition; peptides with thioether rings; peptaibols; and 
macrocyclic cysteine knot peptides (Bradshow, 2003; Epand and Vogel, 1999). Table 
7.3 illustrates some features and examples of the different classified structural groups of 
antimicrobial peptides. 
Table 7.3    Classif ication of antimicrobial peptides according to Epand and Vogel (1999)  
Group Features Examples 
Amphipathic and 
hydrophobic helices 
Form membrane pores by end-
to-end association (gramicidin 
A) or toroidal pores 
(alamethicin, magainin) 
Gramicidin A 
Magainin 
Alamethicin 
β-sheet peptides and 
small proteins 
Often cyclical, ring structure 
formed by disulphide bonds or 
by cyclization of the peptide 
backbone 
Tachyplesin 
Protegrin 
Gramicidin S 
Polymixin B 
Tyrocidin 
Defensins 
Thionins  
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Peptides with irregular 
amino acid composition 
Frequently found to contain high 
levels of a single amino acid 
Histatin 
PR-39 
Prophenin 
Triitrpticin 
Indolicidin 
Peptides with thioether 
rings (lantibiotics) 
Contain the unusual amino 
acids lanthionine and β-methyl 
lanthionine, as well as 
dehydrated residues  
Nisin Z 
Cinnamycin 
Peptaibols Conformationally restricted, 
frequently as α- or 310 – helix. 
Have a high proportion of α-
amino-isobutyric acid residues. 
Derive their name from the 1,2-
amino alcohol at the C-terminus  
Trichogin 
Alamethicin 
Macrocyclic cysteine knot 
peptides 
Contain a cysteine knot motif in 
which a disulphide bond is 
threaded through two others 
Circulin A 
Circulin B 
Cyclopsychotride 
Kalata 
There are a number of reasons that make antimicrobial peptides particularly attractive 
as candidates for clinical development. Firstly, their selectivity. Many antimicrobial 
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peptides combine selective activity against prokaryotic cells with broad-spectrum 
activity. Secondly, their speed of action, by targeting the membranes on the outside of 
bacterial cells, antimicrobial peptides can be effective immediately, without the time-lag 
imposed by the need to be internalised to reach a receptor molecule. Thirdly, and 
probably the most attractive reason is that peptides have received so much attention in 
recent years because of the perturbation they cause to fundamental structural 
components of the bacterial cell. It is hoped that bacteria will not easily develop 
resistance against this mechanism of bacterial cell destruction (Bradshow, 2003). 
The concentration of antimicrobial peptide required to inhibit bacterial growth is typically 
in the micromolar range. This concentration drops to around 1 µM for the best synthetic 
analogues. These actions of antimicrobial peptides that act against bacterial cell 
membranes can be attributed to certain gross morphological features. These features 
includes: the helicity or negative charge of the peptides, their overall hydrophobicity, 
their hydrophobic moment and domain size, and their degree of amphipathicity 
(Bradshow, 2003; Epand and Vogel, 1999).    
A study conducted by Milne et al. (1998) indicated that the cyclic dipeptides cyclo(Trp-
Pro), cyclo(Trp-Trp) and cyclo(Phe-Pro) were active against Gram-positive bacteria. 
Cyclo(Trp-Pro) was also effective against Gram-negative bacteria. This finding was 
followed by a study done by Graz et al. (1999), which further confirmed the potential of 
these cyclic dipeptides as antimicrobial agents. Since then, the antimicrobial potential of 
numerous other cyclic dipeptides has been investigated with some showing promising 
potential. Screening of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) as potential 
antimicrobial agents was therefore warranted. 
7.2 Experimental bacterial and fungal cultures 
  Cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) were tested against a broad spectrum 
of Gram-positive and Gram-negative bacteria, as well as a fungal microorganism to 
determine their potential antimicrobial activity. 
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7.2.1 Gram-positive Bacteria 
7.2.1.1 Bacillus subtilis 
Bacillus subtilis are gram-positive rods and is usually large with square ends. It is 
aerobic, sometimes facultative, and catalase positive, a spore forming 
chemoheterothroph that is mostly motile and peritrichously flagellated (Bauman et al., 
2004)   
 7.2.1.2 Staphylococcus aureus  
Staphylococcus aureus is a Gram-positive coccus that is non-motile and non-spore 
forming and can grow either aerobically or anaerobically. Some strains have notable 
capsules, it is a spherical-shaped bacterium and is the causative agent of a wide variety 
of human infections (Bauman et al., 2004; Prescott et al., 2005). Staphylococcus aureus 
cells are characteristically clustered in grapelike arrangements with the cell size ranging 
from 0.5 – 1.0 µm in diameter, they are usually salt tolerant (Bauman et al., 2004). The 
diagnosis of a staphylococcal infection involves the identification of Gram-positive 
bacteria in grapelike arrangements isolated from pus, blood or other body fluids 
(Bauman et al., 2004). S. aureus can then be distinguished from other staphylococci by 
its ability to clot plasma, since S. aureus secretes an enzyme called coagulase which 
activates the clotting mechanism of normal plasma (Bauman et al., 2004). 
 7.2.2 Gram-negative Bacteria 
 7.2.2.1 Escherichia coli 
Coliforms are defined as aerobic or facultatively anaerobic, Gram-negative, rod-shaped 
bacteria that ferment lactose to form gas within 48 hours of being placed in lactose 
broth at 35 °C. They are commonly found in the intestinal tracts of animals and humans, 
in soil, and on plants and decaying vegetation (Prescott et al., 2005). Escherichia coli is 
used as an indicator organism in determining the amount of faecal contamination in 
food and water, since it is one of the predominant facultative anaerobic bacteria of the 
intestinal tract (Bauman et al., 2004). 
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7.2.2.2 Pseudomonas aeruginosa 
Pseudomonas aeruginosa consists of straight or slightly curved Gram-negative rods. 
Their length varies from 0.5 – 1.0 µm by 1.5 – 5.0 µm, they are motile by one or several 
polar flagella and lack prosthecae or sheaths. Aeruginosa is a chemoheterotroph and is 
capable of carrying out respiratory metabolism with oxygen (and sometimes nitrate) as 
the electron acceptor (Prescott et al., 2005). Aeruginosa is a motile non-fermentative 
bacillus, and an obligate aerobe which grows well in most culture media (Bauman et al., 
2004). 
7.2.3 Fungi 
7.2.3 .1 Candida albicans 
Candida albicans is unicellular and usually appear as oval to round, yeast-like cells that 
reproduce sexually by budding (Bauman et al., 2004). They are not dimorphic, although 
chains of cells, each measuring 4 – 6 µm in diameter, sometimes link together, forming 
structures known as pseudohyphae. C. albicans often forms part of the normal 
microbiotica of the skin and the mucous membranes of the mouth, vagina, and intestinal 
tract (Prescott et al., 2005). Disease can only result when a major change in normal 
flora or a disturbance of the normal immune response occurs. Under such conditions 
candida species may multiply rapidly and produce candidiasis (Prescott et al., 2005). 
Most infections involves the skin or mucous membranes, but can on occasion produce 
more serious diseases, such as endocarditis, septicaemia, protracted urinary tract 
infection and oesophagitis (Prescott et al., 2005). Immunocompromised individuals are 
more prone to such systemic diseases (Bauman et al., 2004). 
7.3 Control agents used to compare the antimicrobial activity of the cyclic 
dipeptides 
7.3.1 Amoxicillin  
Penicillins are bactericidal, and act by the inhibition of bacterial cell wall synthesis in 
susceptible organisms. Amoxicillin is a hydroxylated derivative of ampicillin, with 
improved oral bioavailability and similar spectrum of activity. It is the drug of choice for 
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otitis media and bacterial sinusitis, and is widely used in the treatment of lower 
respiratory tract infections. Penicillin remains the agent of choice for numerous 
infections caused by Gram-positive, Gram-negative bacteria and anaerobes. These 
include Streptococcus pyogens, S. pneumoniae, viridans and non-enterococcal group D 
streptococci, anaerobic streptococci, Neisseria meningitidis, Actinomyces, most 
clostridia, Corynebacterium diphtheriae, Treponema pallidum and leptospira (Katzung, 
2009).  
7.3.2 Chloramphenicol 
Chloramphenicol is a broad-spectrum, mainly bacteriostatic antibiotic. Chloramphenicol 
is a potent inhibitor of microbial protein synthesis. It binds reversibly to the 50S subunit 
of the bacterial ribosome, and inhibits the peptidyl transferase step of protein synthesis. 
It is active against staphylococci, streptococci, Haemophilus species, anaerobes, 
rickettsiae, chlamydia and Mycoplasma. It is however, only reserved for serious 
infections, or cases in which tetracyclines are contra-indicated (Katzung, 2009).   
7.4 Methodology 
Methods employed by Stevens and Olsen (1993), Freimoser et al. (1999), Kilian (2002) 
an Janse van Rensburg (2006) were adapted to develop a method to test the 
antimicrobial activity of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro). 
7.4.1 Laboratory conditions 
The following precautions were taken, in order to maintain a clean and sterile working 
environment. Powder-free latex gloves were used when working with any chemicals or 
equipment. The gloves were sprayed with 70% ethanol at regular intervals in order to 
keep them dry and sterile. All other equipment was washed with analytical grade water 
(AGW), and sterilised by moist heat in an autoclave (Model HA-3D, Hirayama 
Manufacturing Corp., Japan) at 121 °C for 15 minutes. All laboratory benches were 
swabbed with 70% ethanol prior to use, and at regular intervals during, and after 
working. Single-strength nutrient broth (Biolab, Merck, Germany) and phosphate-
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buffered saline (PBS) was autoclaved at 121 °C for 15 minutes and filtered through 0.22 
µm Millipore™ cameo 25AS acetate filters (Millipore™, USA) prior to use, in order to 
render them pyrogen-free and sterile. 
7.4.2 Preparations of solutions 
7.4.2 .1 Negative controls 
The negative controls, consisting of cultures of the relevant test organism in sterile 
single-strength nutrient broth and 2% dimethyl sulphoxide (DMSO) (final concentration) 
were utilized to present 100% viability of the test cultures. DMSO was included to assist 
the solubilisation of the relevant cyclic dipeptides to be tested. 
7.4.2.2 Positive controls  
Aseptic preparation of the positive control, chloramphenicol (Sigma chemicals Co., 
USA) at concentrations of 200 µm and 100 µm (final concentrations of 0.25 mg/ml and 
0.5 mg/ml, respectively) in single-strength nutrient broth were utilized to test the viability 
of Gram-negative bacteria. 5% DMSO (final concentration) was added, and together 
with vortex agitation (Vortex mixer BM300, Laboratory supplies (Pty) Ltd, SA) aided in 
the solubilisation of chloramphenicol. For Gram-positive organisms, amoxicillin was 
used as the positive control at a concentration of 1mg/ml and 0.5mg/ml. The positive 
controls were made up to  volume using sterile single-strength nutrient broth, filter-
sterilized through   0.22 µm acetate filters into sterile 2000 µl Eppendorf tubes 
(Eppendorf AG, Germany), and stored at 4 °C until needed. 
7.4.2.3 Cyclic dipeptide solutions  
Cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) were aseptically prepared prior to use. 
5% DMSO (final concentration) was added and together with vortex agitation aided in 
the solubilisation of the cyclic dipeptides. The solution was made up with reverse 
osmosis water to give a stock concentration of 2 mM for each cyclic dipeptide. The 2mM 
stock solutions were then diluted accordingly. Following this, the cyclic dipeptide 
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solutions were filtered through 0.22 µm acetate filters into sterile Schott bottles and 
stored at 4 °C until needed. 
7.4.2 .4 MTT dye solution 
3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide   (MTT) is a 
monotetrazolium, water soluble salt, yielding a yellowish solution when prepared in 
media or salt solutions lacking phenol red. Dissolved MTT is converted to an insoluble 
purple formazan by cleavage of the tetrazolium ring by dehydrogenase enzymes. This 
conversion is only caused by active mitochondrial dehydrogenase of living cells, and not 
dead cells. The water insoluble formazan can then be dissolved using DMSO or other 
relevant solvents and the dissolved material is then measured spectrophotometrically 
yielding absorbance as a function of the converted dye. Absorbance of the converted 
dye is measured at a wavelength of 540 nm with background subtraction at 630-690 
nm.  
MTT (Sigma chemicals Co., USA) was dissolved in 0.1 M PBS (pH 7.4) to give a stock 
concentration of 0.5 mg/ml. The solution was filter-sterilized through a 0.22 µm acetate 
filter and stored, for not more than two weeks, in a sterile Schott bottle at 4 °C and away 
from light until needed. 
7.5 Test organism cultures  
The test organism cultures consisted of Gram-positive B. subtilis and S. aureus; Gram-
negative E. coli and P. aeruginosa; and the fungus C. albicans. The test cultures were 
obtained from the department of Medical Technology, at the Nelson Mandela 
Metropolitan University. Each test organism culture was scraped off its relevant agar 
plate using a flame sterilized platinum loop, and  inoculated into 5 ml of single strength 
nutrient broth (for bacteria) or potato dextrose agar (Merck, Germany) (for C. albicans). 
The cultures were then incubated overnight at 37 °C (for bacteria) or 28 °C (for C. 
albicans) in a Labcon® orbital shaker (Labcon® , SA) at 100 rpm. 
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The overnight cultures were subcultered by transferring 100 µl of the relevant test 
organism into 10 ml of sterile Mueller-Hinton broth (Merck, Germany).  The sub-cultured 
cultures were then incubated for a further 2 hours at 37 °C (for bacteria) or 28 °C (for 
C.albicans) in the orbital shaker at 100 rpm. 
7.6 Standardisation of the inoculum 
In order to improve the reproducibility of the assays, the starting concentrations of all 
cultures were kept constant by standardising the inoculums. The standardisation 
procedure was followed for all cultures, prior to each assay performed on separate 
days. The minimum inhibitory concentration (MIC) is defined as the lowest 
concentration of an antimicrobial agent that inhibits growth of a micro-organism. MIC is 
an important research tool that is used to determine the in vitro antimicrobial activity of 
newly synthesised agents (Andrews, 2001). One of the methods used to determine MIC 
is microdilution testing which uses liquid growth medium, serial dilutions of the 
antimicrobial agents and standard inoculums of bacteria (Dipiro et al., 2011). A flame 
sterilised platinum loop was used to scrape the test organisms off from the relevant agar 
plates. The organisms were then inoculated into 15 ml sterile Mueller-Hinton broth and 
incubated at 37 °C (for bacteria) or 28 °C (for C. albicans) in an orbital shaker (Labcon 
Incubator Labtec (PTY) Ltd, SA) at 100 rpm for 24 hours. The cultures were sub-
cultered by transferring 100 µl of test organism into 15 ml sterile Mueller-Hinton broth 
and incubated for 16 hours at 37 °C (for bacteria) or 28 °C (for C. albicans) in an orbital 
shaker (Labcon Incubator Labtec (PTY) Ltd, SA) at 100 rpm. The turbidity of the test 
cultures was thereafter measured at 540 nm for bacteria and 600 nm for C. albicans 
using sterile Mueller-Hinton broth as a blank. 
 7.7 MTT linearity assay 
A volume of 500 µl of each of the standardised inoculums and their respective serial 
dilutions were placed in separate Eppendorf tubes and 40 µl of MTT tetrazolium dye at 
a concentration of 0.5 mg/ml was added. To obtain a zero time reading, absorbance 
was immediately measured on a microplate reader at 540 nm for bacteria and 600 nm 
for C. albicans. The Eppendorf tubes were then incubated at 37 °C (for bacteria) or 28 
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°C (for C. albicans) in an orbital shaker for four hours. Tubes were subsequently 
removed from the orbital shaker and centrifuged using an Eppendorf® centrifuge 5804R 
(Eppendorf®, Germany) at 14350 x g for 7 minutes to pellet the microorganisms. The 
supernatant liquid in each Eppendorf tube was removed and discarded. The formazan 
product present was dissolved in 500 µl DMSO. Rupture of microorganisms was 
facilitated by vortexing of suspensions. Tubes were centrifuged again at 14350 x g for 5 
minutes to pellet the resultant debris. 40 µl of each dye solution was transferred in 
triplicate to the wells of 96-well flat bottom microtitre plates (Castor, Corning). The 
microtitre plates were then read at 540 nm, with a background subtraction at 690 nm to 
account for cellular debris, utilising a Multiscan MS® (version 4.0) Labsystem® type 352 
microtitre plate spectrophotometer (Multiscan MS®, England). Experiments were 
conducted in triplicate. 
Following the initial adjustments of the test cultures to an absorbance reading of 0.22 
AU, further serial dilutions of each test culture was made as follows: 
0.1 ml standardised culture (0.22 AU) into 9.9 ml sterile water → A 
0.1 ml A into 9.9 ml sterile water → B 
0.1 ml of B into 9.9 ml of sterile water →C 
0.1 ml of C into 9.9 ml of sterile water →D 
0.1 ml of each of the dilutions was subsequently plated onto sterile nutrient agar plates 
for bacteria, and potato dextrose agar plates for the yeast. Plating and counting were 
performed in triplicate and the numbers of micro-organisms per millilitre in the 
standardised culture were subsequently calculated.    
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7.8 Antimicrobial assay 
From the counts performed (Section 7.7), the test cultures were diluted to obtain 1 x 106 
colony forming units CFU\ml (Freimoser et al., 1999). The calculated volumes were 
made up to 10 ml using Mueller-Hinton broth. 
A volume of 50 µl of each test organism was pipette into a 96-well microplate and 
thereafter, 50 µl of either of the stock solutions of the two cyclic dipeptides at 
concentrations of 1 mM and 2 mM were added to the wells, which resulted in a final 
concentration of 0.5 mM and 1 mM in each well. 50 µl of each of the positive controls, 
were pipette into the respective cells according to the test organism cultures, giving final 
concentration of 0.25 mg/ml and 0.5 mg/ml in the respective wells. 50 µl of the negative 
control (7.4.2.1) was pipette to separate wells to indicate 100% viability of the test 
organism growth. 
The 96-well microplates were then incubated for 24 hours at 37 °C for bacteria and 28 
°C for C. albicans in an orbital shaker at 100 rpm. 40 µl of MTT at a concentration of 0.5 
mg/ml was added to each of the cells after incubation. In order to obtain a zero reading 
time, absorbance was immediately measured on a microplatereader at 540 nm for 
bacteria and 600 nm for C. albicans. Following this the 96-well microplates were 
incubated for four hours, in an orbital shaker at 100 rpm to allow for the metabolic 
reduction of MTT. This was followed by centrifugation in an Eppendorf centrifuge at 
3000 rpm for seven minutes to pellet the insoluble formazan product (Freimoser et al., 
1999; Stevens and Olsen, 1993). The supernatant was aspirated from each of the wells 
and discarded. 90 µl of DMSO was subsequently added to each well to solubilise the 
formazan product and placed on a plate shaker for four minutes. The absorbance was 
read immediately at 540 nm for bacteria, and 600 nm for C. Albicans.      
7.9 Statistical analysis      
Results were obtained as triplicate values and represented as a mean ± standard 
deviation (SD). Percentage growth inhibition, after 24 hours of exposure to the cyclic 
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dipeptides, was calculated with reference to the negative control cultures and compared 
to the positive controls.  
Percentage growth inhibition was calculated as follows: 
% inhibition = 
                     
         
       
WHERE NEGGROWTH = NEGT= 24 – NEGT= 0 
               DRUGGROWTH = DRUGT= 24 – DRUGT= 0 
AND NEGT= 24  = Absorbance at 540 nm after incubation for control  
          DRUGT = Absorbance at 540 nm for drug after incubation 
          DRUG0 = Absorbance at 540 nm for drug prior to incubation. 
Data were represented graphically with the aid of statistical software packages, 
Microsoft Excel® (Version 2007) and GraphPad Prism® (version 5). In order to determine 
whether the cyclic dipeptides under investigation caused statistically significant 
reduction in cell viability relative to the negative control, Student‟s t-tests were 
performed on each concentration of the cyclic dipeptides. Calculated P-values of less 
than 0.05 were defined as statistical significant. MTT linearity was determined by 
performing a linear regression analysis, where linearity was defined as a Spearman‟s 
correlation coefficient (R2) of between 0.9 and 1. 
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7.10 Results and discussion  
7.10.1 MTT linearity assay 
A linear relationship between the number of viable organisms and the intensity of MTT–
formazan produced was observed with all organisms tested (Figure 7.8 to 7.12). For all 
the organisms, the correlation values exceeded 0.95.  
    
   
 
  
 
Figure 7.8    B. subtilis linearity of MTT against bacteria count (R2 = 0.958)  
 
 
 
 
Figure 7.9    S. aureus linearity of MTT against bacteria count (R2 = 0.976)  
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Figure 7.10    E. coli linearity of MTT against bacteria count (R2 = 0.974)  
 
 
 
 
      
Figure 7.11    P. aeruginosa linearity of MTT against bacteria count (R2 = 0.982) 
 
 
 
 
 
Figure 7.12    C. albicans linearity of MTT against bacteria count (R2 = 0.969) 
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7.10.2 Cyclic dipeptide antimicrobial assay 
The antimicrobial effects produced by the different screening concentrations of cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin on B. subtilis growth 
after 24 hours of exposure to the compounds are illustrated in Figure 7.13. To 
determine if the growth inhibiting effects produced by chloramphenicol, amoxicillin and 
the cyclic dipeptides were statistically different compared to the normal growth seen in 
the negative controls, Student‟s t-tests were performed on all concentrations of the 
cyclic dipeptide, chloramphenicol and amoxicillin. P-values of less than 0.05 were 
defined as an indication of a statistical significant difference between the means of the 
compounds and the negative controls. Percentage growth inhibition produced by all 
concentrations of the cyclic dipeptides was also compared to that of chloramphenicol 
and amoxicillin. Percentage growth inhibition produced by all screening concentrations 
of cyclo(D-Phe-4Cl-Pro) and cyclo(Phe-4Cl-Pro), was found to be notably less than that 
produced at both concentrations for chloramphenicol and amoxicillin. Chloramphenicol, 
at concentrations of 0.5 mg/ml and 0.25 mg/ml exhibited growth inhibition of 83.61 ± 
4.410% (P < 0.0085) and 68.28 ± 2.945% (P < 0.0103), respectively. Amoxicillin at 
concentrations of 1 mg/ml and 0.5 mg/ml exhibited growth inhibition of 50.61 ± 4.410% 
(P < 0.0316) and 57.55 ± 2.350% (P < 0.0144), respectively while cyclo(D-Phe-4Cl-Pro)  
at concentrations of 1 mM, 0.5 mM, display growth inhibition of 17.83 ± 5.500% (P = 
0.8570), 15.00 ± 1.335% (P = 0.7907). Cyclo(Phe-4Cl-Pro) at concentrations of 1 mM, 
0.5 mM, exhibited growth inhibition of 18.27 ± 2.390% (P = 0.7438), 12.33 ± 2.000% (P 
= 0.4900). Although cyclo(D-Phe-4Cl-Pro) and cyclo(Phe-4Cl-Pro) produced statistically 
significant inhibition of growth, at all concentrations, relative to the negative control, the 
effects were very limited compared to the effects produced by chloramphenicol and 
amoxicillin. The effects produced by cyclo(D-Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro), 
chloramphenicol and amoxicillin, are represented in Table 7.4 
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Figure 7.13    Percentage growth inhibition of B. subtilis after 24 hour exposure to  cyclo(D-Phe-4Cl-
Pro), cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin 
Table 7.4    Percentage growth inhibition of B. subtil is  after 24 hour exposure to cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro),  chloramphenicol and amoxicil lin   
Agent Concentration Percentage 
inhibition (%) 
P-value 
Amoxicillin 1 mg/ml 50.61 ± 4.410 0.0316 
0.5 mg/ml 57.55 ± 2.350 0.0144 
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Chloramphenicol 0.5 mg/ml 83.61 ± 4.410 0.0085 
0.25 mg/ml 68.28 ± 2.945 0.0103 
Cyclo(D-Phe-4Cl-
Pro) 
1 mM 17.83 ± 5.500 0.8570 
0.5 mM 15.00 ± 1.335  0.7907 
cyclo(Phe-4Cl-
Pro) 
1 mM 18.27 ± 2.390  0.7438 
0.5 mM 12.33 ± 2.000  0.4900 
The antimicrobial effects produced by the different screening concentrations of cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin on S. aureus growth 
after 24 hours of exposure to the compounds are illustrated in Figure 7.14. To 
determine if the growth inhibiting effects produced by chloramphenicol, amoxicillin and 
the cyclic dipeptides were statistically different compared to the normal growth seen in 
the negative controls, Student‟s t-tests were performed on all concentrations of the 
cyclic dipeptides, chloramphenicol and amoxicillin. P-values of less than 0.05 were 
defined as an indication of a statistical significant difference between the means of the 
compounds and the negative controls. Percentage growth inhibition produced by all 
concentrations of the cyclic dipeptides was also compared to that of chloramphenicol 
and amoxicillin. Percentage growth inhibition produced by all screening concentrations 
of cyclo(D-Phe-4Cl-Pro) and cyclo(Phe-4Cl-Pro) was found to be notably less than that 
produced at both concentrations for chloramphenicol and amoxicillin. Chloramphenicol, 
at concentrations of 0.5 mg/ml and 0.25 mg/ml caused growth inhibition of 72.60 ± 
6.600% (P = 0.00344) and 69.61 ± 1.610% (P = 0.0177), respectively. Amoxicillin at 
concentrations of 1 mg/ml and 0.5 mg/ml exhibited growth inhibition of 26.40 ± 5.600% 
(P = 0.0501) and 58.60 ± 1.300% (P = 0.0304) respectively while cyclo(D-Phe-4Cl-Pro)  
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at concentrations of 1 mM and 0.5 mM, exhibited growth inhibition of 68.00 ± 2.665% (P 
= 0.0106), 22.17 ± 1.165% (P = 0.05362). Cyclo(Phe-4Cl-Pro) at concentrations of 1 
mM and 0.5 mM, exhibited growth inhibition of 12.22 ± 2.110% (P = 0.0062) and 11.33 
± 9.00% (P = 0.0340). Although cyclo(D-Phe-4Cl-Pro) and cyclo(Phe-4Cl-Pro), 
produced statistically significant inhibition of growth, at all concentrations, relative to the 
negative control, the effects were very limited compared to the effects produced by 
chloramphenicol and amoxicillin. The effects produced by cyclo(D-Phe-4Cl-Pro), 
cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin, are represented in Table 7.5 
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Figure 7.14    Percentage growth inhibition of S. aureus after 24 hour exposure to  cyclo(D-Phe-4Cl-
Pro), cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin 
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Table 7.5    Percentage growth inhibition of S. aureus  after 24 hour exposure to cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro),  chloramphenicol and amoxicil lin   
Agent Concentration Percentage 
inhibition (%) 
P-value 
Amoxicillin 1 mg/ml 26.40 ± 1.5.600  0.0501 
0.5 mg/ml 58.60 ± 1.300  0.0304 
Chloramphenicol 0.5 mg/ml 72.60 ± 6.600  0.00344 
0.25 mg/ml 69.61 ± 1.610 0.0177 
Cyclo(D-Phe-4Cl-
Pro) 
1 mM 68.00 ± 2.665  0.0106 
0.5 mM 22.17 ± 1.165 
 
0.05362 
 
Cyclo(Phe-4Cl-Pro) 1 mM 12.22 ± 2.110 0.0062 
0.5 mM 11.33 ± 9.000 
 
0.0340 
 
The antimicrobial effects produced by the different screening concentrations of cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin on E. coli growth 
after 24 hours of exposure to the compounds are illustrated in Figure 7.15. To 
determine if the growth inhibiting effects produced by chloramphenicol, amoxicillin and 
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the cyclic dipeptides were statistically different compared to the normal growth seen in 
the negative controls, Student‟s t-tests were performed on all concentrations of the 
cyclic dipeptide, chloramphenicol and amoxicillin. P-values of less than 0.05 were 
defined as an indication of a statistical significant difference between the means of the 
compounds and the negative controls. Percentage growth inhibition produced by all 
concentrations of the cyclic dipeptides was also compared to that of chloramphenicol 
and amoxicillin. Percentage growth inhibition produced by all screening concentrations 
of cyclo(D-Phe-4Cl-Pro) and cyclo(Phe-4Cl-Pro), was found to be notably less than that 
produced at both concentrations for chloramphenicol and amoxicillin. Chloramphenicol, 
at concentrations of 0.5 mg/ml and 0.25 mg/ml exhibited growth inhibition of 78.50 ± 
6.165% (P < 0.0312) and 69.66 ± 0.4350% (P < 0.0277), respectively. Amoxicillin at 
concentrations of 1 mg/ml and 0.5 mg/ml exhibited growth inhibition of 73.25 ± 4.350% 
(P < 0.0309) and 68.89 ± 1.335% (P < 0.0293), respectively while cyclo(D-Phe-4Cl-Pro)  
at concentrations of 1 mM, 0.5 mM, exhibited growth inhibition of 25.83 ± 0.500% (P = 
0.7724) and 11.50 ± 0.8350% (P = 0.2771). Cyclo(Phe-4Cl-Pro) at concentrations of 1 
mM, 0.5 mM exhibited growth inhibition of 18.66 ± 1.000% (P = 0.6239), 15.66 ± 
0.6700% (P = 0.4400). Although cyclo(D-Phe-4Cl-Pro) and cyclo(Phe-4Cl-Pro), 
produced statistically significant inhibition of growth, at all concentrations, relative to the 
negative control, the effects were very limited compared to the effects produced by 
chloramphenicol and amoxicillin. The effects produced by cyclo(D-Phe-4Cl-Pro), 
cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin, are represented in Table 7.6 
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Figure 7.15    Percentage growth inhibition of E. coli after 24 hour exposure to  cyclo(D-Phe-4Cl-Pro), 
cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin 
Table 7.6    Percentage growth inhibition of E. coli  after 24 hour exposure to cyclo(Phe-
4Cl-Pro), cyclo(D-Phe-4Cl-Pro), chloramphenicol and amoxicil lin  
Agent Concentration Percentage 
inhibition (%) 
P-value 
Amoxicillin 1 mg/ml 73.25 ± 4.350  0.0309 
0.5 mg/ml 68.89 ± 1.335  0.0293 
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Chloramphenicol 0.5 mg/ml 78.50 ± 6.165  0.0312 
0.25 mg/ml 69.66 ± 0.4350 0.0277 
cyclo(D-Phe-4Cl-
Pro) 
1 mM 25.83 ± 0.500 0.7724 
0.5 mM 11.50 ± 0.8350 
 
0.2771 
 
cyclo(Phe-4Cl-Pro) 1 mM 18.66 ± 1.000  0.6239 
0.5 mM 15.66 ± 0.6700 0.4400 
The antimicrobial effects produced by the different screening concentrations of cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin on P. aeruginosa 
growth after 24 hours of exposure to the compounds are illustrated in Figure 7.16. To 
determine if the growth inhibiting effects produced by chloramphenicol, amoxicillin and 
the cyclic dipeptides were statistically different compared to the normal growth seen in 
the negative controls, Student‟s t-tests were performed on all concentrations of the 
cyclic dipeptides, chloramphenicol and amoxicillin. P-values of less than 0.05 were 
defined as an indication of a statistical significant difference between the means of the 
compounds and the negative controls. Percentage growth inhibition produced by all 
concentrations of the cyclic dipeptides was also compared to that of chloramphenicol 
and amoxicillin. Percentage growth inhibition produced by all screening concentrations 
of cyclo(D-Phe-4Cl-Pro) and cyclo(Phe-4Cl-Pro), was found to be notably less than that 
produced at both concentrations for chloramphenicol and amoxicillin. Chloramphenicol, 
at concentrations of 0.5 mg/ml and 0.25 mg/ml exhibited growth inhibition of 68.91 ± 
5.690% (P < 0.0102) and 54.11 ± 1.775% (P < 0.0036), respectively. Amoxicillin at 
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concentrations of 1 mg/ml and 0.5 mg/ml exhibited growth inhibition of 90.34 ± 2.010% 
(P < 0.0012) and 76.23 ± 1.675% (P < 0.0015) respectively while cyclo(D-Phe-4Cl-Pro) 
at concentrations of 1 mM, 0.5 mM, exhibited growth inhibition of 39.55 ± 3.00% (P = 
0.0143) and 15.61 ± 3.275% (P = 0.2619). Cyclo(Phe-4Cl-Pro) at concentrations of 1 
mM, 0.5 mM, exhibited growth inhibition of 21.50 ± 1.835% (P = 0.0490), 15.99 ± 1.00% 
(P = 0.1061). Although cyclo(D-Phe-4Cl-Pro) and cyclo(Phe-4Cl-Pro), produced 
statistically significant inhibition of growth, at all concentrations, relative to the negative 
control, the effects were very limited compared to the effects produced by 
chloramphenicol and amoxicillin. The effects produced by cyclo(D-Phe-4Cl-Pro), 
cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin, are represented in Table 7.7 
%
 In
hi
bi
tio
n
Am
ox
 1
Am
ox
 2
Ch
lo
ra
 1
Ch
lo
ra
 2
DK
P 
1 
D
DK
P 
2 
D
DK
P 
1 
L
DK
P 
1 
L
0
20
40
60
80
100
 Amoxicillin 1 mg/ml
Amoxicillin 0.5 mg/ml
Chloramphenicol 0.25 mg/ml
Cholramphenicol 0.5 mg/ml
Cyclo(D-Phe-4Cl-Pro) 0.5 mM
Cyclo(D-Phe-4Cl-Pro) 1 mM
Cyclo(Phe-4Cl-Pro) 0.5 mM
Cyclo(Phe-4Cl-Pro) 1 mM
 
Figure 7.16    Percentage growth inhibition of P. aeruginosa after 24 hour exposure to  cyclo(D-Phe-
4Cl-Pro), cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin 
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Table 7.7    Percentage growth inhibition of P. aeruginosa  after 24 hour exposure to 
cyclo(D-Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro),  chloramphenicol and amoxicil l in   
Agent Concentration Percentage 
inhibition (%) 
P-value 
Amoxicillin 1 mg/ml 90.34 ± 2.010  0.0012 
0.5 mg/ml 76.23 ± 1.675  0.0015 
Chloramphenicol 0.5 mg/ml 68.91 ± 5.690  0.0102 
0.25 mg/ml 54.11 ± 1.775 0.0036 
Cyclo(D-Phe-4Cl-
Pro) 
1 mM 39.55 ± 3.000 
 
0.0143 
 
0.5 mM 15.61 ± 3.275 0.2619 
Cyclo(Phe-4Cl-Pro) 1 mM 21.50 ± 1.835  0.0490 
0.5 mM 15.99 ± 1.000  0.1061 
The antimicrobial effects produced by the different screening concentrations of cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin on C. albicans 
growth after 24 hours of exposure to the compounds are illustrated in Figure 7.17. To 
determine if the growth inhibiting effects produced by chloramphenicol, amoxicillin and 
the cyclic dipeptides were statistically different compared to the normal growth seen in 
the negative controls, Student‟s t-tests were performed on all concentrations of the 
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cyclic dipeptide, chloramphenicol and amoxicillin. P-values of less than 0.05 were 
defined as an indication of a statistical significant difference between the means of the 
compounds and the negative controls. Percentage growth inhibition produced by all 
concentrations of the cyclic dipeptides was also compared to that of chloramphenicol 
and amoxicillin. Percentage growth inhibition produced by all screening concentrations 
of cyclo(D-Phe-4Cl-Pro) and cyclo(Phe-4Cl-Pro), was found to be notably less than that 
produced at both concentrations for chloramphenicol and amoxicillin. Chloramphenicol, 
at concentrations of 0.5 mg/ml and 0.25 mg/ml exhibited growth inhibition of 57.61 ± 
2.390% (P < 0.0030) and 82.68 ± 5.345% (P < 0.0054), respectively. Amoxicillin at 
concentrations of 1 mg/ml and 0.5 mg/ml caused growth inhibition of 91.19 ± 1.165% (P 
< 0.0004) and 63.83 ± 2.500% (P < 0.0025) respectively while cyclo(D-Phe-4Cl-Pro)  at 
concentrations of 1 mM, 0.5 mM, exhibited growth inhibition of 54.28 ± 5.055% (P = 
0.0128) and 31.83 ± 9.500% (P = 0.1380). Cyclo(Phe-4Cl-Pro) at concentrations of 1 
mM, 0.5 mM, exhibited growth inhibition of 47.84 ± 7.820% (P = 0.0387), 46.18 ± 
3.854% (P = 0.0114). Although cyclo(D-Phe-4Cl-Pro) and cyclo(Phe-4Cl-Pro) produced 
statistically significant inhibition of growth at all concentrations, relative to the negative 
control, the effects were very limited compared to the effects produced by 
chloramphenicol and amoxicillin. The effects produced by cyclo(D-Phe-4Cl-Pro), 
cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin, are represented in Table 7.8 
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Figure 7.17    Percentage growth inhibition of C. albicans after 24 hour exposure to  cyclo(D-Phe-4Cl-
Pro), cyclo(Phe-4Cl-Pro), chloramphenicol and amoxicillin 
Table 7.8    Percentage growth inhibition of C. albicans  after 24 hour exposure to cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro),  chloramphenicol and amoxicil lin   
Agent Concentration Percentage 
inhibition (%) 
P-value 
Amoxicillin 1 mg/ml 91.19 ± 1.165  0.0004 
0.5 mg/ml 63.83 ± 2.500  0.0025 
Chloramphenicol 0.5 mg/ml 57.61 ± 2.390  0.0030 
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0.25 mg/ml 82.68 ± 5.345 0.0054 
Cyclo(D-Phe-4Cl-
Pro) 
1 mM 54.28 ± 5.055  0.0128 
0.5 mM 31.83 ± 9.500 
 
0.1380 
 
Cyclo(Phe-4Cl-Pro) 1 mM 47.84 ± 7.820  0.0387 
0.5 mM 46.18 ± 3.845  0.0114 
7.11 Conclusion 
The Antimicrobial effects of cyclo(D-Phe-4Cl-Pro) and cyclo(Phe-4Cl-Pro) on the 
different microorganisms remain questionable as the inhibiting effects produced by the 
cyclic dipeptides relative to the positive controls, in each case were minimal.    
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CHAPTER 8 
HEAMATOLOGICAL STUDIES 
8.1 INTRODUCTION 
Blood is a connective tissue composed of a liquid portion called plasma and a cellular 
portion consisting of erythrocytes, leukocytes, platelets and various cell fragments. 
Having a slightly alkaline pH of between 7.35 and 7.45 in healthy individuals with a 
temperature of 38 ˚C (Tortora and Grabowski, 2009). Blood, the only liquid connective 
tissue in the human body, has three general functions: transportation, regulation and 
protection (Tortora and Grabowski, 2009). Blood transports (1) oxygen and nutrients to 
cells, (2) carbon dioxide and wastes from the tissues to the lungs and the kidneys where 
waste can be removed from the body and (3) carries hormones from the endocrine 
glands to the target tissues. Blood helps to regulate body temperature by removing heat 
from active areas, such as skeletal muscles and transporting it to other areas of the 
skin, so that the heat can be dissipated. It plays a significant role in fluid and electrolyte 
balance because salt and plasma proteins contribute to the osmotic pressure by 
providing weight and bulk to the blood and functions in pH regulation through the 
reaction of buffers in the blood. Blood protects the body by initiating clotting 
mechanisms to prevent fluid loss through haemorrhage when blood vessels become 
damaged; certain cells in the blood namely, phagocytic leukocytes, help to protect the 
body against diseases by engulfing and destroying the causative agent (a biological 
agent that causes a disease, toxins or toxic chemicals causing illness); antibodies in the 
plasma for example IgG, IgM, IgE and IgA, help protect against diseases by their 
reactions with offending agents (Hoffbrand and Moss, 2011). 
Blood is denser and more viscous than water and constitutes about 8% of the total body 
weight. The blood volume is 5 to 6 liters in an averaged-sized healthy adult female. 
Blood is composed of two portions: (1) blood plasma, a watery liquid that contains 
dissolved substances such as water, amino acids, proteins, carbohydrates, lipids, 
hormones, vitamins, electrolytes, dissolved gases and cellular wastes and (2) formed 
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elements, including plasma,  erythrocytes, leukocytes and lymphocytes making up the 
remainder (Tortora and Grabowski, 2009). 
8.1.1 Haemostasis 
To maintain blood fluidity within the vascular system is an important human 
physiological process. The term “haemostasis” refers to the normal physiological 
response of the vessel to injury by forming a clot that serves to limit haemorrhage 
(Gentry, 2004). Thrombosis is a pathological clot formation that results when 
haemostasis is excessively activated in the absence of bleeding. Under normal 
physiological conditions there is a delicate equilibrium between the pathological states 
of hypercoagulability and hypocoagulability in the circulating blood. Hypercoagulable 
states and thrombosis are induced by altered blood flow (e.g., stasis, turbulences), 
defects in the endothelium, and changes in the blood constituents (e.g., reduced 
inhibitor capacity of the coagulation system and reduced activity of the fibrinolytic 
system). Hypercoagulable states and bleeding are caused primarily by reduced activity 
of procoagulant factors (e.g., haemophilia), thrombocytopaenia, genetic deficiencies, 
autoimmune disorders and antithrombotic drugs (Rasche, 2001). 
In response to damage, blood vessels rapidly activate the haemostatic apparatus: (1) 
vascular constriction, (2) platelet plug formation, (3) blood clotting via activation of the 
coagulation cascade, (4) fibrinolysis and (5) repair and regeneration of damaged blood 
vessels (Tortora and Grabowski, 2009). 
8.1.2 Vascular constriction 
An immediate vasoconstriction of the injured vessel and reflex constriction of adjacent 
small arteries and arterioles is responsible for an initial slowing of blood flow to the area 
of injury. The reduced blood flow allows contact activation of platelets and the release of 
coagulation factors. The vasoactive amines and thromboxane A2 from platelets, and the 
fibrinopeptides liberated during fibrin formation, may also have vasoconstrictive activity 
(Tortora and Grabowski, 2009). 
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8.1.3 Platelet plug formation 
Following a break in the endothelial lining, there is an initial adherence of platelets to the 
exposed connective tissue. The platelet adhesion is potentiated by von Willebrand 
factor (VWF).  Collagen exposure and thrombin produced at the site of injury causes the 
adherent platelets to release their granule contents which include adenosine 
diphosphate (ADP), serotonin, fibrinogen, lysosomal enzymes and heparin-neutralising 
factor (PF-4). Collagen and thrombin activate platelet prostaglandin synthesis leading to 
the formation of thromboxane A2 which potentiates platelet release reactions, platelet 
aggregation and also powerful vasoconstriction. Released ADP causes platelets to 
swell and aggregate. Additional platelets from the circulating blood are drawn to the 
area of injury. This continuing platelet aggregation promotes the growth of the 
haemostatic plug which soon covers the exposed connective tissue. Released platelet 
granule enzymes, ADP and thrombosthenin may all contribute to the consolidation of 
the accumulated plug (Tortora and Grabowski, 2009). 
8.1.4 Blood clotting via activation of the coagulation cascade  
After primary haemostasis, i.e., instant vasoconstriction and formation of an initial 
platelet plug, activation of the coagulation system is needed to stabilise the loose 
accumulated platelets by cross-linking fibrin. Figure 8.1 illustrates the stages of the 
coagulation cascade (Vogler and Siedlecki, 2009). 
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Figure 8.1    A simplified line diagram of the plasma-coagulation cascade showing intersection of the 
intrinsic and extrinsic pathways (Vogler and Siedlecki, 2009). 
The blood coagulation cascade is composed of two inactive pathways, namely the 
intrinsic and the extrinsic pathway. The two pathways merge and form factor X and V 
which forms part of the prothrombinase complex that leads to factor IIa (thrombin) 
formation. The extrinsic pathway which is responsible for haemostatic regulation and 
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response to vascular injury involves factor VII which is activated by tissue factor (TF). 
The intrinsic pathway involves factor XII, factor XI, factor IX, and factor VIII (Vogler and 
Siedlecki, 2009; Ajjan and Ariëns, 2009; Ajjan and Grant, 2006). The blood coagulation 
cascade consists of a series of interconnected reactions with the resulting pathway of 
one enzyme activating the next enzyme. The cascade is a self-amplifier with zymogens 
being activated to enzymes that lead to the formation of thrombin. The final step of the 
blood coagulation cascade is the conversion of fibrinogen to fibrin by thrombin. The 
fibrin clot is formed after polymerisation (Figure 8.1).The fibrin clot formation involves 
both the platelets and interaction between the coagulation proteins, and is thus a 
complex process. When damage occurs in a vessel wall, TF is brought into contact with 
the plasma. In this initiation phase, TF binds and activates factor VII. The TF/factor VII 
complex activates factor IX and factor X, with factor X activating factor V. Prothrombin is 
cleaved to activate thrombin by factor X and factor V. The thrombin that is released is 
not enough to sustain the thrombus but enough to maintain platelet activation (Vogler 
and Siedlecki, 2009; Ajjan and Ariëns, 2009; Ajjan and Grant, 2006). The adhesion of 
platelets to the site of injury is mediated by the interaction of Von Willebrand Factor 
(VWF) with collagen. The activation of platelets by exposed collagen and thrombin 
brings about full platelet activation and degranulation leading to the release of factor V. 
The coagulation cascade is enhanced, because factor V is activated by factor Xa and 
thrombin, which activates factor VIII that forms anactive complex with factor IXa. The 
generation of sufficient thrombin from the platelet surface factor Xa/Va complex leads to 
the conversion of fibrinogen to fibrin. A stable haemostatic plug is generated after factor 
XIII, a trans-glutaminase that is activated by thrombin, forms cross links in the fibrin clot 
(Vogler and Siedlecki, 2009; Ajjan and Ariëns, 2009; Ajjan and Grant, 2006). 
8.1.5 Fibrinolysis 
Fibrinolysis is a physiological process that involves the dissolution of  blood clots by the 
action of a proteolytic enzyme, such as plasmin (fibrinolysin), that dissolves fibrin 
threads and inactivates fibrinogen and other blood-clotting factors (Tortora and 
Grabowski, 2009). Plasmin the main enzyme involved in fibrinolysis, is formed by the 
action of two plasminogen activators, namely tissue plasminogen activator (t-PA) and 
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urinary plasminogen activator (u-PA) (Castãnon et al., 2007 ; Vadseth et al., 2004). t-PA 
is mainly active in the vascular system. It is the main agent for the dissolution of thrombi 
via the activation of plasminogen to plasmin (Castãnon et al., 2007). u-PA is found in 
connective tissue, and plays a role in tissue remodeling and cell migration (Castãnon et 
al., 2007). The presence of fibrin enhances the activation of plasminogen to plasmin by 
t-PA, whereas no influence is observed in the case of u-PA (Castãnon et al., 2007; 
Bachmann, 2001). 
8.1.6 Repair and regeneration of damaged blood vessels  
Ultimately the haemostatic plug needs to be replaced by a new layer of endothelial cells 
and underlying extracellular matrix. The fibrin clot not only serves to close a damaged 
blood vessel wall, but also acts as a scaffold for invading inflammatory, endothelial, and 
other tissue cells during tissue repair. The formation of a new endothelium proceeds 
through a process referred to as angiogenesis. Furthermore, angiogenesis plays an 
important role in pathological conditions such as cancer (the formation of new blood 
vessels is essential to supply a tumor with oxygen and nutrients) (Tortora and 
Grabowski, 2009). 
8.1.7 Drugs affecting coagulation  
Drugs are used to modify the cascade either when there is a defect in coagulation or 
when there is an unwanted coagulation. 
In genetically determined deficiencies of clotting factors, i.e., classical haemophillia, 
caused by a lack of factor VIII, and haemophillia B, or Christmas disease, caused by a 
lack of factor IX, are treated by giving fresh plasma concentrations or concentrated 
preparations of factor VIII or factor IX. Acquired human defects include liver disease, 
vitamin K deficiency and excessive oral anticoagulant therapy. The above mentioned 
conditions are generally treated with vitamin K (Rang et al., 2011). 
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8.1.8 Drugs used in the treatment of thrombotic and thromboembolic diseases 
Injectable anticoagulants include heparin and the low molecular weight heparins. 
Heparin inhibits coagulation by potentiating the inhibitory effect of antithrombin III on the 
activated forms of clotting factors XII, XI, IX, X and thrombin. Examples of the low 
molecular weight heparins currently in use include enoxaparin, dalteparin and 
nadroparin. The low molecular weight heparins have a longer duration of action than 
unfractionated heparin and are administered once or twice daily (Rang et al., 2011). 
Antithrombin III-independent anticoagulants include hirudin and argatroban and these 
direct inhibitors of thrombin are still under investigation (Rang et al., 2011). 
Oral anticoagulants include warfarin. Warfarin interferes with the pos-translational γ-
carboxylation of glutamic acid residues in clotting factors II, IX an X. This is achieved by 
competitively inhibiting the enzymatic reduction of vitamin K to its active hydroquinone 
form (Rang et al., 2011). 
8.1.9 Antiplatelet drugs 
Aspirin alters the balance between thromboxane (TXA2), which promotes aggregation 
and prostaglandin I2(PGI2), which inhibits it. Aspirin inactivates cyclooxygenase (COX)- 
acting mainly on COX1 by irreversibly acetylating a serine residue in its active site. This 
causes the reduction of both TXA2 synthesis in platelets and PGI2 synthesis in 
endothelium (Rang et al., 2011). 
Glycoprotein IIB/IIIA receptor antagonists includes abciximab, eptifibatide and tirofiban. 
The platelet receptor glycoprotein IIB/IIIA is the final common pathway to platelet 
aggregation. Inhibition at this point thus prevents platelet aggregation regardless of the 
agonist responsible for platelet activation (Rang et al., 2011). 
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8.1.10 Fibrinolytic drugs 
Antithrombotic enzymes convert plasminogen to plasmin, which in return degrades fibrin 
thrombi and fibrinogen.Examples of these agents include streptokinase, alteplase and 
tenecteplase (Rang et al., 2011). 
8.2 Methodology 
A coagulation assay, thrombin assay, platelet aggregation assay and fibrinolysis assay 
were utilised to investigate the effects of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
on haemostasis. All water containing solutions required for experimentation were 
prepared by utilizing analytical grade water (AGW) obtained from an ultra clear TWF UF 
TM reverse osmotic water purification system SG®. To ensure reproducibility all assays 
were performed in quadruplicate. 
8.2.1 Collection and ethical approval of blood used in experiments 
Human blood plasma was used to screen cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
for activity against the various haematological processes. The human ethics committee 
of the Nelson Mandela Metropolitan University (NMMU) approved the use of human 
blood samples in the haematological studies (reference number) (HO6SB-003) 
(September 2006). Human blood used in the platelet aggregation assay was drawn at 
the NMMU clinic on the day of use. Particular criteria with regards to the use of blood 
were as follows (Cunningham, 2006): 
 Blood was to be drawn in the morning, to allow for an overnight fast. A fatty meal 
should have been ingested 6 to 8 hours prior to blood been drawn. Severe 
lipaemia, resulting from a fatty meal, may have decreased the apparent response 
to aggregating agents in the platelet-rich plasma, such that the plasma would 
remain turbid even if all of the platelets had aggregated (Mustard et al., 1989; 
Zucker, 1989). 
 Ingestion of non-steriodal anti-inflammatory drugs (NSAIDs), one week prior to 
blood donation was not permitted. NSAIDs would inhibit the enzyme 
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cyclooxygenase, therefore preventing secretion via the arachidonic pathway 
(Mustard et al., 1989; Zucker, 1989). 
 Collection of blood was to be from the forearm vein. After which, blood had to be 
mixed with an anticoagulant agent, namely trisodium citrate, and frothing avoided 
during the mixing procedure (Mustard et al., 1989; Zucker, 1989). 
 Smoking of cigarettes for a number of hours prior to the collection was prohibited, 
since the smoke from a single cigarette would have increased the response of 
platelets to low adenosine diphosphate (ADP) levels (Zucker, 1989). 
 Donors had to be under minimum stress. Excessive anxiety may have caused an 
abnormally large increase in the primary aggregation reponse to ADP and 
norepinephrine (Zucker, 1989). 
8.2.2Coagulation assay 
The activation of the extrinsic and intrinsic pathways of the coagulation cascade results 
in the generation of thrombin, the activation of fibrinogen, the release of fibrinopeptides, 
the formation of soluble fibrin, and finally the formation of F XIII-mediated cross linked 
insoluble fibrin (Figure 8.1). Prothrombin time (PT) and activated partial thromboplastin 
time (APTT) assays were completed to evaluate the effects of the cyclic dipeptides on 
the extrinsic and intrinsic pathways respectively. The fibrinogen-C test was done to 
investigate if the cyclic dipeptides would possibly limit or inhibit the formation of fibrin 
from fibrinogen. The prolongation of clot formation time and the inhibition of fibrin 
formation would result in less clot formation. Calibration plasma (Beckman) was used to 
conduct the coagulation studies (PT, APTT, D-Dimer and Fibrinogen-C assays). Healthy 
donors were used to prepare calibrated plasma. 
A quantity of 2.78 mg of the cyclic dipeptides were initially dissolved in 1% 
dimethylsulphoxide (DMSO) (Associated Chemical Enterprises (Pty) Ltd, SA) and made 
up to volume with a 0.9 % NaCl solution. The cyclic dipeptides were then made up to 
final concentrations of 100 mM, 50 mM, 25 mM, and 12.5 mM. 
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8.2.2.1 Prothrombin time test 
The PT test which measures the extrinsic pathway is altered when there are changes in 
vitamin K-dependant coagulation factors (Azevedo et al., 2007). These factors include: 
Factor II, VII, V, X. A recomboplastin kit (Beckman, England) was used to determine the 
clotting time. The recomboplastin reagent which is included in the recomboplastin kit is 
a liposomal preparation which contains recombinant human tissue factor in a synthetic 
phospholipid mixture that contains calcium chloride, a buffer, and a preservative (Tripodi 
et al., 1992). Thromboplastin reagent is very sensitive and the recombinant human 
tissue factor contains no contaminating coagulation factors. This makes the PT reagent 
sensitive to deficiencies of factors X, VII, V and II (Quick, 1966). In the PT test, the 
extrinsic pathway is activated by the calcium ions, resulting in the conversion of 
fibrinogen into an insoluble fibrin clot (Quick, 1966).The PT test was performed 
according to the manufacturer‟s instructions. Recomboplastin (200 µl) was incubated at 
37 °C for 180 seconds on the CL Analyser (IVD, Beckman Coultier), while a premix of 
100 µl of plasma was incubated for 180 seconds at 37 °C with either the untreated 
control (C), cyclo(Phe-4Cl-Pro) (1: 4), cyclo(D-Phe-4Cl-Pro) (1: 4) or heparin (0.1 U/ml, 
positive control {PC}) (Bodene). To evaluate the PT, 150 µl of the plasma premix 
solutions were added to the recomboplastin (200 µl) and the clotting time was 
measured.  
8.2.2.2 Activated partial thromboplastin time (APTT) 
Alteration in the level of factors VIII, IX, X, XI and XII has an impact on APTT, which 
measures the integrity of the intrinsic pathways (Azevedo et al., 2007). The SynthASil 
kit (Beckman), which is used to measure APTT contains the APTT buffered reagent. 
The APTT reagent contains synthetic phospholipids (which are required for optimal 
platelet-like activity) and highly defined non-settling colloidal silica. SynthASil is 
sensitive to reduced levels of contact factors (which are involved in the intrinsic and 
common pathways), the anticoagulant effect of heparin and presence of inhibitors. The 
presence of conditions such as: a deficiency of factor XII, X, IX, VIII, or fibrinogen, liver 
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diseases, vitamin K deficiency and the presence of heparin, lupus anticoagulant or other 
inhibitors will prolong the clotting time (Dipiro et al., 2011). 
To evaluate the effect of the cyclic dipeptides on APTT, 100 µl of the APTT reagent was 
added to tubes containing 100 µl of plasma and either the (C), cyclo(Phe-4Cl-Pro) (1: 3) 
and cyclo(D-Phe-4Cl-Pro) (1: 3) or heparin (0.1 U/ml, PC). The mixtures were incubated 
at 37 °C for 180 seconds on the CL Analyser, after which 100 µl of 0.025 M CaCl2 
solution was added to initiate the activation of the intrinsic pathway. The clotting time 
was measured, and the anticoagulatory activity of test samples evaluated relative to the 
untreated control (C).  
8.2.2.3 Fibrinogen-C assay 
Thrombin converts fibrinogen into fibrin in plasma. Under these conditions i.e., high 
thrombin and low fibrinogen levels, the rate of the reaction is a direct function of the 
fibrinogen concentration. 
A Fibrinogen-C kit (Beckman) was used to determine the effect of the cyclic dipeptides 
on the conversion of fibrinogen to fibrin by comparing the protein levels of the treated 
plasma with that of untreated plasma control (C). Impairment in the conversion of 
fibrinogen to fibrin occurs during the coagulation process when there are abnormalities 
in fibrinogen (Dipiro et al., 2011). Fibrinogen levels are used as a diagnostic marker to 
determine disease states that include disseminated intravascular coagulation (DIC), 
liver disease, inflammatory diseases and malignancies. There is a direct correlation 
between high levels of fibrinogen and an increased risk in cardiovascular disease. 
Thrombolytic therapy reduces the fibrinogen levels (Dipiro et al., 2011).  
The Fibrinogen-C assay was performed according to the manufacturer‟s instructions. A 
ten times dilution of diluted plasma (200 µl) was incubated with 50 µl of either the (C), 
cyclo(Phe-4Cl-Pro) (1: 4), cyclo(D-Phe-4Cl-Pro) (1: 4) or heparin (0.1 U/ml, PC) at 37 
°C on the CL Analyser for 180 seconds. After the incubation period, a thrombin 
(Beckman) solution (35 U/ml); 100 µl) was added and the effect of the conversion of 
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fibrinogen to fibrin was evaluated by comparing the fibrin levels of the treated plasma 
with that of the untreated plasma control (C). 
8.2.2.4 D-Dimer 
When plasmin digests the insoluble fibrin, it yields a variety of soluble derivatives. 
These derivatives contain a D-Dimer domain which was not present on the original 
fibrinogen molecule, its degradation products, or on the insoluble fibrin (Palareti, 1993). 
The D-Dimer test is used widely as a diagnostic tool for thrombosis and monitoring 
thrombolytic therapy (Bounameaux et al., 1994). High levels of D-Dimer are present in 
conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE) and 
disseminated intravascular coagulation (DIC) (Gaffney et al., 1988). 
The D-Dimer latex reagent (Beckman) has a suspension of polystyrene latex particles 
that are coated with a monoclonal antibody that is highly specific for the D-Dimer 
domain. The coated latex particles (Latex reagent) agglutinate when plasma contains 
the D-Dimer domain. The degree of agglutination is directly proportional to the D-Dimer 
concentration, which is determined by a turbidimetric immunoassay that measures the 
amount of transmitted light at 405 nm. The reduction of the amount of transmitted light 
is caused by the formation of the aggregates (Newman et al., 1992). 
The D-Dimer assay was performed according to the manufacturer‟s instructions. The 
buffer (150 µl) was added to 42 µl of the plasma containing 8 µl of either the 
(C),cyclo(Phe-4Cl-Pro) (1: 3) or cyclo(D-Phe-4Cl-Pro) (1: 3). The mixture was then 
incubated at 37 °C in the CL Analyser for 15 minutes. After the incubation period the 
latex D-Dimer was subsequently added, the effect of the cyclic dipeptides on the rate of 
fibrinolysis via D-Dimer formation was evaluated by comparing the protein levels of the 
treated plasma with that of the untreated plasma control. Heparin (0.1 U/ml) was used 
as the positive control for this assay.   
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8.3 Platelet aggregation/adhesion studies 
Platelets prevent blood loss by constantly “guarding” the inner surface of blood vessels 
searching for “leaks” to be sealed. Platelets respond to injury in three phases:  
(1) Adhesion 
During this phase platelets adhere to the injured vessel via their receptors GPIb and 
GPIIb/IIIa mediated by the ligand vWF. 
(2) Aggregation 
Platelets adhere to each other via fibrinogen binding GPIIb/IIIa 
(3) Secretion 
Granules are released by exocytosis when the platelets are activated, forming a 
haemostatic plug. Flow cytometry allows researchers to mimic one or several aspects of 
these three phases to obtain relevant data (Reininger, 2006). 
Platelet aggregation and adhesion studies were done to investigate the effects of the 
cyclic dipeptides on platelet activity. 
8.3.1 Isolation of platelets   
Blood was drawn by venepuncture from healthy human subjects into sterile 4.5 ml tubes 
containing 0.5 ml of 0.105 M trisodium citrate (BD Vacutainer Systems, UK). Healthy 
individuals were defined as people who have not been sick for three months prior to the 
experiment and were not using any medication. Platelet rich plasma (PRP) was 
obtained by centrifuging at 300 x g for 10 minutes. The platelets were gently suspended 
in a buffer composed of 145 mmol/L NaCl, 5 mmol/L KCl, 10 mmol/L HEPES, 0.5 
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mmol/L Na2HPO4, 6 mmol/L glucose, and 0.2% bovine serum albumin (BSA), pH 7.4 
(buffer A). The platelet suspension was kept at room temperature and utilised within one 
hour. Ten minutes prior to use the platelets were warmed at 37 °C (Bellavite et al., 
1994). 
8.3.2 Platelet count 
A rapid spectrophotometric method for determining the number of platelets in a platelet 
suspension and in blood plasma developed by Walkowiak et al. (1997) was used. 
Platelet suspensions (200 µl) were placed in a 96-well microtiter plate for measurement 
of turbidity (Bio Tek Power Wave XS) (600 nm). Each sample was also used to perform 
triplicate platelet counts using a haemocytometer chamber. A standard curve was 
constructed correlating to the number of platelets at an absorbance of A600 nm (Figure 
8.2) 
 
 
 
 
 
Figure 8.2    Standard curve illustrating the correlation between platelet count numbers and absorbance 
(R
2
 = 0.9976)   
8.3.3 Platelet aggregation (flow-cytometry method) 
One unique future of flow-cytometry is that it measures fluorescence per cell or particle. 
Spectrophotometry, in contrast, measures the percent absorption and transmission of a 
specific wavelength of light for a given sample. Flow-cytometry uses the principles of 
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light scattering, light excitation, and emission of fluorochrome molecules to generate 
specific multi-parameter data from particles and cells in the size range of 0.5-40 µm in 
diameter. Recent developments in flow-cytometric analysis have made it possible to 
detect specific markers of platelet activation. The most studied markers are P-selectin, a 
marker for platelet degranulation, and PAC-1, a marker for GPIIb/IIIa activation 
(Michelson et al., 2000).Flow-cytometry can be used to determine both the activation 
state of circulating platelets and the reactivity of circulating platelets (Kasuya et al., 
2006). The monoclonal antibody used was anti-PAC-1. Anti-PAC-1 (BD-Biosciences) is 
an antibody that binds to the fibrinogen-binding site exposed by the conformational 
change that occurs in the GPIIb-IIIa complex when it is activated (Michelson et al., 
2000). 
 
Figure 8.3    The effect of platelet activation on monoclonal antibody binding (Michelson et al., 2000) 
A method adapted from Michelson et al., (2000), was used for the experiment. A platelet 
rich plasma (PRP) sample containing a platelet count of 3 x 107 platelets/ml was used 
for all cytometry experiments. A volume of 40 µl of PRP was placed into tubes 
containing 10 µl of a 200 µg/ml saturated concentration of fluorescein isothiocyanate 
(FITC)-PAC1 (BD Biosciences). The binding of fibrinogen to the gpIIb/IIIa receptor is 
required for platelet aggregation. PAC-1 binds only to activated platelets and appears to 
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be specific for this recognition site within gpIIb/IIIa. PAC-1 inhibits fibrinogen-mediated 
platelet aggregation (Michelson et al., 2000). 
To inhibit fibrin polymerization, 2 µl of 2.5 mmol/L (final concentration) of peptide glycol-
L-prolyl-L-arginyl-L-proline (GPRP) (Sigma) was added. For a positive control (PC), 100 
µl of thrombin stock (50 U/ml) was added to give final concentration of 10 U/ml, the 
same volume of buffer was added for an untreated control (C), cyclo(Phe-4Cl-Pro) (1: 3) 
or cyclo(D-Phe-4Cl-Pro) (1: 3) were added. Unstained cells were used to determine 
background staining. The tubes were then incubated at room temperature for fifteen 
minutes. Following the incubation period the platelets were fixed with 2: 1 ratio of 1% 
formaldehyde for thirty minutes at room temperature. A threefold volume of Tyrode‟s 
buffer was added and the cells were immediately analysed with a Beckman flow 
cytometer (Coultier, Cytomics FC 500). All parameters were collected in list mode files 
and then analysed.  
8.4 Statistical analysis 
Results were obtained as quadruplicate values and represented as a mean ± standard 
deviation (SD). Data was represented graphically with the aid of statistical software 
packages, Microsoft Excel® (Version 2007) and Graph Pad Prism® (Version 5). 
Statistical analysis was then carried out on the resultant graph slopes, which represent 
either inhibition or acceleration of the relevant coagulation pathways. Student‟s t-tests 
performed in order to determine if the mean response to each cyclic dipeptide 
concentration indicated significant inhibition or acceleration of a particular coagulation 
pathway. Calculated p-values of less than 0.05 were defined as an indication of 
statistical significance. The p-values were compared to the relevant positive controls. 
8.5 Results and discussion 
8.5.1 Activated partial thromboplastin time assay (APTT) 
The effects of heparin (positive control), cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
on the intrinsic pathway are illustrated in Figure 8.4 and summarised in Table 8.1. APTT 
221 
 
represents the time in seconds it takes for plasma to clot after the addition of an intrinsic 
pathway activator and calcium. The normal APTT range in human plasma is 24 to 39 
seconds. Heparin at a screening concentration of 0.1 U/ml significantly prolonged the 
clotting time to 106.0 ± 1.350 seconds. Cyclo(Phe-4Cl-Pro) at a screening concentration 
of 50 mM produced a clotting time of 27.95 ± 0.4000 seconds (P = 0.0003). The 
screening concentrations of 25 mM and 12.5 mM, however produced a shorter clotting 
time of 20.28 ± 1.055 seconds (P = 0.0004) and 10.78 ± 0.4450 seconds (P = 0.0002), 
respectively.Cyclo(D-Phe-4Cl-Pro) at screening concentrations of 50 mM, 25 mM and 
12.5mM, produced clotting times of 26.15 ± 0.7050 seconds (P = 0.0004), 14.61 ± 
0.6150 seconds (P = 0.0003) and 8.110 ± 0.5500 seconds (P = 0.0002). 
Table 8.1    Effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on APTT 
clott ing times 
Compound Concentration Clotting time 
(seconds) 
P-value 
Heparin 0.1 U\ml 106 ± 1.350 0.0003 
 
Cyclo(Phe-4Cl-
Pro) 
50 mM 27.95 ± 0.4000 
 
0.0003 
25 mM 
20.28 ± 1.055  
0.0004 
 
12.5 mM 
10.78 ± 0.4450  
0.0002 
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Cyclo(D-Phe-4Cl-
Pro) 
50 mM 
26.15 ± 0.7050  
0.0004 
 
25 mM 
14.61 ± 0.6150  
0.0003 
 
12.5 mM 
8.110 ± 0.5500  
0.0002 
 
(P-values are calculated relative to the positive control) 
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Figure 8.4    Effects of heparin (positive control), cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on APTT 
clotting time 
8.5.2 Prothrombin time assay (PT) 
Prothrombin time represents the time in seconds it takes for plasma to clot after the 
addition of calcium and thromboplastin. The normal PT range is 11 to 13.5 seconds. 
The effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on PT clotting time 
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are illustrated in Figure 8.5 and summarised in Table 8.2. Heparin at a screening 
concentration of 0.1 U/ml, significantly prolonged PT clotting time to 88.80 ± 1.805 
seconds. Cyclo(Phe-4Cl-Pro) at screening concentrations of 50 mM, 25 mM produced 
longer PT clotting times of 20.53 ± 0.9250 seconds (P = 0.2374), 17.13 ± 0.1700 
seconds (P = 0.0055). Cyclo(Phe-4Cl-Pro) at a screening concentration of 12.5 mM, 
however produced a PT clotting time of 14.41 ± 0.810014 seconds (P = 0.0125). 
Cyclo(D-Phe-4Cl-Pro) at screening concentrations of 50 mM, 25 mM and 12.5 mM, 
produced PT clotting times of 17.66 ± 0.6700 seconds (P = 0.0266), 11.85 ± 0.8550 
seconds (P = 0.0078) and 10.75 ± 0.4500 seconds (P = 0.0024), respectively. 
Table 8.2    Effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on PT 
clott ing times 
Compound Concentration Clotting time 
(seconds) 
P-value 
Heparin 0.1 U/ml 88.80 ± 1.805 0.0009 
 
Cyclo(Phe-4Cl-
Pro) 
50 mM 20.53 ± 0.9250 
 
 
0.2374 
25 mM 
17.13 ± 0.1700  0.0055 
12.5 mM 
14.41 ± 0.8100  0.0125 
Cyclo(D-Phe-4Cl- 50 mM 
17.66 ± 0.6700  0.0266 
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Pro) 
25 mM 
11.85 ± 0.8550  0.0078 
12.5 mM 
10.75 ± 0.4500  0.0024 
(P-values are calculated relative to the positive control) 
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Figure 8.5    Effects of heparin (positive control), cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on PT 
clotting time 
8.5.3 Fibrinogen-C assay (Fib-C) 
The activity of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on fibrin formation 
is illustrated in Figure 8.6 andsummarised in Table 8.3. The conversion of fibrinogen to 
fibrin elicit a series of reactions that cross-link adjacent fibrin monomers which then 
stabilises the formed clot (Dipiro et al., 2011). The addition of 100 µl of thrombin to the 
negative control (untreated plasma) resulted in the formation of 470.29 ± 0.510 mg/dL 
fibrin. Heparin (positive control) at a screening concentration of 0.1 U/ml decreased the 
formation of fibrin to 73.66 ± 3.670 mg/dL (P = 0.0144). Cyclo(Phe-4Cl-Pro) formed 
116.7 ± 3.725 mg/dL (P = 0.0144) at 50mM, 273.2 ± 3.830 mg/dL (P = 0.0007) at 25 
mM, 292.5 ± 2.500 mg/dL (P = 0.0004) at 12.5 mM. Cyclo(D-Phe-4Cl-Pro) formed 172.0 
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± 2.000 mg/dL (P = 0.0018) at 50 mM, 313.4 ± 2.545 mg /dL (P = 0.0003) at 25 mM and 
369.8 ± 0.8350 mg/dL (P = 0.0002) at 12.5 mM. 
Table 8.3    Effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on the 
formation of f ibrin 
Compound Concentration Fibrin formation 
(mg/dL) 
P-value 
Heparin 0.1 U/ml 73.66 ± 3.670 
 
0.0144 
 
Cyclo(Phe-4Cl-
Pro) 
50 mM 116.7 ± 3.725  
 
 
 
 
0.0144 
25 mM 273.2 ± 3.830  0.0007 
 
12.5 mM 292.5 ± 2.500  
 
0.0004 
 
Cyclo(D-Phe-4Cl- 50 mM  
0.0018 
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Pro) 
172.0 ± 2.000  
 
 
25 mM 313.4 ± 2.545  
 
0.0003 
 
 
12.5 mM 369.8 ± 0.8350  
 
0.0002 
 
(P-values are calculated relative to the positive control) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
227 
 
 
F
ib
ri
n
 f
o
rm
a
ti
o
n
 (
m
g
/d
L
)
PC 50 mM 25 mM 12.5 mM 50 mM 25 mM 12.5 mM
0
100
200
300
400
Cyclo(Phe-4Cl-Pro)
Cyclo(D-Phe-4Cl-Pro)
 
Figure 8.6    Effects of heparin (positive control), cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on 
decreasing the formation of fibrin 
8.5.4 D-Dimer assay 
The effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on D-Dimer levels 
are illustrated in Figure 8.7 and summarised in Table 8.4. Heparin at a screening 
concentration of 0.1 U/ml significantly decreased the levels of D-Dimer (36.99 ± 1.000 
ng/ml). Cyclo(Phe-4Cl-Pro) at screening concentrations of 50 mM, 25 mM and 12.5 mM, 
produced results of 69.39 ± 1.055 ng/ml (P = 0.0020), 65.43 ± 2.875 ng/ml (P = 0.0113) 
and 53.10 ± 2.105 ng/ml (P = 0.0203). Cyclo(D-Phe-4Cl-Pro) at screening 
concentrations of 50 mM, 25 mM and 12.5 mM, produced results of 53.91 ± 0.3100 
ng/ml (P = 0.0038), 49.16 ± 0.1700 ng/ml (P = 0.0069) and 43.95 ± 0.9550 ng/ml (P = 
0.0373), respectively. D-Dimer levels should under normal physiological conditions not 
be detectable in blood plasma, except when the coagulation cascade has been 
activated. High D-Dimer levels in plasma indicate elevated levels of fibrin formation and 
reflect a state of hypercoagulability (Moresco et al., 2006). The cyclic dipeptides caused 
elevation of D-Dimer formation. 
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Table 8.4    Effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on D-Dimer 
formation 
Compound Concentration D-Dimer formation 
(ng/ml) 
P-value 
Heparin 0.1 U/ml 36.99 ± 1.000 0.0020 
Cyclo(Phe-4Cl-
Pro) 
50 mM 69.39 ± 1.055  
 
 
 
 
0.0020 
25 mM 
65.43 ± 2.875  0.0113 
12.5 mM 
53.10 ± 2.105  0.0203 
Cyclo(D-Phe-4Cl-
Pro) 
50 mM 
53.91 ± 0.3100  0.0038 
25 mM 
49.16 ± 0.1700  
0.0069 
 
12.5 mM 
43.95 ± 0.9550  0.0373 
(P-values are calculated relative to the positive control) 
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Figure 8.7    Effects of heparin (positive control), cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on D-
Dimer formation 
8.5.5    Platelet aggregation studies 
Figures 8.8 to 8.17 illustrate the flow-cytometry diagrams and cell density plots for the 
untreated control (PRP), treated control (PRP with 50U/ml thrombin), cyclo(Phe-4Cl-
Pro) and cyclo(D-Phe-4Cl-Pro), at screening concentrations of 50 mM, 25 mM and 12.5 
mM and 3.125 mM. In order to obtain the percentage of cells that stained positive, a 
region gate was drawn around a population of intact cells to exclude cell debris and 
clumped cells. The platelet particles that exhibited aggregation were excluded by the 
defined gate. 
For the untreated control 1.3% of the cells exhibited aggregation. The positive control 
(thrombin 50 U/ml) indicated an 7.6% increase in aggregation. Cyclo(Phe-4Cl-Pro) 
increased the aggregation to 95.2%, 94.4%, 92.6 and 90.5% at screening 
concentrations of 50 mM, 25 mM, 12.5 mM and 3.125 mM respectively. Cyclo(D-Phe-
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4Cl-Pro) produced percentage aggregations of 93.5%, 32.4%, 0.2% and 0.3% at 
screening concentrations of 50 mM, 25 mM, 12.5 mM and 3.125 mM respectively. 
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Figure 8.8    Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by the untreated control (PRP) 
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Figure 8.9    Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by the positive control (PRP with thrombin 50 U/ml) 
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Figure 8.10    Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 50 mM cyclo(Phe-4Cl-Pro)  
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Figure 8.11    Fluorescence intensity and cell density plot representation of platelet aggregation caused 
by 25 mM cyclo(Phe-4Cl-Pro)  
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Figure 8.12    Fluorescence intensity and cell density plot representation of platelet aggregation caused 
by 12.5 mM cyclo(Phe-4Cl-Pro) 
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Figure 8.13    Fluorescence intensity and cell density plot representation of platelet aggregation 
caused by 3.125 mM cyclo(Phe-4Cl-Pro) 
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Figure 8.14    Fluorescence intensity and cell density plot representation of platelet aggregation caused 
by 50 mM cyclo(D-Phe-4Cl-Pro) 
 
238 
 
 
 
Figure 8.15    Fluorescence intensity and cell density plot representation of platelet aggregation caused 
by 25 mM cyclo(D-Phe-4Cl-Pro) 
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Figure 8.16    Fluorescence intensity and cell density plot representation of platelet aggregation caused     
                         by 12.5 mM cyclo(D-Phe-4Cl-Pro) 
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Figure 8.17    Fluorescence intensity and cell density plot representation of platelet aggregation caused 
by 3.125 mM cyclo(D-Phe-4Cl-Pro) 
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8.6 Summary 
Variables such as blood collection methods, the collection container characteristics, 
sample storage prior to use and contact activation time could have affected the results 
obtained from the coagulation and flow-cytometry assay. 
The activity of both cyclic dipeptides on the extrinsic and intrinsic pathways was 
evaluated by conducting APTT and PT assays. The effect of both cyclic dipeptides on 
prolonging clotting time in both assays was found to be insignificant. It can be 
concluded therefore that the compounds yielded no anticoagulant activity. 
The cyclic dipeptides showed significant reduction of fibrin formation and D-Dimer levels 
when compared with the relevant controls. The results were however not significant 
enough to indicate a strong potential for the compounds to be used clinically. 
The results of the platelet aggregation assay showed that both cyclic dipeptides 
enhanced aggregation. The compounds can for this reason not be used as anti-platelet 
agents. Cyclo (D-Phe-4Cl-Pro) at 12.5 mM and 3.125 mM exhibited the most anti-
platelet activity. Future studies could possibly involve conducting further serial dilutions 
of cyclo(D-Phe-4Cl-Pro), and looking at dose response curves. 
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CHAPTER 9 
ANTI-DIABETES 
9.1 Introduction 
Diabetes mellitus (DM) is a metabolic disorder which has reached epidemic status 
(Stunvoll et al., 2005; Bakker et al., 2009). By 2030 366 million people are predicted to 
be diagnosed with DM (Stunvoll et al., 2005; Bakker et al., 2009). Type 1 DM (T1DM) is 
characterised by the loss of insulin production due to β-cell failure, while type 2 DM 
(T2DM) is characterised by the development of insulin resistance in responsive tissues, 
particularly muscle line and adipose. This impaired insulin production in conjunction with 
decreased response to insulin results in hyperglycemia. T2DM is the most common 
form of DM, since it accounts for more than 90% of DM cases (Bakker et al., 2009).  
9.2 Physiology of the Islet of Langerhans 
The Islet of Langerhans within the pancreas are the primary regulators of blood glucose 
and  contain four main cell types: β-cells secrete insulin and islet amyloid in response to 
elevated blood glucose levels, A-cells secrete glucagon when blood glucose levels are 
depressed, D-cells secrete somatostatin and PP cells secrete pancreatic polypeptide. 
The core of each islet mainly consists of β-cells. Islet amyloid delays gastric emptying 
and opposes insulin by stimulating glycogen breakdown in striated muscle. Glucagon 
also opposes insulin, increasing blood glucose and stimulating protein breakdown in 
muscle. Somatostatin inhibits insulin and glucagon secretion. Somatostatin is also 
released from the hypothalamus, inhibiting the release of growth hormone from the 
pituitary (Rang et al., 2011).   
9.3. Regulation of glucagon and insulin secretion    
The principal action of glucagon is to increase blood glucose levels when it falls below 
normal. In contrast, insulin helps lower the blood glucose levels when it is too high 
(enables cellular uptake of glucose to provide energy for the cell). Low blood glucose 
levels (hypoglycaemia) stimulate the secretion of glucagon from A-cells of the 
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pancreatic islets. Glucagon then acts on the hepatocytes to accelerate the conversion of 
glycogen into glucose (glycogenolysis) and to promote the formation of glucose from 
lactic acid and certain amino acids (gluconeogenesis). Consequently hepatocytes 
release glucose into the blood more rapidly, and the blood glucose levels rise. If blood 
glucose levels continue to rise, high blood glucose level (hyperglycaemia) inhibits the 
release of glucagon and stimulates the release of insulin by the β-cells of the pancreatic 
islets. Insulin acts on various cells in the body to accelerate facilitated diffusion of 
glucose into cells, especially skeletal muscle fibers, in order to (I) speed the conversion 
of glucose into glycogen (glycogenesis), (II) to increase the uptake of amino acids by 
cells and (III) to increase protein synthesis, to speed up the synthesis of fatty acids 
(lipogenesis) and (IV) to slow glycogenolysis, and gluconeogenesis. Consequently the 
blood glucose levels fall. If the blood glucose levels drop below normal, low blood 
glucose inhibits the release of insulin. Table 9.1 summarises the metabolic effects of 
insulin and glucagon 
Table 9.1    The metabolic effects of insulin and glucogan (Dipiro et al ., 2011)  
cellular activity Insulin glucagon 
Glycogenesis ↑ ↓ 
Glycogenolysis ↓ ↑ 
Gluconeogenesis ↓ ↑ 
Ketogenesis ↓ ↑ 
Lipolysis ↓ ↑ 
Lipogenesis ↑ ↓ 
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9.4. Diabetes Mellitus  
Diabetes Mellitus is a chronic metabolic disorder characterised by a high blood glucose 
concentration (fasting plasma glucose > 7.0 mmol/L, or plasma glucose >11.1 mmol/L), 
caused by insulin deficiency, often combined with insulin resistance. Hallmarks of DM 
are excessive urine production, due to an inability of the kidneys to reabsorb water 
(polyuria), excessive thirst (polydipsia) and excessive eating (polyphagia) (Rang et al., 
2011).   
9.4.1 Type 1 DM (T1DM) 
Type 1 DM is an autoimmune disease in which the person‟s immune system destroys 
the pancreatic β-cells, causing low insulin levels in the body. Here insulin injections are 
required to prevent death, and it is for this reason that the disease is also called insulin-
dependent diabetes mellitus (IDDM). Since insulin is not present to aid entry of glucose 
into body cells, most cells use fatty acids to produce adenosine triphosphate (ATP). 
Stores of triglycerides in adipose tissues are catabolised to yield fatty acids and 
glycerol. The by-products of fatty acid breakdown, ketones, accumulate and cause the 
blood pH to fall (ketoacidosis). The breakdown of stored triglycerides also results in 
weight loss. Lipid particles are deposited on the walls of the blood vessels, leading to 
atherosclerosis and a multitude of cardiovascular problems. A major complication of 
diabetes is (I) loss of vision, when excessive glucose attaches to the lens proteins 
causing cloudiness or (II) when damaged is caused to the blood vessels of the retina 
(Dipiro et al., 2011). 
9.4.2 Type 2 DM (T2DM) 
In Type 2 DM, β-cells slowly lose their capacity to produce insulin due to damage 
caused by increased demand on these cells; and target tissues receptors show reduced 
sensitivity to insulin. The result is reduced glucose uptake and hyperglycaemia (Dipiro 
et al., 2011). 
245 
 
9.4.3 Diagnosis of DM  
Diagnosis of insulin dependent diabetes mellitus (IDDM) is based on the presence of 
elevated blood glucose levels (hyperglycaemia), the presence of glucose in the urine 
(glucosuria) and excessive production of urine (polyuria), all resulting from a lack of 
insulin secretion. For non insulin dependent diabetes mellitus (NIDDM) the glucose 
tolerance test (GTT) is used. The GTT evaluates the ability of an individual‟s cells to 
take up and metabolise glucose. After an oral dose of glucose is given, its level in the 
blood and urine is monitored. If the blood glucose level goes up and remains elevated, it 
is a sign that insulin secretion is inadequate to cope with the absorbed glucose (Dipiro 
et al., 2011). 
 9.4.4 Treatment of DM 
The main aim of DM treatment is the restoration of glucose metabolism. Treatment of 
IDDM is predominantly by subcutaneous injection of insulin. Meals, consisting of high 
percentage carbohydrates and low percentage fats, must be taken at regular time 
intervals, with frequent snacks between meals. Foods rich in sugars are strictly limited 
as they release glucose from the gastric intestinal lumen into the blood more rapidly 
than the amount injected insulin can cope with. Battery-powered insulin infusion pumps 
provide a continuous insulin supply through a subcutaneous needle or intravenously. 
Transplantation of the pancreas is also being explored (Dipiro et al., 2011). 
In the early stages of NIDDM the disease can be controlled with diet and exercise, 
because both contribute to weight loss. As weight is reduced the insulin receptor 
numbers on normally insulin responsive cells increase and insulin resistance is 
diminished (Dipiro et al., 2011). 
9.5 Anti-diabetic drugs 
9.5.1 Thiazolidinediones 
The thiazolidinediones (TZDs) enhance insulin sensitivity, thereby, reducing glucose 
levels. The TZDs also improve endothelial and inflammatory function, dislipidemia, and 
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dissolution of blood clots (fibrinolysis). The TZDs have a high affinity for a specific 
peroxisome proliferator-activated receptor (PPAR) subtype (Nathason and NystrÖm, 
2009; Jellinger and Mace, 2007; Stunvoll et al., 2005). There are three PPAR subtypes. 
Firstly, PPARα which is expressed abundantly in the liver, heart muscle and vascular 
wall. Secondly, PPARα/β which is abundantly expressed in skin, brain and adipose 
tissue and thirdly, PPARα which is predominantly expressed in adipose tissue but also 
in pancreatic β-cells, the endothelium and macrophages (Nathason and NystrÖm, 
2009). TZDs bind to PPARα and are for this reason thought to act primarily in adipose 
tissue. TZDs improve insulin sensitivity by causing the redistribution of tissue 
triglycerides or fats from visceral stores to subcutaneous adipose tissue. The action of 
TZDs not only reduces „non-esterified fatty acids‟ circulating levels but also reduces the 
plasma levels of free fatty acids, while increasing the levels of adiponectin. TZDs also 
improve renal function by improving albumin excretion (Jellinger and Mace, 2007; 
Stunvoll et al., 2005). Currently available TZDs include pioglitazone and rosiglitazone 
(Dipiro et al., 2011). 
9.5.2 Biguanides 
Metformin is the drug of choice for T2DM in combination with diet and exercise. It 
improves insulin sensitivity in tissues by decreasing hepatic glucose production and 
increasing glucose uptake in skeletal muscle and adipose tissues with minimum risk of 
hypoglycaemia. It also reduces appetite and consequently calorie intake and may 
improve insulin secretion by pancreatic β-cells (Dipiro et al., 2011). Metformin reduces 
the level of circulating triglycerides, free fatty acids and low density lipoprotein 
cholesterol, while increasing the levels of high density lipoprotein cholesterol. Metformin 
also improves endothelial function (Nathason and NystrÖm, 2009; Jellinger and Mace, 
2007; Stunvoll et al., 2005). The mechanism of action of metformin is thought be via the 
activation of 5‟ adenosine monophosphate-activated protein kinase (AMPK). Metformin 
indirectly activates AMPK by activating complex-1 in the respiration chain. The 
activation of AMPK down-regulates gluconeogenesis, cholesterol biosynthesis, and the 
fatty acid synthesis pathway. AMPK activation in the endothelium and myocardial tissue 
is also associated with angiogenesis regulation (Nathason and NystrÖm, 2009). 
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Metformin also possesses anti-thrombotic effects by lowering the in vivo levels of factor 
(f) VII and fibrinogen and increases fibrinolysis by lowering the levels of PAI-1 
(Nathason and NystrÖm, 2009). 
9.5.3 α-Glucosidase inhibitors 
Acarbose reduces the blood glucose levels. It mediates this action by inhibiting α-
glucosidase found in the small intestine. α-Glucosidase converts oligosaccharides to 
monosaccharides (Nathason and NystrÖm, 2009). 
9.5.4 Sulphonylurea derivatives 
Sulphonylureas (SUs), increase insulin secretion by closing ATP-dependent K+-
channels that are found in a variety of cells, including pancreatic β-cells, skeletal muscle 
tissues, vascular smooth muscle cells, the endothelium, kidney and central nervous 
system. The ATP-dependent K+-channels are made up of two sulphonylurea proteins, 
sulphonylurea receptor 1 (SUR1) and sulphonylurea receptor 2 (SUR2) and Kir 6.2 
SUR1 is expressed in β-cells, while SUR2 is expressed in myocardial cells. Kir 6.2 is a 
pore-forming unit K+-inward rectifier channel. The SUs close the K+-channels by binding 
to the pancreatic β-cell SUR1/Kir 6.2 protein. The influx of Ca2+, because of membrane 
depolarisation, the leads to the exocytosis of insulin vesicles. They also improve 
endothelial function (Dipiro et al., 2011). 
Examples of the SUs currently in use are glibenclamide, gliclazide, glimepiride and 
glipizide. Gliclazide and glipizide have a short duration of action, while glibenclamide 
and glimepiride have a longer duration of action that can last up to 24 hours. The risk of 
hypoglycaemia is lower in SUs that have a short duration of action, and gliclazide can 
be used in patients with reduced renal function. The SUs also decrease the levels of 
glycosylated haemoglobin (Nathason and NystrÖm, 2009). 
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9.5.5 Meglitinides 
Nateglinide, like SUs, also binds to SUR1. Repaglinide stimulates insulin secretion by 
binding to a different site on the receptor. The advantage of using meglitinides is that 
they do not cause hypoglycaemia, but compared with the SUs, have a shorter duration 
of action. Meglitinides can also be used in patients with reduced renal function (Dipiro et 
al., 2011).    
9.5.6 Glucagon-like peptide 1 
Glucagon-like peptide 1 (GLP-1) is formed from the partial proteolysis of 
preproglucagon that is produced in the small and large intestine by the enteroendocrine 
L-cells. GLP-1 causes high insulin responses that are glucose dependent, increases the 
mass of β-cells, and inhibits intestinal motility. GLP-1 is rapidly degraded by dipeptidyl 
peptidase IV (DPPIV), and consequently has a very short half-life of between 1 and 2 
minutes. It is for this reason that GLP analogues with a longer half-life, such as 
exenatide and liraglutide and inhibitors of DPPIV have been developed. GLP-1 has also 
been reported to improve vascular integrity and protects against endothelial dysfunction 
(Nathason and NystrÖm, 2009). 
9.6 Methodology   
The anti-diabetic effects of the cyclic dipeptides were determined by conducting α-
glucosidase and α-amylase assays. The α-glucosidase enzyme is responsible for the 
conversion or breakdown of carbohydrates into monosaccharides. Monosaccharides 
are absorbed in the small intestine resulting in elevated blood glucose levels. α-Amylase 
assays hydrolysis α-bonds of large α-linked polysaccharides, yielding glucose and 
maltose  (Dipiro et al., 2011). 
9.6.1 Preparation of test solutions 
100 mg of rat intestinal acetone powder was suspended in 3 ml of 0.01 M phosphate 
buffer (pH 7.0) and sonicated for 30 seconds, 12 times in an ice bath. The solution was 
centrifuged at 3000 rpm at 4 °C for 20 minutes. The crude enzyme solution was 
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removed and the pellets were also discarded. The supernatant solution was kept on ice 
prior to use. 
9.6.1.1 Positive control   
A 500 mM stock solution of acarbose was prepared by dissolving 0.321 g/ml in reverse 
osmosis water. The stock solution was diluted with reverse osmosis water to give a final 
screening concentration of 50 mM, then filter-sterilised through 0.22 µm acetate filters 
prior to use.   
9.6.1.2 4-Nitrophenyl-α-D-glucopyranoside 
A stock concentration of 0.5 mM 4-nitrophenyl-α-D-glucopyranoside was prepared by 
dissolving 1.5065 mg in 10 ml of 0.1 M phosphate buffer (pH 7.0). The solution was 
filter-sterilised through 0.22 µm acetate filters prior to use. 
9.6.1.3 Sodium carbonate 
A stock concentration of 0.2 M sodium carbonate solution was prepared by dissolving 
1.06 g sodium carbonate in 50 ml reverse osmosis water. The solution was filter-
sterilised through 0.22 µm acetate filters prior to use. 
9.6.2 α-glucosidase assay  
Methods employed by Sancheti et al. (2009) were adapted to determine the effects of 
cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on the activity of the α-glucosidase 
enzyme. 
Mixtures consisting of 50 µl of the 0.1 M phosphate buffer, 25 µl of the 0.5 mM 4-
nitrophenyl-α-D-glucopyranoside solution, 10 µl of either the acarbose solution, 
cyclo(Phe-4Cl-Pro) solution or cyclo(D-Phe-4Cl-Pro) solution were incubated at 37 °C 
for 30 minutes. After incubation 100 µl of 0.2 M sodium carbonate solution was added to 
terminate the enzymatic reaction. The amount of p-nitrophenol released in the reaction 
was determined spectrophotometrically at 410 nm using a microplate reader (BioTek 
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Power Wave XS). The amount of p-nitrophenol released was proportional to the 
enzymatic hydrolysis of the substrate. Experiments were conducted in triplicate. 
α-Glucosidase inhibition was calculated as a percentage of the control using the 
formula: 
Percentage inhibition = 
     
  
  x 100 
Where Ac is the change in absorbance of the blank control and As is the change in 
absorbance that occurs between the time the substrate is added to the mixture and 30 
minutes after incubation. 
9.6.3 α-Amylase assay 
Methods developed by Fuwa (1954) and modified by Xiao et al. (2006) were adapted to 
determine the effects of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on α-amylase 
activity. The microplate-based starch-iodine assay was utilised. This assay is based on 
the development of color that results when iodine binds to starch polymers. The amount 
of starch degraded determines the activity of α-amylase. 
40 µl of starch (Sigma) solution and 40 µl of the α-amylase enzyme (in 0.1 M phosphate 
buffer at pH 7.0) were pipetted into microplate wells and incubated at 50 °C for 30 
minutes. After incubation 20 µl of 1 M HCl was added to terminate the enzymatic 
reaction. 100 µl of iodine reagent (5 mM iodine and 5 mM potassium iodide) was then 
added. When color development was evident, 150 µl of the iodine-treated sample was 
transferred into a transparent 96-well flat-bottomed microplate and the absorbance was 
read at 580 nm, using a microplate reader (BioTek Power Wave XS). The experiment 
was conducted in triplicate.    
α-Amylase activity was determined as relative activity according to the following 
formula: 
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Dextrinising activity = 
      
  
 x 
   
  
 
Where D is the absorbance of the enzyme sample and D0 is the absorbance of the 
amylase control without the addition of enzyme. 
9.7 Statistical analysis 
Data was represented graphically with the aid of statistical software packages, Microsoft 
Excel® (Version 2007) and Graph Pad Prism® (Version 5). The results obtained from the 
α-glucosidase and the α-amylase assays were compared with the controls without 
inhibitor using the Student‟s t-test and expressed as mean ± SD. 
9.8 Results and discussion 
9.8.1 α-Glucosidase assay  
The effects of acarbose (positive control) at a screening concentration of 50 mM, 1 mM 
of cyclo(Phe-4Cl-Pro) and 1 mM of cyclo(D-Phe-4Cl-Pro) on the activity of α-
glucosidase are shown in Figure 9.1 
Acarbose at a screening concentration of 50 mM inhibited the activity of the α-
glucosidase enzyme by 51.11% ± 4.498 (P < 0.0001) while cyclo(Phe-4Cl-Pro) and 
cyclo(D-Phe-4Cl-Pro) inhibited the activity by -4.352% ± 1.477 (P < 0.0001) and -
6.953% ± 1.740 (P < 0.0001), respectively. These negative values obtained, indicates a 
stimulation of the α-glucosidase enzyme and thus an increase in the conversion of 
carbohydrates to monosaccharides and elevated blood glucose levels. 
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Figure 9.1    α-Glucosidase enzyme inhibition caused by acarbose (positive control), cyclo(Phe-4Cl-Pro) 
and cyclo(D-Phe-4Cl-Pro) 
9.8.2 α-Amylase activity 
 The effects of acarbose, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on the activity of 
α-amylase are shown in Figure 9.2. 
Acarbose inhibited the activity of the α-amylase enzyme by 55.51% ± 2.786 (P < 
0.0001) at a screening concentration of 50 mM. Cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-
4Cl-Pro) inhibited the enzyme‟s activity by 5.654% ± 0.02507 (P < 0.0001) and 5.530% 
± 0.05743 (P < 0.0001), respectively. 
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Figure 9.2    α-Amylase enzyme inhibition caused by acarbose, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-
4Cl-Pro) 
9.9 Summary  
The inhibition of activity of the α-glucosidase and α-amylase enzymes caused by both 
cyclic dipeptides was revealed to be insignificant as both cyclic dipeptides had an 
enzyme inhibition of less than 10%. It can also be noted that both cyclic dipeptides 
slightly increased the activity of the α-glucosidase enzyme. For these reasons it was 
concluded that cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) have no therapeutic 
potential in inhibiting α-glucosidase and α-amylase enzymes. Future studies could 
include conducting cellular assays of the relevant cyclic dipeptides. 
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CHAPTER 10 
CONCLUSIONS AND RECOMMENDATIONS 
The cyclic dipeptides cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro), were successfully 
synthesised from their corresponding linear precursors using a modified phenol-induced 
cyclisation procedure. Yields of 54% and 62% were obtained for cyclo(Phe-4Cl-Pro) and 
cyclo(D-Phe-4Cl-Pro) respectively. Qualitative analysis, purity determination and 
evaluation of the physiochemical properties of the cyclic dipeptides were achieved by 
high-performance liquid chromatography, scanning electron microscopy, 
thermogravimetric analysis, differential scanning calorimetry and X-ray diffraction. 
Results confirmed that that the synthesised cyclic dipeptides were free from impurities 
and could therefore be used for further biological studies.  
Infrared spectroscopy, mass spectroscopy, nuclear magnetic resonance spectroscopy 
and molecular modelling were utilised to conduct the structural and conformational 
analysis of the synthesised compounds. The proposed structures of cyclo(Phe-4Cl-Pro) 
and cyclo(D-Phe-4Cl-Pro) were confirmed. 
Anticancer, antimicrobial, haematological and anti-diabetic studies were conducted to 
determine the biological activity of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro). The 
use of dimethyl sulphoxide in the experiments aided in dissolving the respective cyclic 
dipeptides and other compounds, but was used at minimum concentrations that were 
not toxic to the cells and would therefore not interfere with the biological studies. 
Cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) exhibited limited clinical potential as 
anticancer agents against HeLa (cervical cancer), HT-29 (colon cancer) and MCF-7 
(breast cancer) cell lines, when compared to Melphalan. The limited anticancer activity 
demonstrated by both cyclic dipeptides may be as a result of their hydrophilic nature, 
which hinders their ability to cross the respective cell membranes. Of the three cancer 
cell lines, the growth of MCF-7 cell was inhibited the most by the cyclic dipeptides. The 
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greatest inhibition of MCF-7 cell growth displayed by the cyclic dipeptides, was 
produced by cyclo(Phe-4Clo-Pro) at a concentration of 200 µM. Additional anticancer 
studies could include the biological testing of both cyclic dipeptides against other cancer 
cell lines, since cyclic dipeptides have shown to exhibit anticancer effects against a 
broad spectrum of human cancer cell lines. Studies can also be conducted to determine 
the effect of both cyclic dipeptides on non cancerous cell lines. Dose response curves 
should be calculated, where growth inhibitory effects are statistically and clinically 
significant, in order to determine the minimum inhibitory concentrations (MIC) of the 
cyclic dipeptides. The cyclic dipeptides could also be tested in combination to determine 
if they could exert synergistic inhibitory effects on cancer growth. Studies should be 
performed to determine the selectivity of the cyclic dipeptides for the cancer cells, as 
antineoplastic therapy is aimed to eliminate cancer cells and inflict minimal damage to 
normal cells.        
Cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) exhibited very limited broad antibacterial 
and antifungal activity. Both cyclic dipeptides showed limited activity against the Gram-
positive bacteria. Cyclo(Phe-4Cl-Pro) at a concentration of 1 mM, exhibited the greatest 
inhibition for  B. subtilis, with an inhibition of 18.27%. For S. aureus cyclo(D-Phe-4Cl-
Pro) at a concentration of 1 mM, displayed the greatest inhibition of 68.00% ± 2.665. 
Further studies are required to determine dose response curves to determine the effect 
of cyclo(D-Phe-4Cl-Pro) on  S. aureus. For E. coli, cyclo(D-Phe-4Cl-Pro) at a 
concentration of 1 mM displayed the greatest inhibition of 25.83% . For P. aeruginosa, 
cyclo(D-Phe-4Cl-Pro) at a concentration of 1 mM, exhibited the greatest inhibition of 
39.55%. For C. albicans, Cyclo(D-Phe-4Cl-Pro), at a concentration of 1 mM,  exhibited 
the greatest inhibition of 54.28%. The limited antimicrobial activity demonstrated by both 
the cyclic dipeptides may be as a result of their hydrophilic nature, which hinders their 
ability to cross the lipid membranes of the microorganisms. Although the cyclic 
dipeptides were limited against the selected microorganisms in the antimicrobial study, 
it is recommended that that the respective cyclic dipeptides be tested for activity against 
other microbial species, including plasmodium, viral and mycobacterium species. MICs 
should be determined for microorganisms, where statistically and clinically significant 
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inhibitory effects are observed. Studies should be performed to determine the selectivity 
of the cyclic dipeptides for the microorganisms. The cyclic dipeptides could also be 
tested in combination to determine if they could exert synergistic inhibitory effects on 
microbial growth. 
Cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) exhibited very limited effects on the 
selected haematological studies. Cyclo(Phe-4Cl-Pro) at a concentration of 50 mM, 
produced the greatest prolongation of the APTT and PT clotting times, with a clotting 
times of 27.95 seconds and 20.53 seconds, respectively. Cyclo(D-Phe-4Cl-Pro) at a 
concentration of 12.5 mM produced the highest fibrin formation of 369.8 mg/dL. 
Cyclo(D-Phe-4Cl-Pro) at a concentration of 12.5 mM, produced the lowest D-Dimer 
formation of 43.95 ng/dL. Cyclo(D-Phe-4Cl-Pro) at concentrations of 12.5 mM and 
3.125 mM, displayed the greatest ant-platelet activity with 0.2% and 0.3%, respectively. 
Cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) exhibited very limited effects on the 
selected α-amylase and α-glucosidase assays. Cyclo(D-Phe-4Cl-Pro) at a concentration 
of 1 mM exhibited the greatest inhibition of α-amylase, with an inhibition of 5.65%. 
Future studies could include conducting cellular assays. 
Some drugs have an optimum concentration range within which maximum therapeutic 
effects exists, and concentrations above or below this range can be toxic or produce no 
therapeutic benefit at all. To minimise drug degradation and loss, to prevent harmful 
side effects and to increase drug bioavailability and the fraction of the drug accumulated 
in the required region remains the top priority of pharmaceutical scientists. Various drug 
delivery and drug targeting systems are currently under investigation. Among the drug 
carriers are soluble polymers, microparticles made of insoluble or biodegradable natural 
and synthetic polymers, microcapsules, cells, cell ghosts, lipoproteins, liposomes and 
micelles. Liposomal formulations have been extensively studied to enhance the 
efficiency of the delivery of drugs via several routes of administration (Kaparissides et 
al., 2006), and have been suggested to improve cyclic dipeptides delivery 
(Cunningham, 2006; Van der Merwe, 2005; Kilian, 2010). Liposomes are a form of 
vesicles that consist either of many, few or just one phospholipid bilayers. The polar 
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character of the liposomal core enables polar drug molecules to be encapsulated 
(Kaparissides et al., 2006). The limited biological activity of cyclo(Phe-4Cl-Pro) and 
cyclo(D-Phe-4Cl-Pro) is believed to be due to their hydrophilic nature which would 
impede their movement across lipophilic cell membranes. Utilising liposomes would 
therefore aid in encapsulating the cyclic dipeptides and therefore improve their 
penetration through the cell membranes, resulting in greater bioavailability and 
subsequent increased activity.    
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APPENDIX A 
LIST OF CHEMICALS 
Acetic acid (glacial) SAARCHEM (Pty) Ltd., SA 
Acetonitrile BDH Hypersolv™ for HPLC, BDH 
Laboratory Supplies, England. 
Anisole BDH Laboratory Supplies, England 
Bovine serum albumin Highveld Biological, SA 
Thrombin Sigma Chemical Co., SA 
Chloramphenicol Sigma Chemicals Co., USA 
Chloroform SAARCHEM (Pty) Ltd., SA 
Dimethyl sulphoxide (DMSO) SAARCHEM (Pty) Ltd., SA 
Dichloromethane SAARCHEM (Pty) Ltd., SA 
Diethyl ether SAARCHEM (Pty) Ltd., SA 
1,2-Dimethoxyethane BioChemika Fluka, Germany. 
Disodium hydrogen phosphate Merck, SA. 
Ethanol Associated Chemical Enterprises (Pty) 
Ltd., SA/BDH Laboratory Supplies, 
England. 
Ethylenediaminetetra-acetic acid BDH Laboratory Supplies, England. 
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Formic acid SAARCHEM (Pty) Ltd., SA. 
Foetal Calf Serum Adcock Ingram, SA 
Glucose SAARCHEM (Pty) Ltd., SA 
Heparin sodium (5000 IU/ml) Fresenius-Kabi, SA. 
HEPES Sigma Chemicals Co., USA 
n-Hexane BDH Laboratory Supplies, England 
Hydrochloric acid Merck, England/SAARCHEM (Pty) Ltd., 
SA. 
Iodine SAARCHEM (Pty) Ltd., SA 
Magnesium chloride Associated Chemical Enterprises (Pty) SA. 
Methanol BDH Laboratory Supplies, England/ 
SAARCHEM (Pty) Ltd., SA. 
3-(4,5-dimethylthiazole-2yl)-2,5- 
Diphenyltetrazolium bromide 
Sigma Chemicals Co., USA 
Mueller hinton  
Nutrient Agar Biolab, Merck, Germany 
Potato dextrose agar  
Pottasium chloride Merck, Germany 
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RPMI 1640 growth medium Highveld Biological, SA. 
Sec-butanol SAARCHEM (Pty)., SA. 
Sodium chloride Labchem (Pty) Ltd., SA. 
Sodium hydroxide BDH Laboratory Supplies, England. 
Sodium hydrogen carbonate Associated Chemical Enterprises (Pty) 
Ltd., SA. 
Sodium hydrogen phosphate Associated Chemical Enterprises (Pty) 
Ltd., SA. 
Toluene SAARCHEM (Pty) Ltd., SA. 
Triethylamine BioChemika Fluka, Germany. 
Trifluoroacetic acid SAARCHEM (Pty) Ltd., SA. 
Tris Roche Diagnostics GmbH, Mannheim 
Water: Analytical grade, reverse osmosis Ultra Clear TWF UV TM Reverse Osmotic 
water purification system SG® 
Water: Double-distilled, de-ionised Buchi Fontavapor 285 Milli-Q™, Millipore. 
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APPENDIX B 
LIST OF SOLUTIONS 
Buffer A 
NaCl      145 mM 
KCl      5 mM 
HEPES     10 mM 
Na2HPO4     0.5 mM 
Bovine serum albumin   0.2% 
Glucose     6 mM 
Analytical grade water to   100% 
 
Mueller Hinton broth 
Mueller hinton    23 g 
Analytical grade water to    1000 ml 
 
Nutrient agar 
Nutrient agar     31 g 
Analytical grade water to   1000 ml 
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MTT (determination of cell viability) 
3-(4,5-dimethylthiazole-2yl)-2,5-  0.5% (0.1 g) 
Diphenyltetrazolium bromide 
Analytical grade water to    20 ml 
Phosphate-buffered saline (PBS) 
NaCl      8 g 
KH2PO4     0.24 g 
Na2HPO4.12H2O    1.44 g 
KCl      0.2 g 
MgCl2      0.047 g 
Analytical grade water to   1000 ml (pH 7.4) 
Tris buffer 
Tris      50 mM 
EDTA      7.4 mM 
NaCl      175 mM 
Analytical grade water to   100%  (pH 7.4) 
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APPENDIX C 
LIST OF EQUIPMENT 
Autoclave Model HA-3D, Hirayama Manufacturing 
Corp., Japan 
Centrifuge Eppendorf Centrifuge® 5804R, Germany. 
Computational modeling  Spartan ‟10 (Version 1.0.0) Wavefunction 
Inc., USA 
Culture flasks Corningware, Cambridge, USA 
Differential Scanning Calorimetry SDT Q600 V4.2E Simultaneous 
Differential Scanning Calorimeter and 
Thermogravimetric Analyser (TA 
Instruments ™, USA. 
Electronic Balance Mettler Toledo®, AB104, Switzerland. 
Eppendorfs Eppendorf AG, Germany 
Filter (sterile) Cameo 25AS acetate filter (Millipore®, 
Billerica) 
High Performance Liquid Chromatography 
packing column 
Shimadzu LC2020 (Shimadzu, Tokyo, 
Japan) 
Wavelength of maximum absorbance UV-1601 UV Visible Spectrophotometer 
(Shimadzu®, Japan). 
Humidifier Labotec® ThermoForma, SA 
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Haemocytometer Neubauer Improved Bright-line Superior, 
Germany 
Laminar Airflow (anticancer studies) Labotec, Bioflow II, fitted with a Type A/B3 
filter, Labotec, SA. 
Incubator Labcon® orbital shaker. 
Infrared Spectroscopy Shimadzu 1600 spectrophotometer 
(Shimadzu, Tokyo, Japan) 
Orbital shaker Labchem® orbital shaker 
Mass Spectrometry VG-7070E mass spectrometer (VF, 
Biotech, Altrincham, UK); VG 2035 data 
system. 
Microscale Sartorius GMBH, Gottingen. 
Micropipette (1000 µl, 200 µl) Nichiryo, Japan. 
Microtitre plates (96-well, flat bottom) Highveld Biological®, SA. 
Microtitre plates (96-well)  
Nuclear Magnetic Resonance 
Spectroscopy 
Bruker Advanced DPX 300 NMR 
Spectrometer; Bruker Win-NMR® 
Software 
pH meter 744 pH meter, Metrohm®. 
Scanning Electron Microscopy Philips® XL30 Scanning Electron 
Microscope (Philips, Eindhoven 
Netherlands); Novotech SEMprep 2®- 
sputter coater (Novotech, USA). 
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Spectrophotometer BioTek Power Wave XS 
Statistical software packages Microsoft Excel® (version 2010), 
GraphPad Prism® version 5 
Thermogravimetric Analysis SDT Q600 V2.2E Simultaneous 
Differential Scanning Calorimeter and 
Thermogravimetric Analyser (TA 
Instruments™, USA. 
Water bath Labcon®; Labdesign Engineering (Pty) 
Ltd. 
Vortex Vortex Mixer BM300; Laboratory Supplies 
(Pty) Ltd 
X-Ray Powder Diffraction Bruker Advanced Solutions XRD 
Commander Diffractometer (DiffracPlus 
Version 2.3, Germany); Bruker Advanced 
X-ray Solutions; Eva software (DiffracPlus 
Version 10.0 Rev.1). 
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ABSTRACT 
Cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro), were synthesised from their corresponding linear 
precursors using the method of Milne et al. (1992). The phenol induced cyclisation procedure resulted in 
good yields and purity of the cyclic dipeptides. Quantitative analysis and evaluation of the physiochemical 
properties of the cyclic dipeptides was achieved by using high-performance liquid chromatography, 
scanning electron microscopy, thermal analysis and X-ray powder diffraction. Structural elucidation of the 
cyclic dipeptides was done by means of infrared spectroscopy, mass spectroscopy, nuclear magnetic 
resonance spectroscopy and molecular modelling. The study anticipated that by introducing chlorine into 
the aromatic ring and consequently altering the structure of the diketopiperazines, the biological 
properties of the compounds would be enhanced (Naumann, 1999). The anticancer results obtained 
indicated that both cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) produced lower inhibitions than that 
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obtained by Graz et al. (2000), or  Brauns et al., (2004). Antimicrobial studies revealed that both 
cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro), demonstrated insignificant effects on Gram-positive and 
Gram-negative organisms, but illustrated significant effects against C.albicans. The haematological 
studies revealed that cyclo(D-Phe-4Cl-Pro) at a concentration of 12.5 mM significantly shortened the  
Activated partial thromboplastin time and prothrombin time clotting times. cyclo(D-Phe-4Cl-Pro) at a 
concentration of 12.5 mM, and 3.125 mM produced significant anti-platelet properties. The anti-diabetic 
studies demonstrated limited activity of both cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) in inhibiting the 
activity of α-glucosidase and α-amylase enzymes. 
Key words: cyclic dipeptides, chlorine, antimicrobial, anticancer, haemostasis, antidiabetic 
INTRODUCTION 
The study aimed to determine the biological activity of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
(Figures 1 and 2 respectively) with respect to their anticancer, antimicrobial, heamatological and anti-
diabetic effects.   
All living tissues consist of proteins. Proteins play a major role in regulating most signal transductions in 
eukaryotic cells and as hormones, neurotransmitters and neuromodulaters (Nelson and Cox, 2005). Even 
though the use of peptides as novel drug compounds has been limited by their poor chemical and 
physical properties, structural similarities of cyclic dipeptides, also known as diketopiperazines (DKPs), 
cyclo dipeptides, 2,5-diketopiperazines (DKPs), 2,5-dioxopiperazines (DOPs), or dipeptide anhydrides to 
peptides, the abundance of their ring structure in several natural products coupled with the simplicity of 
their chemical structure has inspired new research (Witak and Wei, 1990).  
2,5-Diketopiperazines (DKPs) are cyclic dipeptide derivatives, which show a multitude of interesting 
biological activities including efficient interactions with opioid receptors, potent cytotoxic effects and 
neuroprotective effects. Recently, they have also been associated with blockade of L-type calcium 
channels, tryptase inhibition, oxytocin receptor antagonism and plasminogen activator inhibition (Wyatt et 
al., 2005). 
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 MATERIALS AND METHODS 
Molecular modeling methods 
The energetically favourable conformation distributions of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) 
was elucidated by using Spartan‟10
® 
(Professional Version 1.10) computer molecular modeling software. 
Local minima conformations were obtained for each cyclic dipeptide by the use of molecular mechanics 
(AMBER force field) optimisation methods, due to the fact that it does not consider hydrogens explicitly 
(Wishart and Case, 2001). 
The cyclic dipeptides cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) were initially built by using the amino 
acid database included in the Spartan‟10
® 
software. A step-wise approach to energy minimisation was 
then followed. Geometrical optimisation was achieved by an initial steepest-descent run, which was run 
for at least 200 cycles or until the root mean square (RMS) of 0.1 kcal.mol
-1
Å
-1
 was achieved. Geometrical 
optimisation of the cyclic dipeptides was then followed by a PolakRibiere (Conjugated gradient) 
minimisation, which was done in repeated runs of 32560 cycles, until suitable low energy conformations 
with RMS of less than 0.001 kcal.mol
-1
Å
-1
 was obtained. The conformational search was executed in 
order to identify the three lowest energy conformations, which could then be analysed to produce 
conclusions on the conformations of the cyclic dipeptides. 
Anticancer methods 
Three human cancerous cell lines, namely HeLa (cervical carcinoma), HT-29 (colon carcinoma) and 
MCF-7 (breast carcinoma), were used in the experiments to determine the potential anticancer activity of 
cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro).  Primary cell cultures were obtained from Highveld 
Biological, South Africa (SA), and were stored in liquid nitrogen until needed. Tetrazolium salt 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was used in the microculture assay to 
measure cell growth and viability. 
All experiments were conducted in accordance with standard sterile culture techniques and all procedures 
were carried out under aseptic conditions in laminar flow units. HeLa, HT-29 and MCF-7 cell lines were 
maintained in RPMI 1640 growth medium (Sigma-Aldrich) in culture flasks (Corningware, USA) 
supplemented with 10% heat-inactivated bovine foetal calf serum (FCS) (Adcock Ingram, SA) at 37 °C 
with 5% CO2 humidification (Labtec
®
 ThermoForma
®
). The RPMI 1640 (Sigma-Aldrich) growth medium 
was replaced every 48 hours by aspirating the old medium off, washing twice with phosphate buffered 
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saline (PBS) and adding fresh medium. Cell lines were cultured until they achieved approximately 80% 
confluence and were then sub-cultured by aspirating medium from the confluent flasks, and washed twice 
with 1 ml of 0.25% trypsin in ethylenediaminetetraacetic acid (EDTA), pre-warmed to 37 °C. Cells were 
dissociated by adding 1 ml trypsin/EDTA for approximately 5 minutes at 37 °C. The cells were incubated 
in  a Labtec
®
 humidified CO2 incubator (Labcon, SA) for 10 minutes and suspended in 9 ml growth 
medium and incubated at 37°C. Portions from each sub-cultured generation were stored in liquid nitrogen 
for preservation of the cell line. 
Prior to use the cells were dissociated from the culture flasks by adding 1 ml of 0.25% trypsin (Highveld 
Biological, SA). Trypsin was deactivated by adding 10 ml of RPMI 1640 (Sigma-Aldrich) growth medium. 
The cells were gently agitated to disperse and suspend them into single-cell suspensions. The 
concentration of the cells was determined with a haemocytometer by utilizing tryphan-blue staining. The 
cell suspensions were then diluted with culture medium to obtain a standard of 6000 cells/ml. 
Each cell line was tested in separate 96-well flat-bottom microtitre plates (Costar, Corning). 200 µl of each 
cell suspension was transferred to the wells of 96-well flat-bottom microtitre, plates leaving a control set of 
4 replicate wells that contained the medium alone (blanks for MTT) assay. This was incubated at 37 °C 
with 5% CO2 humidification for 24 hours. After incubation the cells had attached to the bottom of the 
wells, which enabled the growth medium to be aspirated off. The negative controls, positive control and 
cyclic dipeptide solutions were then added to the wells in aliquots of 200 µl at appropriate final 
concentration in culture medium, such that each treatment yielded results in quadruplicate. The microtitre 
plates were subsequently incubated at 37 °C with 5% CO2 humidification for a further 48 hours. 
Incubation allowed for the drug compounds to interact with the respective cell lines. After 48 hours of 
incubation the growth medium was aspirated off and discarded from each well. 200 µl aliquots of MTT 
solution were then added to each well of the microtitre plates. The MTT containing microtitre plates were 
then incubated at 37 °C with 5% CO2 humidification for three hours to allow for the metabolic reduction of 
the MTT. This resulted in the formation of insoluble formazan precipitates. The MTT supernatant was 
aspirated off and discarded, and replaced with 200 µl aliquots of DMSO, which were required to dissolve 
the formazan precipitate. Each microtitre plate was then placed on a plate shaker for 5 minutes and the 
absorbance read immediately at 540 nm on a multiscan MS
®
 (version 4.0) Labsystem
®
 type 352 microtitre 
plate spectrophotometer (Multiscan MS
®
, England) (Huq et al., 2004; Cunningham, 2006). Experiments 
were conducted in quadruplicate. Results were reported as the percentage inhibition of growth for each 
cell culture, after 48 hours of exposure to the cyclic dipeptides or the positive control, relative to the 
appropriate negative vehicle control culture. 
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Antimicrobial methods 
The colony numbers of the bacteria and fungus were standardised by dilution and plating methods. From 
the counts the test cultures were diluted to obtain 1 x 10
6
 CFU/ml (colony forming units). The calculated 
volumes were then made up to 10 ml using Mueller-Hinton broth.   
50 µl of each test organism was pipette into a 96-well microplate and thereafter, 50 µl of either of the 
stock solutions of the two cyclic dipeptides at concentrations of 1 mM and 2 mM were added to the wells, 
which resulted in a final concentration of 0.5 mM and 1 mM in each well. 50 µl of each of the positive 
controls, were pipette into the respective cells according to the test organism cultures, giving final 
concentration of 0.25 mg/ml and 0.5 mg/ml in the respective wells. 50 µl of the negative control was 
pipette to separate wells to indicate 100% viability of the test organism growth. 
The 96-well microplates were then incubated for 24 hours at 37 °C for bacteria and 28 °C for C. albicans 
in an orbital shaker at 100 rpm. 40 µl of MTT at a concentration of 0.5 mg/ml was added to each of the 
cells after incubation. In order to obtain a zero reading time, absorbance was immediately measured on a 
microplatereader at 540 nm for bacteria and 600 nm for C. albicans. Following this the 96-well 
microplates were incubated for four hours, in an orbital shaker at 100 rpm to allow for the metabolic 
reduction of MTT. This was followed by centrifugation in an Eppendorf centrifuge at 3000 rpm for seven 
minutes to pellet the insoluble formazan product (Freimoser et al., 1999; Stevens and Olsen, 1993). The 
supernatant was aspirated from each of the wells and discarded. 90 µl of DMSO was subsequently added 
to each well to solubilise the formazan product and placed on a plate shaker for four minutes. The 
absorbance was read immediately at 540 nm for bacteria, and 600 nm for C. Albicans. The 96-well 
microplates were incubated thereafter for 4 hours at 37°C, in an orbital shaker at 100 rpm to allow for the 
metabolic reduction of MTT. This was followed by centrifugation in an Eppendorf centrifuge at 3000 rpm 
for seven minutes to pellet the insoluble formazan product (Freimoser et al., 1999; Stevens and Olsen, 
1993). The supernatant was aspirated off from each of the cells and discarded. 90 µl of DMSO was 
subsequently added to each well to solubilise the formazan product and placed on a plate shaker for 4 
minutes. The absorbance was read immediately at 540 nm for bacteria and 600 nm for C.albicans. The 
results calculated as illustrated below, were reported as percentage inhibition relative to the respective 
negative control.  
   % inhibition = 
                     
         
       
WHERE NEGGROWTH = NEGT= 24 – NEGT= 0 
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               DRUGGROWTH = DRUGT= 24 – DRUGT= 0 
AND NEGT= 24  = Absorbance at 540 nm after incubation for control  
          DRUGT = Absorbance at 540 nm for drug after incubation 
          DRUG0 = Absorbance at 540 nm for drug prior to incubation.    
 Haematological methods 
Prothrombin time (PT), activated partial thromboplastin time (APTT) and 
fibrinogen-C assays 
A CL Analyser (Instrumental Laboratory Corporation, Beckman) and an ACL-assay reagent kit 
(Instrumental Laboratory Corporation, Beckman) were used to perform the assays. The in vitro tests were 
performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines and the 
manufacturer‟s package insert guidelines. 
Activated partial thromboplastin time (APTT) 
A Synthasil kit (Beckman) was used in the assay and consist of APTT buffered reagent and a contact 
activator. The reagent contains synthetic phospholipids, which are required for optimal platelet-like activity 
and highly defined non-settling colloidal silica. 
The APTT assay was conducted by adding 100 µl of the APTT reagent to tubes containing 100 µl of 
plasma and either the (C), cyclo(Phe-4Cl-Pro) (1: 3) and cyclo(D-Phe-4Cl-Pro) (1: 3) or heparin (0.1 U/ml, 
PC). The mixtures were incubated at 37 °C for 180 seconds on the CL Analyser, after which 100 µl of 
0.025 M CaCl2 solution was added to initiate the activation of the intrinsic pathway. The clotting time was 
measured, and the anticoagulatory activity of test samples evaluated relative to the untreated control (C). 
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 Prothrombin time assay 
A RecombiPlastin kit (Beckman) was used in the assay. The thromboplastin reagent (phospholip/tissue 
factor preparation), included in the Recomboplastin kit, is a liposomal preparation which constitutes of 
recombinant human tissue factor in a phospholipid mixture with calcium chloride, buffer and a 
preservative. 
Recomboplastin (200 µl) was incubated at 37 °C for 180 seconds on the CL Analyser (IVD, Beckman 
Coultier), while a premix of 100 µl of plasma was incubated for 180 seconds at 37 °C with either the 
untreated control (C), cyclo(Phe-4Cl-Pro) (1: 4), cyclo(D-Phe-4Cl-Pro) (1: 4) or heparin (0.1 U/ml, positive 
control {PC}) (Bodene). To evaluate the PT, 150 µl of the plasma premix solutions were added to the 
recomboplastin (200 µl) and the clotting time was measured.  
Fibrinogen-C assay 
A fibrinogen-C kit (Beckman) was used in evaluating the effect of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-
4Cl-Pro) on conversion of fibrinogen to fibrin by comparing the protein levels of the treated plasma with 
those of the untreated plasma controls. A ten times dilution of diluted plasma (200 µl) was incubated with 
50 µl of either the (C), cyclo(Phe-4Cl-Pro) (1: 4), cyclo(D-Phe-4Cl-Pro) (1: 4) or heparin (0.1 U/ml, PC) at 
37 °C on the CL Analyser for 180 seconds. After the incubation period, a thrombin (Beckman) solution (35 
U/ml); 100µl) was added and the effect of the conversion of fibrinogen to fibrin was evaluated by 
comparing the fibrin levels of the treated plasma with that of the untreated plasma control (C). 
D-Dimer assay 
A D-Dimer kit was used in the assay. The kit consisted of a D-Dimer latex reagent and reaction buffer 
(Beckman). The latex reagent is a suspension of uniform sized polystyrene latex particles coated with a 
monoclonal antibody that is highly specific for the D-Dimer domain. When plama containing D-Dimer is 
mixed with the latex reagent and reaction buffer the coated latex particles agglutinate. The degree of 
agglutination is directly proportional to the concentration of D-Dimer in the solution. The buffer (150 µl) 
was added to 42 µl of the plasma containing 8 µl of either the (C),cyclo(Phe-4Cl-Pro) (1: 3) or cyclo(D-
Phe-4Cl-Pro) (1: 3). The mixture was then incubated at 37 °C in the CL Analyser for 15 minutes. After the 
incubation period the latex D-Dimer was subsequently added, the effect of the cyclic dipeptides on the 
rate of fibrinolysis via D-Dimer formation was evaluated by comparing the protein levels of the treated 
297 
 
plasma with that of the untreated plasma control. Heparin (0.1 U/ml) was used as the positive control for 
this assay.   
Platelet aggregation/adhesion studies 
Human blood plasma was used to screen cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) for activity 
against the various haematological processes. The human ethics committee of the Nelson Mandela 
Metropolitan University (NMMU) approved the use of human blood samples in the haematological studies 
(reference number) (HO6SB-003) (September 2006). Human blood used in the platelet aggregation 
assay was drawn at the NMMU clinic on the day of use. 
A method adapted from Michelson et al., (2000), was used for the experiment. A platelet rich plasma 
(PRP) sample containing a platelet count of 3 x 10
7
 platelets/ml was used for all cytometry experiments. A 
volume of 40 µl of PRP was placed into tubes containing 10 µl of a 200 µg/ml saturated concentration of 
fluorescein isothiocyanate (FITC)-PAC1 (BD Biosciences). The binding of fibrinogen to the gpIIb/IIIa 
receptor is required for platelet aggregation. PAC-1 binds only to activated platelets and appears to be 
specific for this recognition site within gpIIb/IIIa. PAC-1 inhibits fibrinogen-mediated platelet aggregation 
(Michelson et al., 2000). 
To inhibit fibrin polymerization, 2 µl of 2.5 mmol/L (final concentration) of peptide glycol-L-prolyl-L-arginyl-
L-proline (GPRP) (Sigma) was added. For a positive control (PC), 100 µl of thrombin stock (50 U/ml) was 
added to give final concentration of 10 U/ml, the same volume of buffer was added for an untreated 
control (C), cyclo(Phe-4Cl-Pro) (1: 3) or cyclo(D-Phe-4Cl-Pro) (1: 3) were added. Unstained cells were 
used to determine background staining. The tubes were then incubated at room temperature for fifteen 
minutes. Following the incubation period the platelets were fixed with 2: 1 ratio of 1% formaldehyde for 
thirty minutes at room temperature. A threefold volume of Tyrode‟s buffer was added and the cells were 
immediately analysed with a Beckman flow cytometer (Coultier, Cytomics FC 500). All parameters were 
collected in list mode files and then analysed.  
Anti-diabetic studies 
The anti-diabetic effects of the cyclic dipeptides were determined by conducting α-glucosidase and α-
amylase assays. 
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α-glucosidase assay 
 Methods employed by Sancheti et al. (2009) were adapted to determine the effects of cyclo(Phe-4Cl-
Pro) and cyclo(D-Phe-4Cl-Pro) on the activity of the α-glucosidase enzyme. 
Mixtures consisting of 50 µl of the 0.1 M phosphate buffer, 25 µl of the 0.5 mM 4-nitrophenyl-α-D-
glucopyranoside solution, 10 µl of either the acarbose solution, cyclo(Phe-4Cl-Pro) solution or cyclo(D-
Phe-4Cl-Pro) solution were incubated at 37 °C for 30 minutes. After incubation 100 µl of 0.2 M sodium 
carbonate solution was added to terminate the enzymatic reaction. The amount of p-nitrophenol released 
in the reaction was determined spectrophotometrically at 410 nm using a microplate reader (BioTek 
Power Wave XS). The amount of p-nitrophenol released was proportional to the enzymatic hydrolysis of 
the substrate. Experiments were conducted in triplicate. 
α-Glucosidase inhibition was calculated as a percentage of the control using the formula: 
Percentage inhibition = 
     
  
  x 100 
Where Ac is the change in absorbance of the blank control and As is the change in absorbance that 
occurs between the time the substrate is added to the mixture and 30 minutes after incubation. 
α-Amylase assay 
Methods developed by Fuwa (1954) and modified by Xiao et al. (2006) were adapted to determine the 
effects of cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on α-amylase activity. The microplate-based 
starch-iodine assay was utilised. This assay is based on the development of color that results when 
iodine binds to starch polymers. The amount of starch degraded determines the activity of α-amylase. 
40 µl of starch (Sigma) solution and 40 µl of the α-amylase enzyme (in 0.1 M phosphate buffer at pH 7.0) 
were pipetted into microplate wells and incubated at 50 °C for 30 minutes. After incubation 20 µl of 1 M 
HCl was added to terminate the enzymatic reaction. 100 µl of iodine reagent (5 mM iodine and 5 mM 
potassium iodide) was then added. When color development was evident, 150 µl of the iodine-treated 
sample was transferred into a transparent 96-well flat-bottomed microplate and the absorbance was read 
at 580 nm, using a microplate reader (BioTek Power Wave XS). The experiment was conducted in 
triplicate.    
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α-Amylase activity was determined as relative activity according to the following formula: 
Dextrinising activity = 
      
  
 x 
   
  
 
Where D is the absorbance of the enzyme sample and D0 is the absorbance of the amylase control 
without the addition of enzyme. 
Statistical analysis 
Al the results obtained were obtained as triplicate values and represented as a mean ± standard deviation 
(SD). Data were represented graphically with the aid of statistical software packages, Microsoft Excel
®
 
(Version 2007) and GraphPad Prism
® 
(version 5). In order to determine whether the cyclic dipeptides 
under investigation caused statistically significant effects relative to the controls, Student‟s t-tests were 
performed on each concentration of the cyclic dipeptides. Calculated P-values of less than 0.05 were 
defined as statistical significant. 
RESULTS AND DISCUSSION 
Molecular modeling 
The Boltzman n distribution obtained from the molecular calculations of the DKPs in the gas phase, water 
and DMSO indicated conformer one as the most stable conformer for each of the DKPs (Figure 3 and 4). 
The molecular calculations for each DKP in the gas phase, water and DMSO are illustrated in Tables 1, 2, 
3, 4, 5 and 6. These conformers have the lowest relative energies and are most likely to found under 
standard conditions. The different conformations of the water phase are not illustrated, due to the fact 
energies and conformations in the water phase were almost similar to that of the gas phase. DMSO was 
used as the solvent to dissolve the cyclic dipeptides for most of the biological studies and for this reason 
necessitates the illustration of the different conformations and molecular calculations. 
Anticancer studies 
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cyclo(Phe-4Cl-Pro)   
The results obtained from individual t-tests which were performed by comparing the percentage inhibition 
of growth by Melphalan and the DKPs relative to 100% cell line viability. The percentage inhibition of the 
HeLa, MCF-7 and HT-29 cancer cell lines caused by cyclo(Phe-4Cl-Pro) and Melphalan, with and without 
0.05% PEG 300 are illustrated in figures 5 and 6 respectively. The conjugation of 0.05% PEG 300 with 
Melphalan enhanced the inhibition of growth against all cell lines with significant percent inhibitions of 
86.88% ± 5.869 (P< 0.0001) against the HeLa, 82.39% ± 2.058 (P< 0.0001) against MCF-7 and 71.30% ± 
1.035 (P = 0.0006) against HT-29. 
Cyclo(Phe-4Cl-Pro) at a screening concentration of 2 mM showed significant percentage inhibitions when 
compared with the screening concentrations of 1 mM. Cyclo(Phe-4Cl-Pro) showed the highest 
percentage inhibition against MCF-7 with a percentage inhibition of 71.62% ± 0.1252 (P < 0.0001). 
Percentage inhibitions of 55.28% ± 0.4332 (P<0.0001) and 56.65% ± 0.3647 (P = 0.0006) were observed 
for HeLa and HT-29 cell lines at a screening concentration of 2 mM. It was also apparent that at a 
screening concentration of 1 mM, cyclo(Phe-4Cl-Pro) showed no significant effect on the HeLa cell line. 
The lower concentrations of cyclo(Phe-4Cl-Pro) (1 mM) showed percentage growth inhibitions of   31.66% 
± 1.127 (P<0.0001) and 35.73% ± 2.645 (P< 0.0001) against the MCF-7 and HT-29 cell lines respectively. 
The percentage growth inhibitions of HeLa, MCF-7 and HT-29 cell lines by Melphalan and cyclo(Phe-4Cl-
Pro), without 0.05% PEG 300 (Figure), yielded interesting results. Melphalan at a screening concentration 
of 0.5 mM caused greater inhibition of the MCF-7 (86.06% ± 1.632) cell line compared to HeLa (14.47% ± 
6.606) and HT-29 (44.45% ± 3.370) cell lines. 
Cyclo(Phe-4Cl-Pro) at a screening concentration of 2 mM, without 0.05% PEG 300,  inhibited the growth 
of HeLa and HT-29, but caused marginal stimulation of MCF-7 cell line. With percentage inhibitions of 
34.61 ± 1.4519 (P= 0.0402) against the HeLa, 18.56% ± 1.972 (P< 0.0001) against MCF-7 and 25.66% ± 
1.525 (P= 0.0007) against HT-29 cell line. At a screening concentration of 1 mM, cyclo(Phe-4Cl-Pro) 
caused percentage inhibitions of 26.29% ± 1.4287 (P <0.0001), -5.499% ± 0.5015 (P< 0.0001) and 
17.83% ± 0.992 (P = 0.0007) against HeLa, MCF-7 and HT-29, respectively. 
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Cyclo(D-Phe-4Cl-Pro) 
The percentage growth inhibitions caused by Melphalan 0.5 mM and cyclo(D-Phe-4Cl-Pro) at screening 
concentrations of 2 mM, and 1 mM, conjugated with 0.05% PEG 300 are illustrated in Figure 7. 
Melphalan at a screening concentration of 0.5 mM caused inhibitions of 86.88% ± 5.869 (P< 0.0001) 
against the HeLa, 82.39% ± 2.058 (P< 0.0001) against MCF-7 and 71.30% ± 1.035 (P = 0.0006) against 
HT-29. 
Cyclo(D-Phe-4Cl-Pro) inhibited the growth of  the MCF-7 cell line by 50.84% ± 0.5489 (P < 0.0001) at a 
screening concentration of 2 mM compared with HeLa (32.13% ± 19.779) (P< 0.0001) and HT-29 
(47.63% ± 1.583) (P< 0.0001). Cyclo(D-Phe-4Cl-Pro) at the lower screening concentration of 1 mM 
showed inhibitions of 11.75% ± 2.697 (P< 0.0001) for HeLa, 29.79% ± 0.9773 (P<0.0001) for MCF-7 and 
32.54% ± 3.261 (P< 0.0001) for HT-29 cell lines. 
The percentage growth inhibitions of HeLa, MCF-7 and HT-29 cell lines by Melphalan and cyclo(Phe-4Cl-
Pro), without 0.05% PEG 300 (Figure 8). Melphalan (0.5 mM) inhibited the growth of HeLa cell line by 
14.47% ± 6.606 (P< 0.0001), the MCF-7 cell line by 86.06% ± 1.632 (P< 0.0001) and the HT-29 cell line 
by 44.45% ± 3.370 (P< 0.0001). At a screening concentration of 2 mM, cyclo(D-Phe-4Cl-Pro) caused 
greater percentage growth inhibitions of the HeLa, MCF-7 and HT-29 cell lines compared with the lower 
screening concentration of 1 mM. Cyclo(D-Phe-4Cl-Pro) at screening concentrations of 2 mM inhibited 
the growth of  the HeLa cell line by  45.86% ± 7.706 (P< 0.0001), the MCF-7 cell line by 21.98091% ± 
4.750 (P = 0.0340) and HT-29 by 24.60% ± 2.4200 (P= 0.0002). At the lower screening concentration of 1 
mM, cyclo(D-Phe-4Cl-Pro) produced percentage growth inhibitions of 19.77% ± 2.382 (P< 0.0001), 
32.13% ± 19.779 (P < 0.0001) and 21.61%± 2.3300 (P < 0.0001) for HeLa, MCF-7 and HT-29 
respectively. 
Antimicrobial studies 
Gram-negative bacteria 
Pseudomonas aeruginosa 
The percentage growth inhibitions caused by amoxicillin, chloramphenicol, cyclo(D-Phe-4Cl-Pro) and 
cyclo(Phe-4Cl-Pro) against Pseudomonas aeruginosa are illustrated in Figure 9 and summarised in Table 
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8. Chloramphenicol at concentrations of 0.5 mg/ml and 0.25 mg/ml inhibited the growth of Pseudomonas 
aeruginosa by 68.91% ± 5.690 and 54.11% ± 1.775 respectively, when compared with amoxicillin. 
Amoxicillin at screening concentrations of 1 mg/ml and 0.5 mg/ml showed percentage inhibitions of  
90.34% ± 2.010 and  76.23% ± 1.675 respectively. At final screening concentrations of 1 mM and 0.5 mM,  
cyclo(D-Phe-4Cl-Pro) showed percentage inhibitions of  39.55% ± 3.000 (P = 0.0143) and 15.61% ± 
3.275 (P = 0.2619) respectively. Cyclo(Phe-4Cl-Pro) at final screening concentrations of 1 mM and 0.5 
mM, caused percentage inhibitions of  21.50% ± 1.835 (P =  0.0490) and  15.99% ± 1.000 (P = 0.1061) 
respectively. 
Escherichia coli 
The percentage growth inhibitions caused by amoxicillin, chloramphenicol, cyclo(D-Phe-4Cl-Pro) and 
cyclo(Phe-4Cl-Pro) against Escherichia coli are illustrated in Figure 10 and summarised in Table 9. 
Chloramphenicol at concentrations of 0.5 mg/ml and 0.25 mg/ml inhibited the growth of Escherichia coli 
by 78.50% ± 6.165 and 69.66% ± 0.4350 respectively, when compared with amoxicillin. Amoxicillin at 
screening concentrations of 1 mg/ml and 0.5 mg/ml showed percentage inhibitions of 73.25% ± 4.350   
and  76.23% ±  68.89% ± 1.335 respectively. At final screening concentrations of 1 mM and 0.5 mM,  
cyclo(D-Phe-4Cl-Pro) showed percentage inhibitions of  25.83% ± 0.500 (P = 0.7724) and 11.50% ± 
0.8350 (P = 0.2771) respectively. Cyclo(Phe-4Cl-Pro) at final screening concentrations of 1 mM and 0.5 
mM, caused percentage inhibitions of  18.66% ± 1.000  (P = 0.6239 ) and  15.66% ± 0.6700 (P = 0.4400) 
respectively. 
Gram-positive bacteria 
Bacillus subtilis 
The percentage growth inhibitions caused by amoxicillin, chloramphenicol, cyclo(D-Phe-4Cl-Pro) and 
cyclo(Phe-4Cl-Pro) against Bacillus subtilis are illustrated in Figure 11 and summarised in Table 10. 
Chloramphenicol at concentrations of 0.5 mg/ml and 0.25 mg/ml inhibited the growth of Bacillus subtilis 
by 83.61% ± 4.410 and 68.28% ± 2.945 respectively, when compared with amoxicillin. Amoxicillin at 
screening concentrations of 1 mg/ml and 0.5 mg/ml showed percentage inhibitions of  50.61% ± 4.410  
and  76.23% ± 57.55% ± 2.350 respectively. At final screening concentrations of 1 mM and 0.5 mM,  
cyclo(D-Phe-4Cl-Pro) showed percentage inhibitions of 17.83% ± 5.500 (P = 0.8570) and 11.50% ± 
15.00% ± 1.335 (P = 0.7907) respectively. Cyclo(Phe-4Cl-Pro) at final screening concentrations of 1 mM 
303 
 
and 0.5 mM, caused percentage inhibitions of  18.27% ± 2.390   (P = 0.7438) and  12.33% ± 2.000  (P 
=0.4900 ) respectively. 
Staphylococcus aureus  
The percentage growth inhibitions caused by amoxicillin, chloramphenicol, cyclo(D-Phe-4Cl-Pro) and 
cyclo(Phe-4Cl-Pro) against Staphylococcus aureus are illustrated in Figure 12 and summarised in Table 
11. Chloramphenicol at concentrations of 0.5 mg/ml and 0.25 mg/ml inhibited the growth of 
Staphylococcus aureus by 72.60% ± 6.600 and 69.61% ± 1.610 respectively, when compared with 
amoxicillin. Amoxicillin at screening concentrations of 1 mg/ml and 0.5 mg/ml showed percentage 
inhibitions of  26.40% ± 1.5.600   and 58.60% ± 1.300  respectively. At final screening concentrations of 1 
mM and 0.5 mM,  cyclo(D-Phe-4Cl-Pro) showed percentage inhibitions of 68.00% ± 2.665 (P =0.0106 ) 
and 11.50% ± 22.17 ± 1.165 (P = 0.05362) respectively. Cyclo(Phe-4Cl-Pro) at final screening 
concentrations of 1 mM and 0.5 mM, caused percentage inhibitions of  12.22% ± 2.110 (P =0.0062 ) and  
11.33% ± 9.000 (P =0.0340) respectively. 
Fungus 
Candida albicans 
The percentage growth inhibitions caused by amoxicillin, chloramphenicol, cyclo(D-Phe-4Cl-Pro) and 
cyclo(Phe-4Cl-Pro) against Candida albicans are illustrated in Figure 13 and summarised in Table 12. 
Chloramphenicol at concentrations of 0.5 mg/ml and 0.25 mg/ml inhibited the growth of Candida albicans 
by 57.61% ± 2.390 and 82.68% ± 5.345 respectively, when compared with amoxicillin. Amoxicillin at 
screening concentrations of 1 mg/ml and 0.5 mg/ml showed percentage inhibitions of 91.19% ± 1.165  
and  63.83% ± 2.500  respectively. At final screening concentrations of 1 mM and 0.5 mM,  cyclo(D-Phe-
4Cl-Pro) showed percentage inhibitions of 54.28% ± 5.055 (P = 0.0128) and 31.83% ± 9.500 (P = 0.1380) 
respectively. Cyclo(Phe-4Cl-Pro) at final screening concentrations of 1 mM and 0.5 mM, caused 
percentage inhibitions of 47.84% ± 7.820 (P = 0.0387) and 46.18% ± 3.845 (P = 0.0114) respectively. 
Haematological studies 
Activated partial thromboplastin time assay (APTT) 
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The effects of heparin (positive control), cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on the intrinsic 
pathway are illustrated in Figure 15 and summarised in Table 13. APTT represents the time in seconds it 
takes for plasma to clot after the addition of an intrinsic pathway activator and calcium. The normal APTT 
range in human plasma is 24 to 39 seconds. Heparin at a screening concentration of 0.1 U/ml 
significantly prolonged the clotting time to 106.0 ± 1.350 seconds. Cyclo(Phe-4Cl-Pro) at a screening 
concentration of 50 mM produced a clotting time of 27.95 ± 0.4000 seconds (P = 0.0003). The screening 
concentrations of 25 mM and 12.5 mM, however produced a shorter clotting time of 20.28 ± 1.055 
seconds (P = 0.0004) and 10.78 ± 0.4450 seconds (P = 0.0002), respectively.Cyclo(D-Phe-4Cl-Pro) at 
screening concentrations of 50 mM, 25 mM and 12.5mM, produced clotting times of 26.15 ± 0.7050 
seconds (P = 0.0004), 14.61 ± 0.6150 seconds (P = 0.0003) and 8.110 ± 0.5500 seconds (P = 0.0002). 
Prothrombin time assay (PT) 
Prothrombin time represents the time in seconds it takes for plasma to clot after the addition of calcium 
and thromboplastin. The normal PT range is 11 to 13.5 seconds. The effects of heparin, cyclo(Phe-4Cl-
Pro) and cyclo(D-Phe-4Cl-Pro) on PT clotting time are illustrated in Figure 14 and summarised in Table 
14. Heparin at a screening concentration of 0.1 U/ml, significantly prolonged PT clotting time to 88.80 ± 
1.805 seconds. Cyclo(Phe-4Cl-Pro) at screening concentrations of 50 mM, 25 mM produced longer PT 
clotting times of 20.53 ± 0.9250 seconds (P = 0.2374), 17.13 ± 0.1700 seconds (P = 0.0055). Cyclo(Phe-
4Cl-Pro) at a screening concentration of 12.5 mM, however produced a PT clotting time of 14.41 ± 
0.810014 seconds (P = 0.0125). Cyclo(D-Phe-4Cl-Pro) at screening concentrations of 50 mM, 25 mM and 
12.5 mM, produced PT clotting times of 17.66 ± 0.6700 seconds (P = 0.0266), 11.85 ± 0.8550 seconds (P 
= 0.0078) and 10.75 ± 0.4500 seconds (P = 0.0024), respectively. 
Fibrinogen-C assay (Fib-C) 
The activity of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on fibrin formation is illustrated in 
Figure 15 and summarised in Table 15. The conversion of fibrinogen to fibrin elicit a series of reactions 
that cross-link adjacent fibrin monomers which then stabilises the formed clot (Dipiro et al., 2011). The 
addition of 100 µl of thrombin to the negative control (untreated plasma) resulted in the formation of 
470.29 ± 0.510 mg/dL fibrin. Heparin (positive control) at a screening concentration of 0.1 U/ml decreased 
the formation of fibrin to 73.66 ± 3.670 mg/dL (P = 0.0144). Cyclo(Phe-4Cl-Pro) formed 116.7 ± 3.725 
mg/dL (P = 0.0144) at 50mM, 273.2 ± 3.830 mg/dL (P = 0.0007) at 25 mM, 292.5 ± 2.500 mg/dL (P = 
0.0004) at 12.5 mM. Cyclo(D-Phe-4Cl-Pro) formed 172.0 ± 2.000 mg/dL (P = 0.0018) at 50 mM, 313.4 ± 
2.545 mg /dL (P = 0.0003) at 25 mM and 369.8 ± 0.8350 mg/dL (P = 0.0002) at 12.5 mM. 
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D-Dimer assay 
The effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on D-Dimer levels are illustrated in 
Figure 16 and summarised in Table 16. Heparin at a screening concentration of 0.1 U/ml significantly 
decreased the levels of D-Dimer (36.99 ± 1.000 ng/ml). Cyclo(Phe-4Cl-Pro) at screening concentrations 
of 50 mM, 25 mM and 12.5 mM, produced results of 69.39 ± 1.055 ng/ml (P = 0.0020), 65.43 ± 2.875 
ng/ml (P = 0.0113) and 53.10 ± 2.105 ng/ml (P = 0.0203). Cyclo(D-Phe-4Cl-Pro) at screening 
concentrations of 50 mM, 25 mM and 12.5 mM, produced results of 53.91 ± 0.3100 ng/ml (P = 0.0038), 
49.16 ± 0.1700 ng/ml (P = 0.0069) and 43.95 ± 0.9550 ng/ml (P = 0.0373), respectively. D-Dimer levels 
should under normal physiological conditions not be detectable in blood plasma, except when the 
coagulation cascade has been activated. High D-Dimer levels in plasma indicate elevated levels of fibrin 
formation and reflect a state of hypercoagulability (Moresco et al., 2006). The cyclic dipeptides caused 
elevation of D-Dimer formation. 
Platelet aggregation studies 
Figures 17 to 26 illustrate the flow-cytometry diagrams and cell density plots for the untreated control 
(PRP), treated control (PRP with 50U/ml thrombin), cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro), at 
screening concentrations of 50 mM, 25 mM and 12.5 mM and 3.125 mM. In order to obtain the 
percentage of cells that stained positive, a region gate was drawn around a population of intact cells to 
exclude cell debris and clumped cells. The platelet particles that exhibited aggregation were excluded by 
the defined gate. 
For the untreated control 1.3% of the cells exhibited aggregation. The positive control (thrombin 50 U/ml) 
indicated an 7.6% increase in aggregation. Cyclo(Phe-4Cl-Pro) increased the aggregation to 95.2%, 
94.4%, 92.6 and 90.5% at screening concentrations of 50 mM, 25 mM, 12.5 mM and 3.125 mM 
respectively. Cyclo(D-Phe-4Cl-Pro) produced percentage aggregations of 93.5%, 32.4%, 0.2% and 0.3% 
at screening concentrations of 50 mM, 25 mM, 12.5 mM and 3.125 mM respectively. 
Anti-diabetes assay 
α-Glucosidase assay 
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 The effects of acarbose (positive control) at a screening concentration of 50 mM, 1 mM of cyclo(Phe-4Cl-
Pro) and 1 mM of cyclo(D-Phe-4Cl-Pro) on the activity of α-glucosidase are shown in Figure 27 
Acarbose at a screening concentration of 50 mM inhibited the activity of the α-glucosidase enzyme by 
51.11% ± 4.498 (P < 0.0001) while cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) inhibited the activity by -
4.352% ± 1.477 (P < 0.0001) and -6.953% ± 1.740 (P < 0.0001), respectively. These negative values 
obtained, indicate a stimulation of the α-glucosidase enzyme and thus an increase in the conversion of 
carbohydrates to monosaccharides and elevated blood glucose levels. 
α-Amylase activity 
The effects of acarbose, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on the activity of α-amylase are 
shown in Figure 28 
Acarbose inhibited the activity of the α-amylase enzyme by 55.51% ± 2.786 (P < 0.0001) at a screening 
concentration of 50 mM. Cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) inhibited the enzyme‟s activity by 
5.654% ± 0.02507 (P < 0.0001) and 5.530% ± 0.05743 (P < 0.0001), respectively. 
Conclusions 
The anticancer results obtained indicated that the percentage growth inhibitions produced by both cyclic 
dipeptides were lower than those proposed by Graz et al. (2000) for proline-containing cyclic dipeptides, 
where a greater than 50% inhibition was observed for cyclo(Phe-Pro), and for (Brauns, 2004) on the 
effects of cyclo(Phe-Pro) on HT-29, HeLa and MCF-7 cell lines showed that cyclo(Phe-Pro) exhibited 
more than 50% growth inhibition (p < 0.01) in the three cell lines. Cyclo(Phe-Pro) exhibited significant 
growth inhibition at concentrations of 5 mM (p < 0.01) and 10 mM (p < 0.01) in all three cell lines. The IC50 
values for cyclo(Phe-Pro) were 5.24 ± 1.25 mM in HT-29, 3.85 ± 1.26 mM in HeLa and 5.07 ± 1.32 mM in 
MCF-7 cells. Antimicrobial effects revealed that both cyclic dipeptides showed marginal effects on Gram-
positive and Gram-negative organisms, but showed significant effects against C.albicans. The 
Haematological studies revealed that cyclo(D-Phe-4Cl-Pro) at screening concentrations of 12.5 mM and 
3.125 mM showed significant anti-platelet activities. 
ACKNOWLEDGEMENTS 
307 
 
I extend my sincere appreciation and grateful thanks to the following people for their continuous 
invaluable support, guidance, time and dedication to this research undertaken: 
Prof PJ Milne, for his constant encouragement, knowledge and guidance. Dr G. Dealtry, to whom I owe 
much gratitude for all her assistance, time and knowledge. Prof C Frost for all her assistance with the 
blood work. Prof C McCleland for his assistance in the molecular modeling studies. Prof M van de Venter, 
for her assistance in the cell and isotope labs. Ms A Van Jaarsveld for all her assistance in the laboratory. 
REFERENCES 
Cunningham TL. 2006. The Medicinal Chemistry of the Selected Glycine-containing Cyclic Dipeptides: 
Cyclo(Gly-Thr) and Cyclo(Gly-Ser). MSc Dissertation. Nelson Mandela Metropolitan University   
Freimoser FM, Jacob CA, Aebi M, Tuor U. 1999. The MTT [3-(4,5 dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] Assay is a Fast and Reliable Method for Colorimetric Determination of 
Fungal Cell Densities. Applied and Environmental Microbiology; 65 (8):3727-3729  
Fuwa H. 1954. A New Method of Microdetermination of Amylase Activity by the Use of Amylase as the 
Substrate. Journal of Biochemistry; 41: 583-603 
Graz CJM, Grant GD, Brauns SC, Hunt A, Jamie H, Milne PJ. 2000. Cyclic Dipeptides in the Induction of 
Maturation for Cancer Therapy. Journal of Pharmaceutical Pharmacology; (52): 75-82 
Huq F, Daghriri H, Yu JQ, Tayyem H, Beale P, Zhang M. 2004. Synthesis, Characterization, Activities, 
Cell Uptake and DNA Binding of [{trans-PtCL(NH3)2} {µ-(H2N(CH2)6NH2)} {trans-PdCL(NH3)2] (NO3)CL. 
European Journal of Medicinal Chemistry; 39: 947-958 
Michelson AD, Barnard MR, Kreuger LA, Frelinger AL, Furman MI. 2000. Evaluation of Platelet Function 
By Flow Cytometry. Methods; (21): 259-270 
Milne PJ, Olivier DW, Roos HM. 1992. Cyclodipeptides: Structure and Conformation of Cyclo(Tyrosyl-
Prolyl). Journal of Crystallographic and Spectroscopic Research, 22(6): 224-230  
308 
 
Naumann K. 1999. Influence of Chlorine Substituents on Biological Activity of Chemicals. Journal Fϋr 
Praktische Chemie; 341 (5): 417-435 
Nelson DL, Cox MM. 2005. Principles of Biochemistry, 4
th
 edition. New York: Freeman and Company; 75-
106 
Sancheti S, Seo S. 2009. Chaenomeles Sinesis: A Potent α-and β-Glucosidase Inhibitor. American 
Journal of Pharmacology and Toxicology; 4 (1): 1-8 
Stevens MG, Olsen SC. 1993. Comparative Analysis of Using MTT and XTT in Colorimetric Assays for 
Quantitative Bovine Neutrophil Bactericidal Activity. Journal of Immunological Methods; 157: 225-231 
Wishart DS, Case DA. 2001. Use of Chemical Shifts in Macromolecular Structure Determination. Methods 
in Enzymology; 338: 3-34 
Witak DT, Wei Y. 1990. Dioxopiperazines: Chemistry and Biology. Progress in Drug Research; 35: 249 
Wyatt PG, Allen MJ, Borthwick AD, Davies DE, Exall AM, Hatley RJD, Irving WR, Livermore DG, Miller 
ND, Nerozzi F, Sollis SL and Szardenings AK. 2005. 2,5-Diketopiperazines as Potent and Selective 
Oxytocin Antagonists 1: Identification, Stereochemistry and Initial SAR. Bioorganic Medicinal Chemistry 
Letters 15 (2005) 2579–2582  
Xiao Z, Storms R, Tsang A. 2006. A Quantitative Starch-iodine Method for Measuring alpha-Amylase and 
Glucosidase activities. Analytical Biochemistry; 351 (1): 146-148 
 
LIST OF ABBREVIATIONS 
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APTT   Activated partial thromboplastin time 
CACl2            calcium chloride 
CFU  Colony forming units 
CLSI   Clinical and Laboratory Standards Institute 
CO2  Carbon Dioxide 
DKPs    Diketopiperazines 
DMSO Dimethyl sulphoxide 
EDTA  Ethylenediaminetetraacetic acid  
FITC  Fluorescein isothiocyanate 
GPRP  Peptide glycol-L-prolyl-L-arginyl-L-proline  
M  Molar concentration 
mg  milligrams 
ml  milliliter 
mM  millimolar 
MTT     3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
PRP   Platelet rich plasma 
PT  Prothrombin time 
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Rel. E  Relative energy  
U/ml  Units per Mililitre 
µl  Microlitre 
VWF  Von Willebrand factor 
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Figure 2 Structure of Cyclo(D-Phe-4Cl-Pro) 
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Figure 3 Conformation 1 of cyclo(Phe-4Cl-Pro) in dimethyl sulphoxide (DMSO) 
 
 
 
Figure 4 Conformation 1 of cyclo(D-Phe-4Cl-Pro) in dimethyl sulphoxide (DMSO) 
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Figure 5 Percentage Inhibition of growth of HeLa, MCF-7 and HT-29 cell lines caused by melphalan (0.5 
mM) and cyclo(Phe-4Cl-Pro) at screening concentrations of 1 mM and 2 mM, all conjugated with 0.05% 
PEG 300 
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Figure 6 Percentage Inhibition of growth of HeLa, MCF-7 and HT-29 cell lines caused by melphalan (0.5 
mM) and cyclo(Phe-4Cl-Pro) at screening concentrations of 1 mM and 2 mM, all conjugated without 
0.05% PEG 300 
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Figure 7 Percentage Inhibition of growth of HeLa, MCF-7 and HT-29 cell lines caused by melphalan (0.5 
mM) and cyclo(D-Phe-4Cl-Pro) at screening concentrations of 1 mM and 2 mM, all conjugated with 0.05% 
PEG 300 
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Figure 8 Percentage Inhibition of growth of HeLa, MCF-7 and HT-29 cell lines caused by melphalan (0.5 
mM) and cyclo(D-Phe-4Cl-Pro) at screening concentrations of 1 mM and 2 mM, all conjugated without 
0.05% PEG 300 
 
 
 
 
 
 
 
316 
 
 
%
 In
hi
bi
tio
n
Am
ox
 1
Am
ox
 2
Ch
lo
ra
 1
Ch
lo
ra
 2
DK
P 
1 
D
DK
P 
2 
D
DK
P 
1 
L
DK
P 
1 
L
0
20
40
60
80
100
 Amoxicillin 1 mg/ml
Amoxicillin 0.5 mg/ml
Chloramphenicol 0.25 mg/ml
Cholramphenicol 0.5 mg/ml
Cyclo(D-Phe-4Cl-Pro) 0.5 mM
Cyclo(D-Phe-4Cl-Pro) 1 mM
Cyclo(Phe-4Cl-Pro) 0.5 mM
Cyclo(Phe-4Cl-Pro) 1 mM
 
Figure 9 Percentage inhibition of P. aeruginosa caused by amoxicillin, chloramphenicol, cyclo(Phe-4Cl-
Pro) and cyclo(D-Phe-4Cl-Pro) 
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Figure 10 Percentage inhibition of E. coli caused by amoxicillin, chloramphenicol, cyclo(Phe-4Cl-Pro) and 
cyclo(D-Phe-4Cl-Pro) 
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Figure 11 Percentage inhibition of B. subtilis caused by amoxicillin, chloramphenicol, cyclo(Phe-4Cl-Pro) 
and cyclo(D-Phe-4Cl-Pro) 
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Figure 12 Percentage inhibition of S. aureus caused by amoxicillin, chloramphenicol, cyclo(Phe-4Cl-Pro) 
and cyclo(D-Phe-4Cl-Pro) 
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Figure 13 Percentage inhibition of C. albicans caused by amoxicillin, chloramphenicol, cyclo(Phe-4Cl-
Pro) and cyclo(D-Phe-4Cl-Pro) 
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Figure 14 Effects of heparin (positive control), cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on PT 
clotting time.   
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Figure 15 Effects of heparin (positive control), cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on 
decreasing the formation of fibrin 
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Figure 16 Effects of heparin (positive control), cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on D-Dimer 
formation 
 
 
Figure 17 Fluorescence intensity and cell density plot representation of platelet aggregation caused by 
the untreated control (PRP) 
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Figure 18 Fluorescence intensity and cell density plot representation of platelet aggregation caused by 
the positive control (PRP with thrombin 50 U/ml) 
   
 
Figure 19 Fluorescence intensity and cell density plot representation of platelet aggregation caused by 
50 mM cyclo(Phe-4Cl-Pro)  
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Figure 20 Fluorescence intensity and cell density plot representation of platelet aggregation caused by 
25 mM cyclo(Phe-4Cl-Pro)  
 
 
Figure 21 Fluorescence intensity and cell density plot representation of platelet aggregation caused by 
12.5 mM cyclo(Phe-4Cl-Pro) 
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Figure 22 Fluorescence intensity and cell density plot representation of platelet aggregation caused by 
3.125 mM cyclo(Phe-4Cl-Pro) 
 
 
Figure 23 Fluorescence intensity and cell density plot representation of platelet aggregation caused by 
50 mM cyclo(D-Phe-4Cl-Pro) 
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Figure 24 Fluorescence intensity and cell density plot representation of platelet aggregation caused by 
25 mM cyclo(D-Phe-4Cl-Pro) 
 
 
Figure 25 Fluorescence intensity and cell density plot representation of platelet aggregation caused by 
12.5 mM cyclo(D-Phe-4Cl-Pro) 
327 
 
    
 
Figure 26 Fluorescence intensity and cell density plot representation of platelet aggregation caused by 
3.125mM cyclo(D-Phe-4Cl-Pro) 
 
 
 
 
 
 
 
 
328 
 
 
P
e
rc
e
n
ta
g
e
 i
n
h
ib
it
io
n
 (
%
)
-20
0
20
40
60
Cyclo(L-Phe-4Cl-Pro)
Cyclo(D-Phe-4Cl-Pro)
Acarbose
 
Figure 27 α-Glucosidase enzyme inhibition caused by acarbose (positive control), cyclo(Phe-4Cl-Pro) 
and cyclo(D-Phe-4Cl-Pro) 
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Figure 28 α-Amylase enzyme inhibition caused by acarbose, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-
Pro) 
Table 1 Conformational search results calculated for cyclo(Phe-4Cl-Pro) in the gas phase 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann 
Distribution 
1 360.77 0 0.924 
2 368.03 7.26 0.049 
3 369.53 8.76 0.027 
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Table 2 Conformational search results calculated for cyclo(Phe-4Cl-Pro) in the solvated (water) phase 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann 
Distribution 
1 287.86 0 0.942 
2 296.19 8.33 0.033 
3 296.84 8.98 0.025 
Table 3 Conformational search results calculated for cyclo(Phe-4Cl-Pro) in dimethyl sulphoxide (DMSO) 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann Distribution 
1 -3315302.5 
 
0 0.648 
 
2 -3315300.02 
 
2.49 0.238 
 
3 -3315298.2 
 
4.3 0.114 
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Table 4 Conformational search results calculated for cyclo(D-Phe-4Cl-Pro) in the gas phase 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann 
Distribution 
1 0 365.03 0.814 
2 3.88 368.91 0.17 
3 9.76 374.8 0.016 
Table 5 Conformational search results calculated for cyclo(D-Phe-4Cl-Pro) in the solvated (water) phase 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann 
Distribution 
1 291.37 0 0.791 
2 294.83 3.46 0.916 
3 301.54 10.16 0.013 
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Table 6 Conformational search results calculated for cyclo(D-Phe-4Cl-Pro) in dimethyl sulphoxide 
(DMSO) 
Conformer Energy (kJ/mol) Rel. E (kJ/mol) Boltzmann 
Distribution 
1 -3315307 
 
 
0 0.673 
 
2 -3315304 
 
 
2.05 0.295 
 
3 -3315299 
 
 
7.54 0.032 
 
Table 7 Effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on APTT clotting times 
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Table 8 Percentage growth inhibit ion of P. aeruginosa after 24 hour exposure to cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro),  chloramphenicol and amoxicil lin   
Agent Concentration Percentage 
inhibition (%) 
P-value 
Amoxicillin 1 mg/ml 90.34 ± 2.010  0.0012 
0.5 mg/ml 76.23 ± 1.675  0.0015 
Chloramphenicol 0.5 mg/ml 68.91 ± 5.690  0.0102 
0.25 mg/ml 54.11 ± 1.775 0.0036 
Cyclo(D-Phe-4Cl-
Pro) 
1 mM 39.55 ± 3.000 
 
0.0143 
 
0.5 mM 15.61 ± 3.275 0.2619 
Cyclo(Phe-4Cl-Pro) 1 mM 21.50 ± 1.835  0.0490 
0.5 mM 15.99 ± 1.000  0.1061 
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Table 9 Percentage growth inhibit ion of E. coli after 24 hour exposure to cyclo(Phe-4Cl-
Pro), cyclo(D-Phe-4Cl-Pro), chloramphenicol and amoxicil l in  
Agent Concentration Percentage 
inhibition (%) 
P-value 
Amoxicillin 1 mg/ml 73.25 ± 4.350  0.0309 
0.5 mg/ml 68.89 ± 1.335  0.0293 
Chloramphenicol 0.5 mg/ml 78.50 ± 6.165  0.0312 
0.25 mg/ml 69.66 ± 0.4350 0.0277 
cyclo(D-Phe-4Cl-
Pro) 
1 mM 25.83 ± 0.500 0.7724 
0.5 mM 11.50 ± 0.8350 
 
0.2771 
 
cyclo(Phe-4Cl-Pro) 1 mM 18.66 ± 1.000  0.6239 
0.5 mM 15.66 ± 0.6700 0.4400 
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Table 10 Percentage growth inhibit ion of B. subtilis  after 24 hour exposure to cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro),  chloramphenicol and amoxicil lin   
Agent Concentration Percentage 
inhibition (%) 
P-value 
Amoxicillin 1 mg/ml 50.61 ± 4.410 0.0316 
0.5 mg/ml 57.55 ± 2.350 0.0144 
Chloramphenicol 0.5 mg/ml 83.61 ± 4.410 0.0085 
0.25 mg/ml 68.28 ± 2.945 0.0103 
Cyclo(D-Phe-4Cl-
Pro) 
1 mM 17.83 ± 5.500 0.8570 
0.5 mM 15.00 ± 1.335  0.7907 
cyclo(Phe-4Cl-
Pro) 
1 mM 18.27 ± 2.390  0.7438 
0.5 mM 12.33 ± 2.000  0.4900 
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Table 11 Percentage growth inhibit ion of S. aureus  after 24 hour exposure to cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro),  chloramphenicol and amoxicil lin   
Agent Concentration Percentage 
inhibition (%) 
P-value 
Amoxicillin 1 mg/ml 26.40 ± 1.5.600  0.0501 
0.5 mg/ml 58.60 ± 1.300  0.0304 
Chloramphenicol 0.5 mg/ml 72.60 ± 6.600  0.00344 
0.25 mg/ml 69.61 ± 1.610 0.0177 
Cyclo(D-Phe-4Cl-
Pro) 
1 mM 68.00 ± 2.665  0.0106 
0.5 mM 22.17 ± 1.165 
 
0.05362 
 
Cyclo(Phe-4Cl-Pro) 1 mM 12.22 ± 2.110 0.0062 
0.5 mM 11.33 ± 9.000 
 
0.0340 
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Table 12 Percentage growth inhibit ion of C. albicans  after 24 hour exposure to cyclo(D-
Phe-4Cl-Pro), cyclo(Phe-4Cl-Pro),  chloramphenicol and amoxicil lin   
Agent Concentration Percentage 
inhibition (%) 
P-value 
Amoxicillin 1 mg/ml 91.19 ± 1.165  0.0004 
0.5 mg/ml 63.83 ± 2.500  0.0025 
Chloramphenicol 0.5 mg/ml 57.61 ± 2.390  0.0030 
0.25 mg/ml 82.68 ± 5.345 0.0054 
Cyclo(D-Phe-4Cl-
Pro) 
1 mM 54.28 ± 5.055  0.0128 
0.5 mM 31.83 ± 9.500 
 
0.1380 
 
Cyclo(Phe-4Cl-Pro) 1 mM 47.84 ± 7.820  0.0387 
0.5 mM 46.18 ± 3.845  0.0114 
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Table 13 Effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on APTT clotting times 
Compound Concentration Clotting time 
(seconds) 
P-value 
Heparin 0.1 U\ml 106 ± 1.350 0.0003 
 
Cyclo(Phe-4Cl-Pro) 50 mM 27.95 ± 0.4000 
 
0.0003 
25 mM 
20.28 ± 1.055  
0.0004 
 
12.5 mM 
10.78 ± 0.4450  
0.0002 
 
Cyclo(D-Phe-4Cl-
Pro) 
50 mM 
26.15 ± 0.7050  
0.0004 
 
25 mM 
14.61 ± 0.6150  
0.0003 
 
12.5 mM 
8.110 ± 0.5500  
0.0002 
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Table 14 Effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on PT clotting times 
Compound Concentration Clotting time 
(seconds) 
P-value 
Heparin 0.1 U/ml 88.80 ± 1.805 0.0009 
 
Cyclo(Phe-4Cl-Pro) 50 mM 20.53 ± 0.9250 
 
 
0.2374 
25 mM 
17.13 ± 0.1700  0.0055 
12.5 mM 
14.41 ± 0.8100  0.0125 
Cyclo(D-Phe-4Cl-
Pro) 
50 mM 
17.66 ± 0.6700  0.0266 
25 mM 
11.85 ± 0.8550  0.0078 
12.5 mM 
10.75 ± 0.4500  0.0024 
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Table 15 Effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on the formation of fibrin 
Compound Concentration Fibrin formation 
(mg/dL) 
P-value 
Heparin 0.1 U/ml 73.66 ± 3.670 
 
0.0144 
 
Cyclo(Phe-4Cl-Pro) 50 mM 116.7 ± 3.725  
 
 
 
 
0.0144 
25 mM 273.2 ± 3.830  0.0007 
 
12.5 mM 292.5 ± 2.500  
 
0.0004 
 
Cyclo(D-Phe-4Cl- 50 mM  
0.0018 
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Pro) 
172.0 ± 2.000  
 
 
25 mM 313.4 ± 2.545  
 
0.0003 
 
 
12.5 mM 369.8 ± 0.8350  
 
0.0002 
 
 
Table 16 Effects of heparin, cyclo(Phe-4Cl-Pro) and cyclo(D-Phe-4Cl-Pro) on D-Dimer formation 
Compound Concentration D-Dimer formation 
(ng/ml) 
P-value 
Heparin 0.1 U/ml 36.99 ± 1.000 0.0020 
Cyclo(Phe-4Cl-Pro) 50 mM 69.39 ± 1.055  
 
 
 
0.0020 
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25 mM 
65.43 ± 2.875  0.0113 
12.5 mM 
53.10 ± 2.105  0.0203 
Cyclo(D-Phe-4Cl-
Pro) 
50 mM 
53.91 ± 0.3100  0.0038 
25 mM 
49.16 ± 0.1700  
0.0069 
 
12.5 mM 
43.95 ± 0.9550  0.0373 
 
 
 
 
 
 
 
